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The ability to induce pluripotency in somatic cells offers unprecedented opportunities in
basic and applied research. The implementation of induced pluripotent stem cells (iPSCs)
into clinical settings, however, is hampered by genetic modifications associated with retro- or
lentivirus-mediated reprogramming. The quest for efficient alternative reprogramming ap-
proaches has been closely connected with the identification of cell sources, which readily
acquire the pluripotent stem cell (PSC) state. Human amniotic fluid cells (AFCs) represent rou-
tinely available cells with stem cell-like features, which could presumably facilitate efficient re-
programming even by non-integrating techniques. The goal of this project was to generate and
comparatively characterize iPSCs derived from human AFCs by viral and non-viral techniques
with respect to human embryonic stem cells (ESCs), the golden standard of PSCs, and iP-
SCs generated from cells of other tissues of origin. Retrovirus-mediated overexpression of the
reprogramming factors in primary human AFCs resulted in fast and efficient generation of iP-
SCs (AFiPSCs), which resembled human ESCs with regards to morphology, proliferation and
marker expression. Their ability to differentiate into derivatives of the three embryonic germ
layers was demonstrated in vitro and in vivo and upon BMP2 and BMP4-treatment expres-
sion of trophoblast markers, including CDX2, KRT7 and HAND1, was confirmed. Detailed
microarray-based transcriptome analysis of ESCs, AFiPSCs, fibroblast-derived iPSCs (FiPSCs)
and the respective parental cell lines revealed the activation of a transcriptional regulatory
network common to all PSCs but also highlighted, for example, residual gene expression sig-
natures in iPSCs from different tissues of origin. These findings were summarized in a concept
coined the LARGE Principle of Cellular Reprogramming. Genetic manipulation of AFiPSCs
was not accomplished. Attempts to reprogram human AFCs by non-viral, non-integrating
methods included nucleofection of episomal plasmids and lipofection of mRNAs encoding
the reprogramming factors. Despite multiple trials fully reprogrammed iPSCs could not be
established. In depth analysis of the cellular response to the transfected mRNAs uncovered an
extensive induction of interferon-regulated immune-related genes to be the key roadblock in
mRNA-mediated reprogramming. Subsequent efforts to identify chemicals which could sup-
press this innate immune reaction did not yield potent candidates. The data presented herein,
however, provide the basis for further investigations into this effect. In summary, this work
highlights the value of human AFCs for the derivation of iPSCs and emphasizes the obstacles





“Regenerative medicine,” as originally described by Kaiser (1992) (given in Lysaght and Crager
(2009)), “[. . . ] attempts to change the course of chronic disease and in many instances will re-
generate tired and failing organ systems.” Since then, the term ‘regenerative medicine’ has been
re-defined by Mason and Dunnill to address all essential aspects of the broad, cross-disciplinary
modern field, while keeping it simple and concise: “Regenerative medicine replaces or re-
generates human cells, tissue or organs to restore or establish normal function” (Mason and
Dunnill, 2008). To meet these requirements regenerative medicine combines cell-based re-
generative therapies, including gene-based methods, molecular medicines, new technologies
such as nanomedicines, biomaterials and tissue engineering (Mason and Dunnill, 2008). In a
pioneering practical example of regenerative medicine, symptoms caused by severe bladder
dysfunction were markedly improved by the implantation of tissue-engineered bladder con-
structs which had been generated from autologous, in vitro expanded urothelial and muscle
cells seeded onto three-dimensional scaffolds (Atala et al., 2006). Due to technical advances,
regenerative therapies based on human cells have a great significance in regenerative medicine
these days (Mason and Dunnill, 2008). However, the access to specialized human cell types
which can be obtained from biopsies, expanded and re-implanted is limited. This therapeutic
strategy is, hence, ineligible for the treatment of a large number of diseases such as, for example,
neuronal diseases. Consequently, the field strives to find sources of stem cells which, due to
their inherent differentiation potential and their ability to self-renew, qualify for broad appli-
cation in regenerative medicine. Accordingly, several kinds of so-called adult stem cells, which
reside in their particular tissue or organ of origin to contribute to homeostasis and repair, are
thought to be applicable in the treatment of various disorders as reviewed by Mimeault et al.
(2007). Their differentiation potential, however, is generally restricted to certain lineages and
numerous groups have reported decreased differentiation potential and limited proliferation
capacities of adult stem cells maintained in vitro (Digirolamo et al., 1999; Banfi et al., 2000;
Glimm et al., 2000; Baxter et al., 2004; Bonab et al., 2006; Wagner et al., 2008; Schellenberg
et al., 2011). Consequently, “the limitations in availability of most specialist somatic cells and
the restriction in the expansion of adult stem cells” drives a great interest in pluripotent stem
cells (PSCs) (Mason and Dunnill, 2008). The term pluripotent refers to the ability to develop
into derivates of all three primary germ layers and, thus, any cell type of the embryo, fetus
1
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and adult (Evans, 2011). Such PSCs naturally occur during early embryonic development of
mammals (Pera et al., 2000; Evans, 2011).
1.2 Human pluripotent stem cells
1.2.1 The first week of human embryonic development
To provide the basis for comprehending the origin and nature of human PSCs, the following
paragraph briefly describes the first week of human embryonic development post-fertilization
(Adjaye et al., 2005; Schoenwolf et al., 2008). The fertilized human egg, the totipotent zygote,
eventually develops into all cell types of the human organism, including extraembryonic tis-
sues such as the placenta. It travels from the ampulla of the oviduct to the uterus, where it
implants by the end of the first week post-fertilization. During this pre-implantation devel-
opment, the oocyte undergoes several symmetric and asymmetric mitotic cell divisions, the
so-called cleavage, giving rise to the two-cell stage embryo, the four- and eight-cell stage embryo
prior to formation of the morula, a compact sphere of blastomeres (Figure 1.1). During cleav-
age, these roundish daughter cells polarize and segregate into a thin outer layer of epithelium,
the trophoblast, and the inner cell mass to form the blastocyst, a fluid filled sphere, by day five
post-fertilization. This represents the first specification of cell fate during embryogenesis. The
surrounding trophectoderm cells, which express trophoblast markers such as BMP4, will later
on give rise to the embryonic part of the placenta and other supporting tissues, whereas the
embryo proper will arise from the OCT4, SOX2, NANOG-expressing pluripotent inner cell
mass or embryoblast.
Figure 1.1: Cleavage and transport down the oviduct. Fertilization occurs in the ampulla of
the oviduct. During the first five days, the zygote undergoes cleavage as it travels down the
oviduct and enters the uterus. On day five, the blastocyst hatches from the zona pellucida and
is then able to implant in the uterine endometrium Taken from Schoenwolf et al. (2008).
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1.2.2 Human embryonic stem cells
Thomson et al. (1998) derived the first pluripotent human embryonic stem cells (ESCs) from
the inner cell mass of surplus blastocyst stage embryos generated by in vitro fertilization
(IVF). These cells maintain the potential to form derivatives of all three embryonic germ
layers throughout pro-longed undifferentiated proliferation in vitro, as characterized by stain-
ing for the non-human primate ESCs and human embryonal carcinoma cell surface markers
stage-specific embryonic antigen (SSEA)-3 and SSEA-4, tumor rejection antigen (TRA)-1-60
and TRA-1-81 and alkaline phosphatase (AP) as well as the formation of teratomas upon in-
jection into immune-compromised mice in vivo (Thomson et al., 1998). Human ESCs grow
as flat, sharp-edged colonies, have a high nucleus to cytoplasmic ratio and express high lev-
els of telomerase activity enabling them to escape senescence and to continuously self-renew
(Thomson et al., 1998). At the molecular level, human ESCs are of epithelial nature. This is
highlighted by the apico-basal polarity, the presence of epithelial cell-cell adhesion complexes
such as cadherin-1(CDH1)-mediated adherens junctions, tight junctions, desmosomes and gap
junctions, correlating with the poor clonal survival of human ESCs (Thomson et al., 1998)
and the lack of, for example, mesenchymal markers such as the intermediate filament vimentin
(Wong et al., 2004; Eastham et al., 2007; Van Hoof et al., 2008).
“The gene-expression program” and, hence, the phenotype of pluripotent human ESCs “is
a product of regulation by specific transcription factors, chromatin-modifying enzymes, regula-
tory RNA molecules (miRNAs), and signal-transduction pathways” as illustrated in Figure 1.2
(Jaenisch and Young, 2008).
Key functions of OCT4, SOX2 and NANOG, the master transcription factors of pluripo-
tent mammalian stem cells (Nichols et al., 1998; Avilion et al., 2003; Chambers et al., 2003;
Hart et al., 2004; Hay et al., 2004; Matin et al., 2004; Babaie et al., 2007; Jung et al., 2010)
in maintaining complex self-renewal- and pluripotency-associated transcriptional regulatory
networks (TRNs) in human ESCs were first identified by Boyer et al. (2005). According to
their findings, these three proteins co-operate to establish auto-regulatory and feed-forward
loops, thereby activating or repressing genes encoding components of distinct signaling path-
ways and developmental processes, chromatin regulators and regulatory miRNAs to shape
ESC identity. Furthermore, various extracellular stimuli contribute to the maintenance of the
undifferentiated human ESC phenotype. As such, basic fibroblast growth factor (bFGF, also
known as FGF2) is a key component of human ESC culture medium designed to maintain
self-renewal and pluripotency of human ESCs in vitro (Thomson et al., 1998; Amit et al.,
2000). Via the activation of the corresponding receptors, FGF2 is believed to be an up-stream
regulator of other key signaling pathways operative in undifferentiated human ESCs (Greber
et al., 2007a). Regarding these, the Smad2/3-mediated branch of the transforming growth fac-
tor β (TGFβ)/Activin A/Nodal signaling pathway is of particular importance to note (James
et al., 2005; Vallier et al., 2005; Greber et al., 2007a; Vallier et al., 2009a). Likewise, canoni-
cal WNT signaling has long been believed to promote self-renewal of human ESCs, however,
the actual relevance of this pathway in this respect remains controversial (Sato et al., 2004;
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Figure 1.2: Pluripotency and the transcriptional regulatory circuitry. Cartoon showing hy-
pothetic connections between signal transduction pathways, transcription factors (blue balls),
chromatin regulators (green balls), and their target genes (orange squares) to form an image of
transcriptional regulatory circuitry. Some target genes produce miRNAs, which function at
posttranscriptional levels. Taken from Jaenisch and Young (2008).
Davidson et al., 2012). Figure 1.3 depicts a simplified scheme of selected pathways to illus-
trate how signals are transduced from the cellular membrane to the nucleus and integrated to
sustain undifferentiated proliferation of human ESCs. Essential steps in this network are the
FGF2-mediated up-regulation of signaling molecule-encoding genes including TGFB1 and IN-
HBA (encoding subunits of ACTIVIN A) which feedback in autocrine and paracrine fashion
upon translation to promote self-renewal and pluripotency (Greber et al., 2007a). Simultane-
ously, differentiation-inducing factors such as BMP4 are either directly or indirectly repressed
by up-regulation of corresponding antagonists such as GREM1 and CER1 (Xu et al., 2005;
Greber et al., 2007a). As a result major self-renewal and pluripotency-associated genes such as
OCT4, SOX2 and NANOG are up-regulated, feeding into the complex human ESC-specific
transcriptional regulatory networks described above. Importantly, mouse embryonic fibrob-
lasts (MEFs) of certain strains, e.g., CF1, NMRI, support the undifferentiated proliferation of
human ESCs due to similar expression patterns and release of homologous signaling molecules
upon FGF2-stimulation. For this reason, MEFs are routinely used in co-culture systems with
human ESCs (Greber et al., 2007a).
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Figure 1.3: Core signaling pathways that maintain self-renewal and pluripotency in undif-
ferentiated human ESCs. Binding of FGF2 to its receptor is regulated by heparan sulfate
proteoglycans. Once initiated FGF2 signaling follows different routes within the cell—only
PI3K/AKT and MAPKK1/2/MAPK1/2 branches, known for their key contribution towards
self-renewal and pluripotency via regulated transcription of distinct target genes, are depicted.
Likewise, active TGFβ/ACTIVIN A/NODAL signaling plays an essential role in undifferen-
tiated human ESCs via SMAD2/3-mediated expression/repression of target genes. Both FGF2
and TGFβ/ACTIVIN A/NODAL signaling interact, e.g. by up-regulation of components of
the respective other pathway, and synergistically suppress BMP-induced differentiation, e.g. via
down-regulation of BMPs and up-regulation of BMP antagonists such as GREM1 and CER1.
As a result, regulated transcripts are indirectly or directly conducive to the establishment and
maintenance of the OCT4, SOX2, NANOG-driven self-renewal and pluripotency-associated
TRN in human ESCs. Various other pathways, branches of pathways and mediators have been
excluded for the sake of clarity.
AKT, AKT kinase; ALK4/5/7 and ALK3/6, anaplastic lymphoma kinase 4/5/7 and anaplastic
lymphoma kinase 3/6; BMP, bone morphogenetic protein; CER1, cerberus protein; GREM1,
gremlin 1 protein; FGF2, fibroblast growth factor 2; FGFR, fibroblast growth factor recep-
tor; FRS2, FGF receptor substrate 2; GRB2, growth factor receptor-bound protein 2 GAB1,
GRB2-associated binding protein 1; HSPG, heparan sulfate proteoglycans; IκB, inhibitor of
κB; IκK, IκB kinase; MAPK1/2, mitogen-activated protein kinase 1/2; MAPKK1/2, mitogen-
activated protein kinase kinase 1/2; mTOR, mammalian target of rapamycin; NFκB, nuclear
factor κ-light-chain-enhancer of activated B cells; PDK1, 3’-phosphoinositide-dependent pro-
tein kinase 1; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol (3,4)-bisphosphate;
PIP3, phosphatidylinositol (3,4,5)-trisphosphate; RAS, rat sarcoma viral oncogene homolog;
RAF, rat fibrosarcoma proto-oncogene serine/threonine-protein kinase; SARA, SMAD an-
chor for receptor activation protein; SHC, SH2 domain containing transforming protein 1;
SOS, son of sevenless; TGFβ, transforming growth factor β; TRN, transcriptional regula-
tory network; TypeIIR, type II receptor. Adapted from http://www.cellsignal.com/reference/
pathway/pdfs/esc_pluripotency.pdf, Nugent and Iozzo (2000); Vallier et al. (2005); Armstrong
et al. (2006); Okita and Yamanaka (2006); Xu et al. (2008); Greber et al. (2007a); Zhou et al.
(2009).
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1.2.2.1 Applications of human ESCs in basic research and regenera-tive medicine
The establishment of in vitro cultures of human ESCs was a major breakthrough in regener-
ative medicine. Thomson and colleagues emphasized the value of human ESCs for studies of
early developmental processes, especially post-implantation processes, and the importance of
unveiling mechanisms underlying their differentiation to distinct cells types. Healthy, diseased
and genetically modified human ESCs provide basic knowledge required for practical applica-
tions of these cells as well as the opportunity to model diseases in a dish (Thomson et al., 1998;
Tropel et al., 2010). To this end, several disease-specific human ESC lines have been established
so far (Table 1.1) (Maury et al., 2011).
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Table 1.1: Disease modeling using human ESCs. Modified from Maury et al. (2011).
Disease (responsible gene) Molecular defect Reference
Huntington (Huntingtin) Not determined Mateizel et al. (2010); Tropel et al.
(2010)
Cystic Fibrosis (CFTR) Not determined Mateizel et al. (2006, 2010); Tropel
et al. (2010)
X-linked myotubular myopathy (MTM1) Not determined Tropel et al. (2010)
Turner syndrome (Monosomy X) Not determined Urbach and Benvenisty (2009)
Fabry syndrome (GLA) Not determined Tropel et al. (2010)
Multiple endocrine neoplasia Type 2 (RET ) Not determined Tropel et al. (2010)
Marfan syndrome (FBN1) Not determined Mateizel et al. (2010)
Charcot-Marie Tooth Type 1A (PMP22) Not determined Mateizel et al. (2010)
Facioscapulohumeral muscular dystrophy Not determined Mateizel et al. (2010)
Spino-cerebellar Ataxia type 2 (ATXN2) Not determined Tropel et al. (2010)
Spino-cerebellar Ataxia type 7 (ATXN2) Not determined Mateizel et al. (2010)
Fragile-X Syndrome (FRM1) Extension of FRM1 expression during early
differentiation
Eiges et al. (2007); Mateizel et al.
(2010)
Myotonic dystrophy type 1 (DMPK) Detection of the ribonuclear inclusions, NMDAR1
alternate splicing defect, defect in neuritogenesis and
synaptogenesis in human ESCs-derived motoneurons
Mateizel et al. (2006,2010);
Marteyn et al. (2011)
Lesch-Nyhan Syndrome (HRPT1), introduction
of the mutation by homologous recombination
Absence of HRPT1 activity, increased production of
uric acid
Urbach et al. (2004)
ATXN2, ataxin 2; CFTR, cystic fibrosis transmembrane conductance regulator; DMPK, dystrophia myotonica-protein kinase; FBN1, fibrillin 1; FRM1, fragile X mental retardation
1; GLA, galactosidase α; HRPT1, hypoxanthine phosphoribosyltransferase 1; MTM1, myotubularin 1; NMDAR1, N-methyl D-aspartate receptor1; PMP22, peripheral myelin
protein 22; RET, ret proto-oncogene.
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Combining the theoretically indefinite proliferation capacities of human ESCs with their
pluripotent differentiation potential, it can be anticipated that human ESCs represent an un-
limited supply of any desired specialized human cell types which are otherwise difficult to
obtain. This offers new perspectives with respect to drug discovery, pre-clinical drug testing,
toxicity tests as well as repair and replacement of impaired tissues (Thomson et al., 1998; Davila
et al., 2004; McNeish, 2004; Jensen et al., 2009).
Concerning the latter aspect, the first clinical trials involving human ESC-derived, spe-
cialized cell types have started. In 2009, approximately ten years after the first human ESC
derivation, Geron, a US-based biopharmaceutical company, was first to be granted approval
by the Food and Drug Administration (FDA) to initiate clinical studies to evaluate human
ESC-based therapies. Geron intended to test oligodendrocyte progenitor cells generated from
human ESCs, which were shown to have “remyelinating and nerve growth-stimulating proper-
ties”, for the treatment of severe spinal injuries in ten patients (Alper, 2009). Following a series
of intermissions by the regulatory authorities (Strauss, 2010), Geron started the treatment of
four patients with their stem cell-based product in 2010 but ended the trial precociously due
to financial concerns in November 2011 (Frantz, 2012). There has yet been no publication
of the clinical results. The second on-going FDA-approved clinical trial of this kind is con-
ducted by Advanced Cell Technology and is meant to examine the safety and effectiveness of
human ESC-derived retinal pigmented cells, transplanted into the sub-retinal space, in rescu-
ing photoreceptor loss and improving vision in patients suffering from macular degeneration,
a leading cause of blindness. Preliminary results of this study in two patients highlighted
the absence of abnormal growth and immune rejection of the grafted cells in the eye, which
is an immune-privileged organ, while visual acuity was slightly improved (Schwartz et al.,
2012b). Furthermore, ViaCyte (formerly Novocell) plans to test human ESCs-derived pan-
creatic progenitor cells for treating type 1 diabetes (Wu and Hochedlinger, 2011). Likewise,
Life Technologies pursue trials to improve symptoms of amyotrophic lateral sclerosis with
astrocyte precursor cells generated from human ESCs (Fox, 2011).
Despite these promises human ESCs have inherent problems. The two most critical issues
when considering the use of human ESCs for any of the above mentioned applications are (i)
the ethical dispute that is associated with the destruction of human pre-implantation embryos
for the purpose of generating human ESCs and (ii) the immune rejection that can be caused if
non-autologous human ESCs are transplanted. There is no apparent way to completely solve
the first issue despite juridically prohibiting human ESC-based research, thereby, abandoning
its tremendous biological value. The latter problem, however, could be resolved by banking
human ESCs in order to provide matching major histocompatibility complex backgrounds
or by genetic modification of human ESCs with the aim of suppressing immune rejection
(Jensen et al., 2009). Yet, human ESC generation and banking, which appear to be technically
less challenging than genetic modification of human ESCs (Strulovici et al., 2007; Maury et al.,
2011), enforce the ethical concerns and are, hence, self-contradictory.
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1.2.3 Human induced pluripotent stem cells
The search for approaches capable of circumventing the two major concerns associated with
human ESCs entailed attempts to de-differentiate somatic cells including somatic cell nuclear
transfer (SCNT) and cell fusion experiments. The term SCNT refers to the transplantation
of a differentiated somatic cell nucleus into an enucleated, unfertilized egg to produce an off-
spring that is genetically identical to the donor of the somatic cell—Dolly the sheep was cloned
using this technique (Wilmut et al., 1997). Instead of using an oocyte, Cowan and colleagues
fused terminally differentiated human fibroblast cells with human ESCs, generating tetraploid
hybrids with human ESC characteristics, to show that human ESCs have the potential to re-set
a somatic cell nucleus to an embryonic-like state (Cowan et al., 2005). These experiments were
of great value for developmental biology as they demonstrated that differentiation processes
are reversible and that certain oocyte- and ESC-specific factors can convey their differentia-
tion potential to terminally differentiated cells. With this in mind, Takahashi and Yamanaka
screened a library of 24 putatively essential pluripotency-associated genes for their potential
to induce pluripotency in somatic cells, leading to the next groundbreaking achievement in
stem cell biology: They found that ectopic expression of a combination of four transcription
factor genes, namely Pou5f1 (encoding the Oct4 protein), Sox2, Klf4 and c-Myc, was sufficient
to reprogram mouse somatic cells back to an ESC-like developmental stage (Takahashi and
Yamanaka, 2006). Without comprising oocytes or human ESCs they managed to turn the de-
velopmental clock of terminally differentiated cells back. One year later, the same research
group could generate such so-called induced pluripotent stem cells (iPSCs) by retroviral over-
expression of the same set of genes in human somatic cells, including neonatal fibroblasts and
cells obtained from skin and synovial tissue biopsies (Takahashi et al., 2007). In parallel, the
group of Thomson reported that human fibroblast cells can also acquire an ESC-like state by
transduction of constitutive lentiviruses encoding a slightly different set of reprogramming
factor genes—POU5F1 (OCT4), SOX2, NANOG and LIN28 (Yu et al., 2007). Hence, in both
protocols OCT4 and SOX2 are obligatory factors to induce pluripotency in somatic cells.
1.2.3.1 Molecular events underlying direct reprogramming
Despite a basic understanding of the OCT4, SOX2, NANOG-regulated TRN that underlies
the undifferentiated human PSC identity (Boyer et al., 2005; Babaie et al., 2007; Jung et al.,
2010), we have a confined knowledge of mechanisms and distinct pathways involved in the
de-differentiation of somatic cells into PSCs. The following paragraphs and Figure 1.4 briefly
summarize what has been known to date.
The most obvious feature of the cellular reprogramming process is the major change of
the transcriptional profile which needs to take place to facilitate the switch of cellular pheno-
types. Thus, epigenetic remodeling through distinct alteration of histone modifications and
CpG methylation patterns is required (Takahashi et al., 2007) in order to repress character-
istic somatic cell-specific genes and to enable transcription of pluripotency-associated genes.
Recently, several genome-wide studies have been conducted to profile the epigenetic landscape
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of parental cells, iPSCs and ESCs and to analyze the kinetics of distinct chromatin remodeling
steps employing both murine and human iPSCs (Kim et al., 2010, 2011; Mattout et al., 2011).
To obtain a better understanding of other molecular events underlying of the reprogram-
ming process we analyzed early events induced in human fibroblasts by retroviral transduction
of the reprogramming factors OCT4, SOX2, KLF4 and c-MYC. This revealed that in response
to viral infection levels of reactive oxygen species (ROS) increased significantly, leading to
DNA damage and ultimately to the activation of p53 (Mah et al., 2011). As this tumor suppres-
sor protein is responsible for arresting the cell cycle and inducing apoptosis and senescence,
p53 activation resulted in an over-representation of transcripts involved in apoptosis, cell cycle
regulation and aging (Mah et al., 2011). Hence, overcoming the p53-mediated cell cycle arrest
is a crucial step in acquiring the pluripotent state.
Another critical step in the process of cellular reprogramming is the suppression of the
epithelial-to-mesenchymal transition (EMT) and promotion of the reverse process, the mes-
enchymal-to-epithelial transition (MET), as shown for mouse cells of mesenchyme origin (Li
et al., 2010; Samavarchi-Tehrani et al., 2010; Liao et al., 2011). Accordingly, we identified the
initiation of MET as an early reprogramming event in human fibroblasts (Mah et al., 2011),
which eventually resulted in the establishment of the epithelial ESC-like phenotype as char-
acterized by multiple cell-cell adhesion complexes (Wong et al., 2004; Eastham et al., 2007;
Van Hoof et al., 2008).
Recent findings from our group (Prigione et al., 2010, 2011b) and from others (Armstrong
et al., 2010; Suhr et al., 2010; Zhu et al., 2010; Folmes et al., 2011; Kelly et al., 2011; Varum
et al., 2011; Zhang et al., 2011a) further suggest that the derivation of iPSCs is associated with
a re-configuration of mitochondria and bioenergetic metabolism. Developing cancer cells are
known to undergo reprogramming of the energy metabolism (Hsu and Sabatini, 2008). As
they proliferate, their metabolism switches from mitochondrial oxidative phosphorylation to
cytoplasmic glycolysis even in the presence of oxygen, a phenomenon known as the Warburg
effect (Warburg, 1956). This is believed to be caused by the change of energy requirements and
anabolic demands of tumor cells as cancer cells need to produce macromolecules to proliferate
while evading the generation of high levels of ROS, a common by-product of mitochondrial
respiration (Vander Heiden et al., 2009). Thus, cancer cells opt for re-routing the energy flux
outside the mitochondria (Drews et al., b). These findings may be transferable to somatic cells
undergoing cellular reprogramming. Accordingly, the quantity of mitochondria within iPSCs
is reduced and they are transformed into an immature state with less well defined cristae (Arm-
strong et al., 2010; Prigione et al., 2010; Suhr et al., 2010; Kelly et al., 2011). Simultaneously,
oxidative phosphorylation is decreased in iPSCs, which translates into increased glycolysis (Pri-
gione et al., 2010; Folmes et al., 2011; Prigione et al., 2011b; Varum et al., 2011; Zhang et al.,
2011a) and lower production of ROS (Armstrong et al., 2010; Prigione et al., 2010, 2011a).
As these metabolic changes occur before the establishment of the human ESC-like properties
they are likely to be essential for the process of cellular reprogramming (Folmes et al., 2011).
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1.2.3.2 The promise and potential of human iPSCs in basic researchand regenerative medicine
Human iPSCs closely resemble ESCs with respect to morphology, expression of ESC-specific
markers, proliferation, the ability to indefinitely self-renew and differentiation potential (Taka-
hashi et al., 2007; Yu et al., 2007). Thus, human iPSCs are considered as equally potent for
studies of differentiation processes, drug discovery, pre-clinical drug testing, toxicity studies
and repair and replacement of impaired tissues. The fact that iPSCs could potentially be derived
from ethically safe biopsies is one of the main advantages of human iPSCs over ESCs. At the
same time, derivation of iPSCs from virtually any individual is feasible, thus, solving immune
rejection concerns. Moreover, iPSCs allow for the reflection of a healthy or diseased indi-
vidual’s genetic background in vitro, without the necessity for banking genetically modified
human ESCs, taking regenerative medicine to a new level of personalized medicine. Alto-
gether, with the development of human iPSCs, there will be a potentially limitless source of
donor-specific differentiated cell types available for disease modeling, drug and toxicity screens
and cellular replacement therapies (Figure 1.4) (Drews et al., b). The full potential of the iPSC
technology can be valued when considering recent achievements using murine iPSCs. Impres-
sively, Jaenisch and colleagues reported amelioration of sickle cell anemia-associated symptoms
in mice following bone marrow transplantation of genetically-corrected hematopoietic pro-
genitors derived from autologous iPSCs (Hanna et al., 2007). Similarly, they could show that
murine iPSC-derived neural precursors efficiently differentiate into various functional neu-
ronal cell types which migrate and integrate into the developing brain upon injection into
the embryonic cerebral ventricles (Wernig et al., 2008). Furthermore, in vitro generated neu-
rons from these iPSCs have the potential to improve behavioral deficits in a rat model of
Parkinson’s disease (Wernig et al., 2008). Accordingly, ViaCyte, for example, also considers
generating pancreatic beta cell progenitors derived from human iPSCs instead of human ESCs,
to pursue treatment of type 1 diabetes (Fox, 2011). Meanwhile, a number of human iPSC lines
have been generated from patients suffering from a variety of diseases. Table 1.2 lists selected
disease models for which iPSC-derived somatic cells have been shown to possess the disease
phenotype or which have been used for drug screens or other functional studies (Drews et al.,
b).
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Figure 1.4: Hallmarks of cellular reprogramming and applications of human iPSCs. Somatic
cells obtained from any given donor can be reprogrammed to induced pluripotent stem cells
(iPSCs) using a number of different techniques. Key molecular events that mark this de-
differentiation process include global chromatin remodeling, circumvention of p53-induced
cell cycle arrest, reprogramming of mitochondria and, in close context the energy metabolism
toward increased glycolysis and decreased mitochondrial oxidative phosphorylation (OX-
PHOS), and the process of mesenchymal-to-epithelial transition (MET). Once human iPSC
lines from healthy or diseased individuals have been established and fully characterized, they
offer unprecedented opportunities in personalized regenerative medicine. Human iPSCs are
valuable tools for studying early developmental processes, to model human diseases in a dish,
thereby enabling the identification of new diagnostic markers and tools and potential new
drug targets, and to perform large scale toxicity and drug screens upon differentiation into ap-
propriate other cell types. Eventually, human iPSCs are envisaged to directly treat a particular
condition of the donor through cellular replacement therapy, if needed by transplantation of
genetically corrected autologous cells. Taken from Drews et al. (b).
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Table 1.2: Examples of successful iPSC-based modeling of complex disorders in a dish. Modified from Drews et al. (b).










Spinal muscular atrophy (SMA) Mutations in SMN1 Astrocytes, neurons,
mature motor neurons
Yes Tobramycin and VPA Ebert et al. (2009)







Hargus et al. (2010);
Park et al. (2008);









No Sanchez-Danes et al.
(2012)
Rett’s syndrome Mutation in MECP2 Neural progenitor
cells
Yes High dose gentamicin
and IGF1





Mutation in NAGLU Differentiated neurons
and neural stem cells
Partially Exogenous NAGLU Lemonnier et al.
(2011)
Schizophrenia Complex trait Neurons Yes Loxapine Brennand et al.
(2011)
Continued on next page
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Table 1.2 – Continued from previous page



















Jang et al. (2011)
Retinitis pigmentosa Mutations in RP9,









Jin et al. (2011)
Alzheimer’s disease (familial
and sporadic)
APP duplication Neurons Yes β-secretase inhibitors Israel et al. (2012)
Mesoderm
Fanconi’s anaemia FAA and FAD2 Hematopoietic cells No (rescued) No Raya et al. (2009)
LEOPARD syndrome Mutation in PTPN11 Cardiomyocytes Yes No Carvajal-Vergara
et al. (2010)
Type 1 long QT syndrome Mutation in KCNQ1 Cardiomyocytes Yes No Moretti et al. (2010)
Continued on next page
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Table 1.2 – Continued from previous page









Type 2 long QT syndrome Mutation in KCNH2 Cardiomyocytes Yes Nifedipine, E-4031,
pinacidil, ranolazine,
cisapride
Itzhaki et al. (2011)
Recessive dystrophic
epidermolysis bullosa (RDEB)
Mutation in COL7A1 Hematopoietic and
non-hematopietic cells
Partially Gene correction with
Col7a1
Tolar et al. (2011)
Familial dilated
cardiomyopathy
Mutation in TNNT2 Cardiomyocytes Partially Metoprolol,
overexpression of
Serca2a
Sun et al. (2012)





No Camnasio et al.
(2012)
Endoderm
Glycogen storage disease Ia
(GSD1a)





Yes No Ghodsizadeh et al.
(2010); Rashid et al.
(2010)
Familial hypercholesterolaemia Mutation in LDLR Hepatocyte-like cells
(fetal)
Yes No Rashid et al. (2010)
Wilson’s disease Mutation in ATP7B Hepatocyte-like cells Yes Gene correction with
ATP7B, curcumin
Zhang et al. (2011b)
Continued on next page
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Table 1.2 – Continued from previous page





















A1AT deficiency Mutation in A1AT Hepatocyte-like cells Yes (corrected) Transplanted into
mice with liver injury
Yusa et al. (2011)
Several germ layers
Down’s syndrome Trisomy 21 Teratoma Yes No Park et al. (2008)






Yes Kinetin Lee and Studer
(2011)
Friedreich’s ataxia (FRDA) GAA repeat in FXN Cardiomyocytes,
peripheral neurons
Partially No Liu et al. (2011)
A1AT,α–1–antitrypsin; ABCD1, ATP–binding cassette, sub–family D, member 1; APP, amyloid–β precursor protein; ATP7B, copper–transporting ATPase 2; CFTR, cystic fibrosis
transmembrane conductance regulator; COL7A1, α1–chain of type VII collagen; FAA, Fanconi’s anaemia, complementation group A; FAD2, Fanconi’s anaemia, complementation
group D2; FXN, frataxin; HCV, hepatitis C virus; HTT, huntingtin; IGF1, insulin–like growth factor 1; IKBKAP, I–κ–B kinase complex–associated protein; KCNH2, potassium
voltage-gated channel, subfamily H (eag-related), member 2; KCNQ1, potassium voltage-gated channel; LDLR, low–density lipoprotein receptor; LRRK2, leucine–rich repeat
kinase 2; MECP2, methyl CpG binding protein 2; NAGLU, α–N-acetylglucosaminidase; PRPH2, peripherin 2; PTPN11, protein tyrosine phosphatase, non–receptor type 11;
RHO, rhodopsin; RP, retinitis pigmentosa; Serca2a, sarcoplasmic/endoplasmic reticulum calcium ATPase 2; SLC37A, solute carrier family 37 (glucose–6–phosphate transporter);
SMN1, survival of motor neuron 1; SNCA, α-synuclein; TNNT2, troponin T type 2; VPA, valproic acid. Modified from Drews et al. (b).
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A contemporary overview of existing human iPSC lines world-wide, with a focus on
disease-specific lines, can be viewed at the International Stem Cell Registry (http://www.
umassmed.edu/iscr/index.aspx). As of today there are 232 records of human iPSC lines that
could be used in basic research and, eventually, for pre-clinical and clinical application. How-
ever, before human iPSCs can be applied in the clinics, it will be essential to obtain a more
detailed understanding of the molecular processes involved in cellular reprogramming, to es-
tablish efficient, non-integrating reprogramming techniques and to clarify the biological and
clinical relevance of mutations that can be induced in the genome of the parental cells. Further-
more, efficient differentiation protocols into mature cell types and high quality purification
of defined, terminally differentiated cells need to be developed in order to generate powerful
therapeutics and to eliminate the risk of tumor formation upon transplantation. Although
hurdles remain before the human iPSCs technology can be utilized as an in vitro model sys-
tem and in the clinics, progress has already been made and the field will benefit from the efforts
which are currently being made with respect to on-going and proposed clinical trials of human
ESC-derived therapeutic products (Drews et al., b).
1.2.3.3 Recent technical progress in the generation of human iPSCstowards clinical application
One major drawback hampering the utilization of human iPSCs in the clinic is owing to
the use of integrating retro- or lentiviruses to generate them. These viruses induce random,
unpredictable genetic modifications in the donor cells that could have an impact on the tu-
morigenicity and differentiation potential of the cells (Takahashi et al., 2007; Yu et al., 2007;
Barrilleaux and Knoepfler, 2011). Aiming at the production of putative clinical grade human
iPSCs, numerous research groups have tried to modify the iPSC generation protocol with the
intention to reduce the number of reprogramming factors and /or vectors required, hence,
minimizing or possibly avoiding insertional mutagenesis in the target cells. There has been a
stunning wave of articles, that have been published since mouse and human iPSC lines were
first established. Due to this abundance of scientific reports, I will particularly focus on publi-
cations related to human iPSCs.
One of the early improvements included the development of single polycistronic lentivi-
ral vectors which encode all necessary reprogramming factors in a single piece of integrating
DNA (Carey et al., 2009; Somers et al., 2010). Additionally, several groups investigated if
such single reprogramming factor cassettes were excisable to offer promising reprogramming
tools. These would be efficient with respect to the levels of ectopic transgene expression due
to the genomic integration but could be excised out of the target cells’ genomes once the
reprogramming process is accomplished. Following this strategy, Somers and colleagues re-
ported successful generation of human iPSCs free of reprogramming factor sequences using
loxP-flanked lentiviruses that could be removed from the iPSCs’ genomes by subsequent ex-
pression of the Cre recombinase (Somers et al., 2010). Yet, despite the targeted excision of
the transgene sequences, one of the inherent disadvantages of the Cre/loxP recombination
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system is that it leaves one of the two loxP sites flanking the transgene behind, thereby, still
modifying the genome (Nagy, 2000; Somers et al., 2010). Another approach to remove trans-
gene sequences upon induction of pluripotency in somatic cells involves the use of class II
transposable elements, namely piggyback transposons. Transfection of doxycycline-inducible
reprogramming factor-encoding transposons successfully enabled the generation of human iP-
SCs, however, the excision of the transgenes from iPSCs to produce footprint-free iPSCs has
only been demonstrated in murine cells to date (Kaji et al., 2009; Woltjen et al., 2009).
In contrast, the use of non-integrating expression systems such as transduction of repro-
gramming factor-encoding adenoviruses (Zhou and Freed, 2009) or repeated transfection of
expression plasmids (those lentiviral vectors used to generate the first iPSCs by overexpression
of OCT4, SOX2, NANOG and LIN28 (Yu et al., 2007)) (Si-Tayeb et al., 2010) yielded hu-
man iPSCs without DNA integration. Furthermore, Yu et al. (2009) succeeded in generating
human iPSCs by electroporation of combinations of large episomal plasmids. These did not
integrate into the genome, instead, remained in the cells as self-replicating episomes and were
successively diluted with pro-longed culture periods and progressive cell divisions. Hence,
these plasmids facilitated efficient transgene expression during the reprogramming process
while being absent in the established iPSC lines (Yu et al., 2009). Similar results were obtained
by Chou et al. (2011) later on, who constructed an improved episomal plasmid. Recently, deep
whole-genome sequencing was used to demonstrate that episomal-derived iPSCs do not har-
bor integration events (Cheng et al., 2012). One of the latest published methods to induce
pluripotency in human somatic cells on the basis of putatively non-integrating DNA vectors
included repeated nucleofections of minicircle DNAs encoding the reprogramming factors
(Jia et al., 2010). One of the major drawbacks of these methods, however, is the necessity of
the DNA to translocate to the nucleus of the target cells to be transcribed. This still poses a
certain risk of random integration into the genome.
To avoid this, Fusaki and co-workers transduced human fibroblast cells with Sendai viruses,
an RNA-based virus, which does not require access to the nucleus of the host cell to produce
the encoded transgenes (Fusaki et al., 2009). While the field has advanced, novel reprogram-
ming techniques have been developed including repeated treatment of human newborn fibrob-
lasts with recombinant reprogramming factor proteins fused with a sequence of nine arginines,
which served as cell-penetrating peptide, thereby, demolishing the risk of genomic insertions
(Kim et al., 2009a). Moreover, delivery of messenger RNAs (mRNAs) of the reprogramming
factors induced up-regulation of pluripotency-associated genes in human somatic cells (Plews
et al., 2010; Yakubov et al., 2010) and ultimately lead to the generation of fully reprogrammed
human cells (Warren et al., 2010). The most recent published progress was reported by An-
okye-Danso et al. (2011) and Anokye-Danso et al. (2011), who expressed human ESC-specific
miRNAs instead of the well established set of reprogramming factors to induce pluripotency
in somatic cells. While Anokye-Danso et al. (2011) made use of constitutive lentiviruses to ex-
press the miR-302/367 cluster, Anokye-Danso et al. (2011) repeatedly transfected the miRNAs
mimics miR-200c together with the miR-302 and miR-369 clusters. Interestingly, since these
non-integrating reprogramming approaches have first been published the stream of follow-up
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reports has markedly diminished indicating that their reproduction and the development of
improved methods are coupled with difficulties.
Along the search for novel techniques to induce pluripotency in somatic cells, research
groups have also been focusing on finding ways to increase the yield of fully reprogrammed
cells in less time, while potentially reducing the number of required reprogramming factors.
The two main routes to accomplish this goal resemble (i) the identification of small molecules
that modify distinct signaling pathways involved in the acquisition of the pluripotent state, e.g.
epigenetic remodeling, MET or metabolic pathways, as mentioned above, and (ii) the choice
of cell type to reprogram which defines the developmental starting point. With regards to
the latter aspect, it can be assumed that cells at different developmental stages require more
or less powerful strategies to enter the pluripotent state. Accordingly, it has been shown, for
example, that human and mouse neural stem cells, which express SOX2, KLF4 and c-MYC
in abundance, can be reprogrammed with only OCT4 instead of the original set of four re-
programming factors (Kim et al., 2009b,c; Medvedev et al., 2011). It is further conceivable,
that the combination of both aspects, i.e. the use of cells amenable for reprogramming plus
supporting chemical conditions, would tremendously alleviate cellular reprogramming pro-
cesses. Along these lines, Huangfu et al. (2008) demonstrated that the addition of valproic
acid (VPA), a substance involved in epigenetic remodeling processes, increased the number
of ESC-like colonies generated by transduction of only three reprogramming factors (OCT4,
SOX2 and KLF4) in human fibroblasts by 10- to 20-fold. Furthermore, VPA treatment facili-
tated the induction of pluripotency even if only OCT4 and SOX2 were ectopically expressed
(Huangfu et al., 2008). Similarly, we were able to show that the combination of VPA together
with 8-bromoadenosine 3’, 5’-cyclic monophosphate (8-Br-cAMP), an analog of cyclic AMP
(cAMP), synergistically increased the yield of iPSCs by 6.5-fold (Wang and Adjaye, 2011). Este-
ban et al. (2010) reported enhanced efficiency of human adipose stem cell reprogramming by
treatment with VPA and vitamin C. Transient inhibition of TGFβ and MAPK/ERK pathways
by combination of the ALK4/5/7 inhibitor SB431542 with the MEK inhibitor PD0325901 to-
gether with thiazovivin, a compound that increases survival of clonal human ESCs, was shown
to increase reprogramming efficiency in human fibroblasts by approximately 200-fold (Lin
et al., 2009). Similarly, the GSK-3 inhibitor CHIR99021 together with Parnate (also known
as tranylcypromine), an inhibitor of lysine-specific demethylase 1, enabled the induction of
pluripotency in human neonatal keratinocytes transduced with only OCT4 and KLF4 (Li
et al., 2009c). In a follow-up study, Sheng Ding and colleagues found PS48, an allosteric activa-
tor of 3’-phosphoinositide-dependent kinase-1 (PDK1), combined with sodium butyrate (NaB,
a histone deacetylase inhibitor) to enhance the efficiency of iPSC generation from two factor-
transduced (OCT4 and KLF4) neonatal human keratinocytes (Zhu et al., 2010). In addition
to that, they were able to establish a protocol based on chemical treatments including NaB,
PS48, A-83-01 (another TGFβ/Activin A/Nodal receptor inhibitor) and PD0325901 as well
as CHIR99021 and Parnate over defined periods of time to reprogram neonatal human ker-
atinocytes, adult human keratinocytes and other human somatic cells by transduction of only
one reprogramming factor—OCT4 (Zhu et al., 2010). Likewise, Yu et al. (2011) enhanced episo-
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mal reprogramming efficiency using a cocktail containing A-83-01, PD0325901, CHIR99021,
ROCK inhibitor HA-100 and human leukemia inhibitory factor (hLIF). Zhao et al. (2008)
reported 100-fold increased reprogramming efficiency by adding two additional factors, UTF1
and an siRNA against the gene TP53, which encodes the tumor suppressor protein p53, to the
OSKM mix of reprogramming factors. Subsequently, a series of five reports was published in
Nature, volume 460, highlighting that direct or indirect down-regulation of p53 enhanced cel-
lular reprogramming events in mouse and human somatic cells (Hong et al., 2009; Kawamura
et al., 2009; Li et al., 2009b; Marion et al., 2009; Utikal et al., 2009b). Accordingly, we could
also show that the transient down-regulation of p53 is likely to be one of the mechanisms
leading to an increased efficiency of inducing pluripotency in fibroblast cells following the
above mentioned, combined treatment with VPA and 8-Br-cAMP (Wang and Adjaye, 2011).
As the identification of other molecules supporting cellular reprogramming requires in-
sight into the mechanisms underlying cellular reprogramming, the quest for eligible small
molecule cocktails continues as the field advances. In this respect, the development of drug-
inducible lentiviral vectors which allow reproducible generation of homogeneous, so-called
‘secondary’ human iPSCs (reprogramming of somatic cells to iPSCs, differentiation of these
iPSCs to somatic cells, 2nd round of reprogramming of the iPSC-derived somatic cells) with
100-fold higher efficiency when compared to first round iPSC generation should prove use-
ful for studies of kinetics and mechanisms underlying cellular reprogramming as well as for
screening the potential of small molecules in increasing reprogramming efficiency (Maherali
et al., 2008; Hockemeyer et al., 2008).
As a result of all the efforts that have been made in the iPSC field, a variety of more or less
terminally differentiated human cell types have been reprogrammed to an embryonic-like state
besides the original publications based on fetal, neonatal and adult human fibroblasts as well
as fibroblast-like synoviocytes from synovial tissue (Takahashi et al., 2007; Yu et al., 2007). As
partly mentioned above, these include, for instance, lung fibroblasts (Haase et al., 2009), neona-
tal and adult keratinocytes (Aasen et al., 2008; Li et al., 2009c; Zhu et al., 2010), melanocytes
(Utikal et al., 2009a), human umbilical vein endothelial cells (Zhu et al., 2010), cord blood-
derived cells (Haase et al., 2009; Chou et al., 2011; Yu et al., 2011) and adult peripheral blood
cells (Loh et al., 2009; Chou et al., 2011; Kunisato et al., 2011), cells derived from adipose tissue
(Sun et al., 2009; Esteban et al., 2010; Miyoshi et al., 2011; Yu et al., 2011), pancreatic islet β
cells (Bar-Nur et al., 2011), hepatocytes (Ohi et al., 2011), retinal-pigmented cells (Hu et al.,
2010b) and fetal neural stem cells (Medvedev et al., 2011). Besides the advances in refining repro-
gramming techniques, the development of feeder-free and xeno-free iPSC derivation strategies
further drive potential clinical applications of human iPSCs forward (Rodríguez-Pizà et al.,
2010; Ross et al., 2010; Sugii et al., 2010; Yu et al., 2011).
In view of the rapid recent progress that has been made within the last four years it can
be assumed that, from a technical point of view, genetically unimpaired human iPSCs could
soon be generated with high efficiency. However, as mentioned above, an in-depth biological
understanding of the reprogramming process itself and the properties of human iPSCs are re-
quired before human iPSCs could actually find their way into the clinics. Consequently, basic
Chapter 1. Introduction 21
research with respect to human iPSCs and ESCs, as an essential reference, the gold standard of
human PSCs, will need to be perpetuated.
1.3 Human amniotic fluid cells
Human amniotic fluid cells (AFCs) are obtained from the amniotic cavity of a developing
fetus in a procedure called amniocentesis. During folding of the embryo, the amniotic cav-
ity successively encloses the entire embryo. It fills with fluid and fills out and fuses with the
chorion by 4 to 8 weeks of gestation (Figure 1.5 (A)). Initially, fluid is transported across the
amniotic membrane. At later stages of gestation fetal urine contributes to the composition of
amniotic fluid as well. As blood plasma, human amniotic fluid comprises metabolic byprod-
ucts, yet, additionally it contains cells of fetal origin, putatively shed from different tissues
such as skin, the urogenital, respiratory and digestive systems as well as cells from the amnion
depending on the gestational age and potential fetal pathologies (Hoehn and Salk, 1982; Prusa
and Hengstschlager, 2002; Schoenwolf et al., 2008). Amniocentesis is one of four main tech-
niques used in prenatal pediatrics (Schoenwolf et al., 2008). It is normally performed during
14 to 16 weeks of gestation (Figure 1.5 (B)) to detect, for instance, chromosomal aberrations or
infections and to evaluate lung maturity amongst others by examining the cells, metabolites
or other constituents of the fluid withdrawn (Schoenwolf et al., 2008).
1.3.1 Biological characteristics of human AFCs
Although the isolation of human AFCs for prenatal diagnostic purposes can be traced back
to the year 1956 (Sachs et al., 1956), considerably little has initially been published on the
biological features of these cells. Only within the last two decades molecular biology-based
studies have revealed remarkable features of human AFCs. In 1999, for instance, activity of the
telomere-elongating enzyme telomerase, an essential prerequisite for human ESC self-renewal,
was detected in young AFCs, yet, with decreasing activity in aged AFCs (Mosquera et al., 1999).
Likewise, the presence of cells exhibiting certain human ESC features, including expression of
the key pluripotency-associated transcription factor OCT4, among bulk primary AFCs has
been reported (Prusa et al., 2003; Karlmark et al., 2005). Due to the heterogeneity of AFCs and
varying selection procedures during in vitro cell culture, some of the more recently published
data are different from previous findings. In ’t Anker et al. (2003), for example, demonstrated
the existence of mesenchymal stem cells (MSCs), a certain adult stem cell type, within the
amniotic fluid. De Coppi et al. (2007) confirmed several earlier findings to some extent by
highlighting that clonal amniotic fluid cell lines are capable of self-renewal for about 250 pas-
sages in vitro, express some embryonic but also adult stem cell markers and have the potential
to differentiate into functional derivatives of all three embryonic germ layers in vitro. For
this reason, they describe human AFCs as broadly multipotent. Likewise, Kim et al. (2007)
stated that some of the AFCs have stem cell-like immunophenotypes and expression profiles.
They also suggest these cells also to have multi-lineage differentiation potential, however, they
refer to these cells as ‘pluripotent stem cells’. The same group reported senescence of their
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Figure 1.5: Expansion of the amniotic cavity and amniocentesis. (A) The rapidly expanding
amniotic cavity fills with fluid and obliterates the chorionic cavity between weeks four to
eight (B) Schematic illustration of amniocentesis. Guided by ultrasound the amniotic cavity
is punctured and a volume of approximately fifteen to twenty milliliters of amniotic fluid is
withdrawn for down-stream analysis. Modified from Schoenwolf et al. (2008).
human amniotic fluid-derived stem cells after about 27 passages in vitro which proves against
true self-renewal capacities and, hence, pluripotency of these cells. Aside from that, Iacovitti
et al. (2008). could not generate functional dopamine neurons from AFCs in vitro or after
transplantation in vivo. Furthermore, AFCs have not been shown to induce teratomas to date
(De Coppi et al., 2007; Li et al., 2009a; You et al., 2009) suggesting that these cells are not truly
pluripotent.
As the composition of the amniotic fluid samples varies between different individuals and
depending on the gestational age at the time of isolation (Prusa and Hengstschlager, 2002), a
thorough biological characterization of human AFCs is rather impossible. However, further
studies are required to integrate the existing data and to decipher the existence of distinct
subpopulations of stem cell-like cells within human amniotic fluid.
1.3.2 The potential of human AFCs in regenerative medicine
With respect to potential application of human AFCs, multipotent properties (Chiavegato
et al., 2007; De Coppi et al., 2007; Wang et al., 2008; Ditadi et al., 2009) and potential immune-
privileged characteristics of particular subpopulations of AFCs (Fauza, 2004; Walther et al.,
2009) support the notion that amniotic fluid is a suitable source of fetal stem cells with po-
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tential use in regenerative medicine, especially in fetal tissue engineering approaches (Fauza,
2004). However, the relatively early onset of senescence in bulk primary cultures of human
AFCs (Wolfrum et al., 2010; Kim et al., 2007) impedes their application in clinical settings.
Moreover, as the capacity of AFCs to form specialized cell types and to contribute to the for-
mation of certain tissues or organs in vitro and in xenotransplantation experiments in vivo is
a subject of debate (Chiavegato et al., 2007; Cipriani et al., 2007; De Coppi et al., 2007; Perin
et al., 2007; Carraro et al., 2008; Iacovitti et al., 2008; Trovato et al., 2009; Gekas et al., 2010;
Yeh et al., 2010), the differentiation potential of human AFCs generally seems to be restricted
when compared with human PSCs, thus, further limiting feasible applications.
1.4 Aim of this work
Driven by the intention to provide a more detailed understanding of the molecular-biological
characteristics of putatively clinically relevant human iPSCs, we sought to exploit the stem
cell-like characteristics of distinct human AFC subpopulations in order to mediate efficient
cellular reprogramming even without genetic modification of the target cells. As a result of
re-setting the developmental clock in human AFCs, their limited proliferation and differenti-
ation potential should be enhanced to the levels of PSCs. Furthermore, the establishment of
viral and non-viral-derived human iPSCs from the same donor cells would allow for compar-
ative studies of human iPSCs with identical genetic background with respect to the effects of
viral integrations on self-renewal and pluripotent differentiation potential.
• Hence, this PhD thesis first aimed at inducing pluripotency in human AFCs using the ro-
bust protocol of retroviral overexpression of the reprogramming factors OCT4, SOX2,
KLF4 and c-MYC.
– To putatively enhance the efficiency of this process, stem cell-like subpopulations
should be sorted from bulk primary AFCs and used as target cells for cellular
reprogramming.
– The generation of amniotic fluid-derived iPSCs should be followed by an in-depth
characterization.
– Furthermore, the resulting human iPSCs should be used to study the role of a
recently identified pluripotency-associated gene, USP44, including human ESCs as
a reference.
• Subsequently, this project was designed to reprogram the original stem cell-like subpopu-
lations of human AFCs using alternative, non-integrating techniques, followed, in turn,




Auxiliary samples of human AFCs obtained during routine amniocentesis after written in-
formed consent were kindly donated by Prof. Dr. Wegner and PD Dr. Stumm (Zentrum
für Pränataldiagnostik, Kudamm-199, Berlin, Germany) and passed on by the laboratory of
Prof. Dr. Sperling, Institute of Human Genetics, Charité - Universitätsmedizin Berlin. Utiliza-
tion of these cells was approved by the ethics commission of the Charité Universitätsmedizin
Berlin.
2.2 In vitro cell culture conditions
All procedures involving mammalian cell culture were carried out under aseptic conditions on
laminar flow clean benches (HERAsafe HSP12, Heraeus, Thermo Fischer Scientific, Waltham,
MA, USA). Cells were incubated in a humidified 5 % CO2 / 95 % air atmosphere at 37
◦C
(Innova CO-170 Incubator, New Brunswick Scientific, Edison, NJ, USA).
2.2.1 Maintenance of non-pluripotent human cell lines
Human AFCs were obtained as aliquots of frozen cells at approximately passage 2 (P2). For
the initial culture period (up to P5) AFCs were grown in AmnioMAX-C100 (Invitrogen/Life
Technologies, Grand Island, NY, USA). Subsequently, AFCs were cultured in what is hence-
forth referred to as ‘DeCoppi medium’ (De Coppi et al., 2007) (Section A.1). Human foreskin
fibroblasts (HFF1 and BJ, SCRC-1041 and CRL-2522 from ATCC, respectively) as well as
HEK293 (CRL-1573, ATCC) and Phoenix amphotropic 293 cells (PA cells, SD-3443, ATCC)
were maintained in DMEM (Gibco/Life Technologies) containing 10 % fetal bovine serum
(FBS, Biochrom, Berlin, Germany). Growth media were replaced every 2 to 3 d. All cell lines
were routinely passaged when 80-90 % confluent. To this end, cells were washed twice with
PBS devoid of Ca2+ and Mg2+ and treated with 2 ml 0.05 % Trypsin/EDTA (Gibco) per T75
culture flask (TPP, Trasadingen, Switzerland) for 5 min at 37 ◦C. Tryptic activity was termi-
nated by the addition of at least one volume fresh medium containing FBS. Cells were further
detached from the flask by pipetting and collected, followed by 5 min centrifugation at 300× g.
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The supernatant was completely aspirated, the cell pellet was resuspended in complete optimal
medium and re-plated at ratios of 1:3 to 1:6.
2.2.1.1 Cryopreservation and thawing of non-pluripotent human celllines
To cryopreserve non-pluripotent human cell lines, cell monolayers were harvested by 0.05 %
Trypsin/EDTA-treatment as during routine passaging. Cell pellets were then resuspended in
cold freezing medium (Section A.1), dispensed into a suitable number of freezing vials (TPP)
and kept in a pre-cooled (at 4 ◦C) freezing container (‘Mr. Frosty’, Nalgene/Thermo Fischer
Scientific) at −80 ◦C ON to ensure a cooling rate of −1 ◦C/min. The following day, vials of
frozen cells were transferred into liquid nitrogen for long-term storage.
To recover frozen cells, the desired number of vials were thawed quickly in a 37 ◦C water
bath until only a few ice crystals remained. The cell suspension was then immediately trans-
ferred into 10 ml of the respective warm growth medium drop-wise. After mixing, cells were
pelleted by centrifugation at 300× g for 5 min, resuspended in fresh complete optimal medium
and seeded with respect to suitable splitting ratios.
2.2.2 Human PSC culture conditions
To exploit the full potential of human ESCs or iPSCs it is crucial to maintain their undif-
ferentiated state even during long-term culture in vitro. Ever since human ESCs were first
established (Thomson et al., 1998), mouse embryonic fibroblasts (MEFs) have been widely
used due to their highly efficient support of the undifferentiated growth of human pluripotent
stem cells (PSCs). Thus, human PSCs cultured in the course of this PhD project were usually
maintained and expanded on a layer of mitotically-inactivated MEFs, especially after thawing.
However, human PSCs were switched to feeder-free conditions prior to performing experi-
ments to assess human PSC characteristics. The protocol of human PSCs culture described
herein combines methods adapted from several published protocols (Thomson et al., 1998; Xu
et al., 2001; Du and Zhang, 2010) and applies to the culture of H1 and H9 (WiCell Research
Institute, Madison, WI, USA) human ESCs on one hand and AFiPSCs, which were derived in
the course of this PhD project, on the other hand.
2.2.2.1 Isolation and maintenance of MEFs
MEF isolation from pregnant CF-1 mice (Harlan Laboratories, Indianapolis, IN, USA) was
performed following the detailed protocol, which is currently being published by our labo-
ratory (Jozefczuk et al.). Freshly isolated MEFs were grown in MEF medium (Section A.1),
which was replaced 1 d post-isolation and every other day henceforth. At 80-90 % confluency,
P0 cells were either frozen or expanded for a maximum of four to five passages. Before the
onset of senescence MEFs were mitotically inactivated and utilized as feeder cells to support
the undifferentiated growth of human PSCs either as a basal cell layer in a co-culture system
or in the form of MEF-conditioned medium (CM).
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2.2.2.2 Passaging, cryopreservation and thawing of MEFs
To split MEF cultures, MEFs were trypsinized as described above for non-pluripotent human
cell lines. During the early passages MEFs were re-plated at ratios of up to 1:6. However, the
splitting ratio was reduced to 1:2 or 1:3 after P3. To cryopreserve MEFs, the cell pellet ob-
tained by the passaging procedure was resuspended with cold freezing medium (Section A.1)
and divided into a suitable number of freezing vials (TPP, e.g. half of the cells of a T150 flask
per vial). As described before, these aliquots were kept at−80 ◦C ON before being transferred
to liquid nitrogen.
Thawing of MEFs was carried out as described for non-pluripotent human cell lines.
2.2.2.3 Mitotic inactivation of MEFs and plating for downstream ap-plications
Mitotic inactivation of MEFs by mitomycin C-treatment was carried out following the de-
tailed protocol, which is currently being published by our laboratory (Jozefczuk et al.).
If used as a feeder cell layer, freshly inactivated MEFs or frozen feeder cells were plated onto
Matrigel-coated 6-well plates (TPP, for Matrigel preparations and coating of labware refer to
Section A.1) at a density of 0.2× 106 or 0.23× 106 cells per well, respectively, in MEF medium
the day before needed for human PSC culture.
If to be used for preparing CM, freshly inactivated MEFs are seeded into T150 cell culture
flasks coated with 0.2 % gelatine (from bovine skin, Sigma, autoclaved, 0.2 µm filter-sterilized)
for a minimum of 1 h at a density of 56,000 cells / cm2 and incubated for 24 h at 37 ◦C before
the production of MEF-CM was initiated.
2.2.2.4 Preparation of MEF-CM
Preparation of MEF-CM was carried out following the detailed protocol, which is currently
being published by our laboratory (Jozefczuk et al.). FGF2 (4 ng/ml, Peprotech, Rocky Hill,
NJ, USA) was added directly before its utilization for culturing human PSCs.
During the second half of this PhD project, MEF isolation, culture, inactivation and prepara-
tion of CM were done by Elisabeth Socha, the technical assistant of the laboratory.
2.2.2.5 Feeder-dependent maintenance of human PSCs
One day after plating feeder cells onto Matrigel-coated 6-well cell culture plates they were
washed three times with Ca2+/Mg2+-free PBS. Next, unconditioned human ESC medium
(UM) supplemented with FGF2 was added to the wells and human ESCs or AFiPSCs were
seeded onto these feeder cells. Nutrient-depleted medium was replaced daily.
Once the human PSC colonies took up 80-90 % of the well and contacted each other
(normally within 7 to 10 d), human PSCs were passaged by a combination of enzymatic and
mechanical splitting techniques and re-seeded at a ratio of up to 1:4. To this end, the culture
plates were taken to a semi-open clean bench (HERAguard HPH9, Heraeus, Thermo Fischer
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Scientific Inc.) with a stereomicroscope (MZ9.5, LEICA, Vashaw Scientific Inc.) placed in it.
There, the majority of spontaneously differentiated cells (readily identifiable due to the for-
mation of less compact colonies with irregular shapes and stronger light scattering properties
when compared to human PSCs) were manually removed from the cultures using sterile 10 to
20 µl pipet tips (SafeSeal-Tips, Biozym, Hessisch Oldendorf, Germany). Back at the laminar
flow cabinet, floating cell aggregates were aspirated, 1 ml Collagenase IV (Roche, 1 mg/ml in
UM, 0.2 µm filter-sterilized) added per well of a 6-well cell culture plate (6-well) and the cells
were incubated at 37 ◦C for 20 to 30 min. During this time the feeder cells detached from the
plate and the edges of human PSC colonies curled up. Following this incubation the colonies
were completely dislodged from the plate using a sterile cell lifter (TPP) and carefully collected
in a 15 ml tube (Corning). The human PSC colonies settled down within a few minutes. At
this point the supernatant was aspirated and the cells were washed with 3 to 4 ml of fresh UM.
Washing was repeated two more times. Meanwhile human PSC colonies were dissociated by
pipetting the clumps up and down approximately three times. Following the last washing step,
the supernatant was aspirated once more, fresh UM was added to the cells and the cell suspen-
sion was transferred into an appropriate number of Matrigel-coated wells prepared with feeder
cells as described above. During the entire period of manipulation and splitting the human
PSCs were kept at 37 ◦C from time to time to ensure sufficient warming of the cells.
2.2.2.6 Feeder-free maintenance of human PSCs
Under feeder-free conditions human PSCs were maintained on 6-well cell culture dishes pre-
coated with Matrigel (Growth factor reduced, BD, Section A.1) in MEF-CM or commercially
available chemically defined human ESC media, e.g. N2B27 (Invitrogen) or mTeSR1 (STEM-
CELL Technologies, Vancouver, BC, Canada) as indicated. Medium was changed daily until
the colonies become 80-90 % confluent.
Splitting of human PSCs in feeder-free conditions was done as follows: First, spontaneously
differentiated human PSC colonies were manually removed as described above. The remaining
human PSC colonies were cut into equally large squares using a BD Microlance 3 injection nee-
dle (ca. 19 G, BD). Next, the medium including floating cell clusters was aspirated and the cells
were washed with Ca2+/Mg2+-free PBS once before 1 ml of Dispase solution (Gibco, 5 mg/ml
in Knockout DMEM, 0.2 µm sterile-filtered) was added to each well. The plate was incubated
at 37 ◦C for 3 to 4 min until the edges of the colony pieces lifted up while the centers of the
cell clusters remained attached to the plate. At this point the cells were gently washed three
times with UM to remove any residual Dispase. Subsequently, the human PSC aggregates were
completely detached from the bottom of the cell culture dish using a cell lifter, collected in
15 ml tubes and pelleted by centrifugation at 200× g for 15 s. The resulting pellet was gently
resuspended in pre-warmed, fresh CM (or defined medium) and dispensed into Matrigel-coated
plates at a ratio of up to 1:4. During the entire period of manipulation and splitting human
PSCs were kept at 37 ◦C from time to time to ensure sufficient warming of the cells.
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2.2.2.7 Cryopreservation and thawing of human PSCs
To cryopreserve human PSCs, they were split according to the appropriate one of the two
above described methods. Fragments of human PSC colonies were slightly larger than those
obtained during routine passaging procedures to warrant high cell viability after thawing.
Human PSC colony pieces were resuspended in human PSC freezing medium (Section A.1),
aliquoted into freezing vials and immediately kept at−80 ◦C in a pre-cooled freezing container
before being transferred to liquid nitrogen the next day.
Human PSCs were quickly thawed in a 37 ◦C water bath. Immediately afterwards, the
colonies were transferred drop-wise into 10 ml of warm UM, followed by centrifugation for
15 s at 200× g. The medium, containing DMSO, was completely aspirated and fresh UM added
to dispense the colonies into the appropriate amount of Matrigel-coated wells prepared with
a layer of mouse feeder cells washed and covered with UM. It could take up to two weeks for
colonies to emerge and grow. Until colonies were ready to be passaged, UM was exchanged
daily and, if necessary, switched to CM after 10 days (once the mitotically-inactivated feeder
cells were exhausted).
2.3 Basic molecular biology methods
2.3.1 RNA isolation
For comparative gene expression analysis ESCs and AFiPSCs were adapted to feeder-free cul-
ture conditions in mTeSR1 (Stemcell Technologies, Vancouver, BC, Canada). All other cell
lines were maintained in their respective growth medium.
Total RNA was isolated from cell lysates using the RNeasy Mini Kit (Qiagen, German-
town, MD, USA) according to the manufacturer’s instructions. Cells were either directly lysed
on the cell culture plate or trypsinized, pelleted by centrifugation and subsequently lysed us-
ing the lysis buffer RLT provided by the manufacturer including β-mercaptoethanol (Sigmal,
10 µl per 1 ml buffer); all samples of one experiment were treated as equal. The optional on
column DNase I-treatment was included in the isolation procedure.
2.3.2 Measuring RNA concentration and assessing RNA integrity
Concentrations of the resulting RNA eluates were determined by UV spectrophotometric
measurements using the NanoDrop (NanoDrop Technologies, Wilmington, DE, USA) at
260 nm. RNA quality was assessed by measurements at 280 nm/260 nm and 260 nm/230 nm
(both ratios must be > 1.8). 1 % agarose (Roth, Karlsruhe, Germany) gel electrophoresis of
total RNA had to reveal a 2:1 ratio of sharp 28 S vs. 18 S ribosomal RNA bands without appar-
ent smears especially at low molecular weights. In a few cases, the Agilent RNA 6000 Nano
Kit (Agilent, Santa Clara, CA, USA) was employed to assess RNA quality.
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2.3.3 cDNA synthesis
For M-MLV (Affymetrix/USB Corporation, Cleveland, OH, USA)-driven reverse transcrip-
tion 1 to 1.5 µg RNA, but equal amounts for all samples to be compared, were diluted to 9.5 µl
with RNase/DNase-free distilled water (Gibco). cDNA synthesis was primed by oligo-dT an-
nealing to the poly A-tail of the mRNAs. To this end, 0.5 µl oligo-dT (1 µg/µl, 15mer) were
added, the mixture was incubated at 72 ◦C for 5 min and cooled down on ice. Meanwhile, a
reverse transcription master mix was prepared as follows (per reaction):
RNase/DNase-free dH2O (Gibco) 9.4 µl
5 X M-MLV reaction buffer (USB) 5.0 µl
dATP, dCTP, dGTP, dTTP mix (25 mM each, USB) 0.5 µl
M-MLV (USB) 0.1 µl
15 µl of this master mix were added to each RNA/oligo-dT sample, followed by incubation
at 42 ◦C for 1 h and inactivation of the enzyme at 65 ◦C for 10 min. The resulting cDNA was
kept at 4 ◦C for direct use or stored at −20 ◦C.
2.3.4 Quantitative real-time polymerase chain reaction (qRT-PCR)and data analyses
Small scale gene expression studies were based on qRT-PCR. All primer sequences are provided
in Table A.3. For each target gene (and a house keeping gene (ACTB, GAPDH ) as endogenous
control for normalization) technical triplicates of all samples were amplified; an additional
triplicate served as negative control (no template control, NTC). Target gene-specific reaction
master mixes were prepared as follows (per reaction):
ddH2O 2 µl
fwd/rev primer mix (5 µM each) 1 µl
SYBR Green PCR Master Mix (Applied Biosystems) 3 µl
For each reaction, 6 µl of this mix were pipetted into one well of an ABI PRISM 384-Well Op-
tical Reaction Plate (Applied Biosystems) and 2 µl of 1:8 to 1:12-diluted M-MLV-synthesized
cDNA template were added. The PCR was performed on the ABI 7900HT Fast Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA) using the default PCR cycle proto-
col (Section A.3). Dissociation curve analysis was included at the end of each PCR cycle.
Data analysis was carried out using the ABI PRISM SDS 2.2.1 software (Applied Biosys-
tems) and Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). Housekeeping
gene-normalized, relative mRNA levels of each gene were calculated based on the 2−∆∆CT
Method (Livak and Schmittgen, 2001). Data are presented as mean LOG2 ratios with respect
to biological controls and standard deviation.
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2.3.5 Illumina bead chip hybridization and data analyses
Global gene expression analysis was carried out on the Illumina microarray platform. For each
sample, 500 ng quality-checked total RNA were used as input for the amplification and biotin
labeling reactions (Illumina TotalPrep RNA Amplification Kit, Ambion, Austin, TX, USA),
which precede bead chip hybridizations. Briefly, the mRNA present in the samples was used
as template to generate first and second strand cDNA. After degradation of all RNAs, this
cDNA, in turn, served as template to synthesize biotinylated antisense RNA copies (cRNA)
of the original mRNA. Purified cRNA was hybridized to Illumina HumanRef-8 v3 Expres-
sion BeadChips (Illumina, San Diego, CA, USA) on the Illumina Beadstation 500 platform
followed by washing and blocking of the samples, staining with streptavidin-Cy3 and quantita-
tive detection of the resulting fluorescent array image. RNA preparations and hybridizations
were carried out by Aydah Sabah and Claudia Vogelgesang of the Illumina Microarray Core
Facility of the Max Planck Institute for Molecular Genetics.
The resulting gene expression data were background subtracted and normalized on the
basis of the ‘rank invariant’ algorithm of the Gene Expression Module version 1.8.0 pro-
vided with the GenomeStudio software (formerly BeadStudio, Illumina). An arbitrary cut-off
value was set to eliminate negative gene expression signals, which may have resulted from
background subtraction. GenomeStudio calculates a ‘Detection p-value’ for every gene by
comparing its signal intensity with that of negative control beads to determine the probability
that this gene is expressed. For the generation of Venn Diagrams and to carry out correlation
coefficient analyses, the normalized data sets were filtered for genes present in either sample or
in at least one of the samples under investigation (‘Detection p-value’/pdet < 0.01). Differential
gene expression was computed using the ‘Illumina Custom Model’ (Kuhn et al., 2004). Result-
ing ‘Diff p-values’ (p-value, describing the probability that a gene’s signal intensity has changed
between two samples or groups of samples) were adjusted by the Benjamini and Hochberg false
discovery rate (FDR) correction algorithm (Benjamini and Hochberg, 1995). To be considered
differentially expressed, genes had to be at least 1.5 fold up- or down-regulated between the
samples of interest and the corresponding FDR-adjusted ‘Diff p-value’ had to be padj < 0.05.
Functional annotation and enrichment analyses were performed using the DAVID plat-
form version 6.7 (http://david.abcc.ncifcrf.gov/home.jsp) (Dennis et al., 2003; Huang da et al.,
2009). Illumina ProbeIDs or official gene symbols were used as input against the background
of Homo sapiens; analyses were executed based on DAVID default parameter settings. Graph-
ical representation of the transcriptome data with respect to distinct cellular processes was
achieved through the KEGG database (Kanehisa and Goto, 2000). The AmiGO Browser ver-
sion 1.7 of the Gene Ontology database (http://www.geneontology.org) (Ashburner et al.,
2000) was utilized in addition to the publication by Vaziri et al. (Vaziri et al., 2010) to derive
the list of human senescence-associated genes. Interferon-regulated genes were identified with
the help of the Interferome database (Samarajiwa et al., 2009). Heatmaps were either created
using the MultiExperiment Viewer software (MeV v4.4.1, http://www.tm4.org/mev/) (Saeed
et al., 2003, 2006) or the gplots package (Warnes et al., 2010) in R (http://www.r-project.org/)
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(R Development Core Team, 2010).
2.3.6 DNA isolation
Cells were harvested by trypsinization and genomic DNA was isolated from the cell pellets
using the PureLinkTM Genomic DNA Mini Kit (Invitrogen) according to the manufacturer’s
guidelines. Subsequently, DNA concentration and quality was assessed by NanoDrop mea-
surements as described for RNA samples before.
2.3.7 Immunofluorescent protein labeling
To assess the expression of proteins, cells were fixed in 4 % PBS (Calbiochem/Merck, Darm-
stadt, Germany)-buffered paraformaldehyde (PFA, Electron Microscopy Sciences, Hatfield,
PA, USA) for 12 min at RT, while shaking, followed by two washes with 0.05 % Tween 20
(Sigma) in PBS (PBST) and permeabilization with 1 % Triton X-100 (Sigma) diluted in PBS.
Cells were washed again twice and blocked in a solution containing 5 % FBS and 1 % bovine
serum albumin (BSA, Sigma) in PBST for 1 h at RT. Incubation with the primary antibody was
carried out for 1 h at RT. The list of primary and secondary antibodies and the respective di-
lutions used are provided in Table A.1. Prior to and following the 1 h incubation period with
the secondary antibody, cells were washed five times with PBST, 5 min each. Counterstain-
ing of cell nuclei was achieved by incubation with 100 ng/ml 4’,6-diamidino-2-phenylindole
(DAPI, Vector Laboratories, Burlingame, CA, USA) in PBST for 12 min at RT. Finally, cells
were washed thoroughly with PBST.
All stainings were visualized and images were acquired using the confocal microscope LSM
510 Meta (Carl Zeiss, Oberkochen, Germany) in combination with the AxioVision V4.6.3.0
software (Zeiss). Processing of images was done with the help of AxioVision and Adobe Pho-
toshop CS version 8.0 (Adobe, Munich, Germany).
2.3.8 Plasmid DNA amplification
All plasmids used in the course of this PhD project are listed in Table A.2. If purchased as
purified plasmids, DNA constructs were first transformed into competent Escherichia coli
(E.coli) JM109 by means of heat shock and glycerol stocks were established as described in
Section A.2. Plasmid-carrying bacteria were selectively expanded in growth medium, includ-
ing adequate antibiotics (Table A.2), and amplified plasmids were purified by application of
the NucleoBond Xtra Maxi EF Kit (MACHEREY-NAGEL, Düren, Germany). Plasmid yield
was determined by NanoDrop measurements; plasmid integrity was assessed by 1.5 % agarose
gel electrophoresis. The identity of most plasmids was confirmed by a diagnostic restriction
digest. To this end, 10 to 20 U restriction enzyme (Table A.2) were incubated with 5 µg puri-
fied plasmid DNA in a total volume of 25 µl at 37 ◦C ON, followed by resolution on a 1.5 %
agarose gel.
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2.4 Experimental set-ups
2.4.1 Quantification and sorting of stem cell like sub-populations fromamniotic fluid by fluorescence-activated cell sorting (FACS)
To quantify and sort the stem cell-like cell population present in samples of bulk AFCs by
FACS, cells were harvested by Accutase-treatment (Millipore, Bilerica, MA, USA), washed
with Ca2+/Mg2+-free PBS and resuspended in 0.5 % FBS in Ca2+/Mg2+-free PBS at a density
of 1× 106 cells per 100 µl. 5 µl APC-conjugated anti-CD117 antibody solution (Invitrogen,
CD11705) was added per 100 µl of cell suspension and incubated for 1 h at 4 ◦C. Next, cells
were washed with approximately 2 ml 0.5 % FBS in Ca2+/Mg2+-free PBS, pelleted by centrifu-
gation at 200× g for 4 min, followed by two additional washes. Finally, stained AFCs were
resuspended in 100 to 200 µl FACSFlow (BD Biosciences), filtered using a 70 µm cell strainer
(BD Falcon), analyzed and sorted at the BD FACSAria II flow cytometry cell sorter (BD Bio-
sciences).
2.4.2 Sorting of stem cell like sub-populations from amniotic fluid bymagnetic activated cell sorting (MACS)
To sort the stem cell-like cell population present in samples of bulk AFCs by MACS, cells
were harvested by Accutase-treatment (and additional Trypsin-treatment if necessary). For the
actual sorting procedure, the human CD117 MicroBead Kit (Miltenyi Biotec, Bergisch Glad-
bach, Germany) was used with the following modifications: Any centrifugation steps were
carried out at 200× g for 4 min. AFCs were passed through a 70 µm cell strainer prior to the
incubation with blocking reagent and before the cell suspension was applied onto the column.
Incubation with the MicroBeads was done in the refrigerator and the cells were shaken every
10 min during this incubation period.
2.4.3 Cellular reprogramming by means of retroviral transduction
2.4.3.1 Production of reprogramming factor-encoding retroviruses
PA cells, which are stably transfected HEK cells encoding the viral gag, pol and env genes re-
quired for retroviral particle formation, were seeded onto 0.2 % gelatin-coated T75 cell culture
flasks (7.5× 6 cells/flask) and grown for 16 h. The cells in each flask were then transfected with
one of the retroviral pMX vectors encoding either POU5F1 (OCT4), SOX2, KLF4 or c-MYC
or the pLIB-GFP vector using the FuGENE HD transfection reagent (Roche, Basel, Switzer-
land) as follows: 12 µg transfer vector were gently mixed with 1 ml OptiMEM (Gibco) and
30 µl FuGENE HD transfection reagent and incubated for 15 min at RT in the dark. Mean-
while, medium of PA cells was replaced by 9 ml of fresh medium. Next, the complex of DNA/
transfection reagent was added to the PA cells drop-wise while the flask was gently swirled to
mix. The PA cells were incubated for 14 to 16 h at 37 ◦C before the medium was replaced by
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fresh medium. The virus-containing supernatant was harvested 48 and 72 h post-transfection,
passed through a 0.45 µm syringe driven filter unit (Millipore) and kept at 4 ◦C.
2.4.3.2 Determination of the retroviral titer
30,000 HFF1 cells were seeded into one well of a 24-well plate. The following day triplicates
of 1, 10 and 100 µl of GFP retrovirus containing supernatant were added to 0.5 ml medium
supplemented with 4 µg/ml polybrene (hexadimethrine bromide, Sigma-Aldrich, Munich,
Germany). The plate was centrifuged at 800× g for 99 min (Centrifuge 5810R, Eppendorf,
Hamburg, Germany). Afterwards, the infectious medium was replaced by fresh medium. 48 h
post-transduction medium was aspirated, the cells were washed with PBS and fixed in 4 % PFA
in PBS for 12 min at RT. Cell nuclei were counterstained using 100 ng/ml DAPI in PBS. Fluo-
rescence was observed using the confocal microscope LSM 510 Meta. The average number of
transducing units per milliliter viral supernatant (TU/ml) was calculated from GFP-positive




(Total number of cells per image) × (Cells seeded per well)× F
where F = 1000 µl ÷ (Volume of viral supernatant added to the corresponding well in µl).
2.4.3.3 Retrovirus-mediated iPSC generation
For the generation of AFiPSCs, 180,000 AFCs (line 101, P5) in one well of a 6-well culture
plate were transduced with a 1:1:1:1 cocktail of the OCT4, SOX2, KLF4 and c-MYC retrovirus-
containing media supplemented with 4 µg/ml polybrene on days 1 and 2 after plating. Based
on the retroviral titer calculations each viral supernatant was calculated to contain a number of
transducing viral units equivalent to 1.25 or 2.5 times the number of plated cells (multiplicity
of infection, MOI= 1.25 or 2.5). Each time, directly after the addition of retroviruses, the en-
tire plates were centrifuged at 800× g for 99 min before replacement of the infectious medium
by fresh medium. On d3, the infected cells were plated onto mitotically inactivated MEFs on
Matrigel-coated dishes in DMEM/10 % FBS. Another 24 h later, the medium was switched to
UM for a total period of 10 d, with replacement on alternate days. Afterwards, the infected
cells were grown in CM, which was also changed at an interval of 2 d. AFiPSC colonies were
manually picked at a stereomicroscope using sterile pipette tips 24 d post-transduction and
expanded under the previously described human PSC conditions.
The generation of FiPSCs from HFF1 and BJ human foreskin fibroblasts used for the
comparative transcriptome analysis has been described (Prigione et al., 2010, 2011b).
2.4.4 AFiPSC characterization
2.4.4.1 Cellular senescence and alkaline phosphatase staining
The Senescence β-Galactosidase Staining Kit (Cell Signaling, Danvers, MA, USA,) was em-
ployed according to the manufacturer’s instructions to stain senescent cells.
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To detect activation of the early pluripotency marker, alkaline phosphatase (AP), the Al-
kaline Phosphatase Detection Kit (Millipore, Billerica, MA, USA) was applied to all manually
picked AFiPSC lines following the manufacturer’s guidelines.
Brightfield and phase contrast images were acquired and analyzed using the LSM510 Meta
microscope.
2.4.4.2 DNA fingerprinting
To amplify genomic regions containing highly variable numbers of tandem tetranucleotide
repeats by polymerase chain reaction the primer pairs D7S796, D10S1214 and D21S2055 (Ta-
ble A.3) (Park et al., 2008) were used. The exact PCR reaction protocol can be found in
Section A.3. The resulting DNA fragments were resolved on a 3 % agarose gel in SB buffer
(Section A.3) at 150 V to portray the cell line-specific band patterns.
2.4.4.3 Karyotyping
To detect potential karyotypic abnormalities in AFiPSC lines 4, 5, 6, and 41, which may have
resulted from the retroviral interference during the process of direct reprogramming, chromo-
somal analysis was performed after GTG-banding at the Human Genetic Center of Berlin. For
each line, 25 metaphases were counted and 10 karyograms analyzed.
2.4.4.4 In vitro and in vivo diﬀerentiation of AFiPSCs
For in vitro differentiation, embryoid body (EB) formation of AFiPSC lines 4, 5 and 41 was
induced in ESC medium lacking FGF2 supplementation by the hanging-drop method (Cer-
dan et al., 2007). After 2 to 3 d, EBs were placed into Ultra Low Attachment Culture Dishes
(Corning). One week later, EBs were plated onto gelatin-coated dishes, allowed to differentiate
for 10 to 14 additional days and then fixed and stained according to the immunofluorescent
protein labeling procedure.
The in vivo differentiation experiments (teratoma formation) were performed by EPO-
Berlin GmbH (Germany, http://www.epo-berlin.de). Briefly, two aliquots of approximately
2× 106 cells of the AFiPSC lines 4 and 41 was collected by combined type IV collagenase-
treatment and 0.05 % Trypsin/EDTA-treatment and washed. Cells were resuspended in Ma-
trigel and immediately injected subcutaneously into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
mice, commonly known as NOD scid gamma (NSG). Mice bearing teratomas were carefully
monitored and sacrificed 63 d after injection. The teratomas were collected and processed by
means of standard procedures for paraffin embedding and hematoxylin and eosin staining.
Histological analysis was performed by a pathologist.
2.4.4.5 Trophoblast diﬀerentiation of AFiPSCs
To induce differentiation into the trophoblast lineage, AFiPSC lines 5 and 41 were trans-
ferred onto Matrigel-coated cell culture dishes after splitting and grown in CM until they
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attained 30 to 50 % confluency. At this point, medium was changed to defined N2B27 medium
lacking FGF2 but supplemented with either 100 ng/ml BMP2 (PeproTech) or BMP4 (R&D
Systems, Minneapolis, MN, USA) for 5 d or a combination of 10 ng/ml BMP4 and 10 µM
SB431542 (Sigma-Aldrich) for 7 d. Undifferentiated controls were maintained in N2B27 in-
cluding 20 ng/ml bFGF instead. After 5 d or 7 d, including daily replacement of media, cells
were harvested for RNA isolation or fixed for immunofluorescence microscopy analysis. For
qRT-PCR analysis of BMP2- or BMP4-induced trophoblast differentiation of AFiPSCs, pla-
cental RNA (Clontech, Mountain View, CA, USA) was used as a positive control.
2.4.5 shRNA-mediated USP44 knock down in human PSCs
2.4.5.1 Production of lentiviral particles
To produce lentiviruses encoding shRNAs against USP44, HEK293 cells were co-transfected
with a combination of the desired transfer vector and compatible, commercially purchased
packaging plasmids (MISSION Lentiviral Packaging Mix, Sigma) as follows: 0.8× 106 HEK293
cells were seeded per T25 cell culture flask (TPP) approximately 24 h prior to transfection. On
the day of transfection 110 µl OptiMEM were mixed with 10 µl MISSION Lentiviral Packaging
Mix, 4 µg of the shRNA-encoding transfer vector or a turboGFP(TGFP)-encoding control vec-
tor (SHC003, Sigma, Table A.2) and 10 µl of FuGENE HD, followed by 15 min incubation at
RT. This transfection cocktail was added drop-wise to the cell culture dish containing 3.3 ml of
DMEM/10 % FBS, while the flask was gently swirled to mix. 18 h later, medium was aspirated,
the cells were washed with PBS and 3.3 ml of UM added to the flask. 48 h post-transfection
the lentivirus-containing supernatant was harvested and replaced by 3.3 ml of fresh UM. The
second harvest was done 72 h post-transfection. Both samples of viral medium were pooled
and filtered using a 0.45 µm syringe-driven filter unit. Half of the virus containing medium was
kept at 4 ◦C for direct use, whereas the volume of other half was filled up to 30 ml with PBS
and centrifuged at 72,000× g and 4 ◦C for 2 h (Beckman L7-65 Ultracentrifuge L7, Beckman
Coulter, Brea, CA, USA). The viral pellet was re-suspended in 120 µl sterile Ca2+/Mg2+-free
PBS containing 1 % BSA, aliquoted and stored at −80 ◦C.
2.4.5.2 Lentiviral test transductions
The efficiency of lentivirus was determined by transducing HFF1 and HEK293T cells with
series of 10, 50 and 100 µl of fresh as well as 2, 4 and 10 µl of frozen TGFP-encoding lentiviral
supernatants in 0.5 ml DMEM/10 %FBS supplemented with 4 µg/ml polybrene per 24-well.
The infected cells were centrifuged on cell culture plates at 800× g for 99 min and the virus
incubated ON before the infectious medium was replaced by fresh growth medium. Cells were
analyzed by microscopy analysis 72 h post-transduction.
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2.4.5.3 Lentiviral transduction of human PSCs
Lentiviral transductions of the human ESC line H1 and AFiPSCs maintained in feeder-free
conditions were based on the protocol of Du and Zhang (2010) including parts of the MIS-
SION RNAi ‘hESC Transduction Protocol’ from Sigma (originally from Dr. J Moore, A.
Toro-Ramos and Dr. R. Cohen, Stem Cell Research Center, Rutgers University, Piscataway,
NJ, USA) and modifications as follows: Briefly, human PSCs were incubated with 10 µM
ROCK inhibitor (Y-27632, Cayman Europe, Tallinn, Estonia) in CM at 37 ◦C 1 h prior to dis-
sociation of the colonies to single cells with TrypLE Select (Gibco), and pelleting of the cells by
centrifugation at 200× g for 4 min. Single cells equivalent to one 12-well were re-suspended in
500 µl CM including polybrene (4 µg/ml) and incubated with 200 µl freshly prepared shRNA-
or TGFP-encoding lentiviral supernatant for 2 h at 37 ◦C (an exact MOI cannot be stated in
this case, as the exact number of human PSCs cannot accurately be determined). The volume
of virus-containing medium was then increased to plate the cells onto Matrigel-coated cell
culture plates. Incubation continued ON, including 10 µM ROCK inhibitor and 2 µM thiazo-
vivin (Stemgent), followed by replacement of the viral medium with fresh complete medium.
In subsequent lentiviral transduction experiments this protocol was modified step-wise:
• The amount of fresh viral supernatant varied from100 to 250 µl per 12-well of human
PSCs to transduce;
• Incubation was pro-longed to 3 h;
• Dissociation of human PSCs into small colony fragments using the Dispase-splitting
procedure prior to lentiviral transduction;
• Direct lentiviral transduction of non-dissociated human PSCs;
• Centrifugation of non-dissociated human PSCs at 811× g for 99 min during the lentivi-
ral incubation period.
2.4.5.4 Transfection of lentiviral plasmids
In addition to the lentiviral transduction approach, human PSCs were subjected to transfec-
tions of the same TGFP and shRNA lentiviral plasmids or two additional reporter constructs
encoding OCT4 promoter-driven enhanced GFP (OCT4-EGFP, kindly provided by Dr. Wei
Cui, Department of Gene Expression and Development, Roslin Institute, Roslin, Midlothian,
UK, described in Gerrard et al. (2005), Table A.2) or a CMV promoter-driven GFP (maxGFP
encoded by the pmaxGFP vector, provided with the VPE-1001 Human MSC Nucleofector
Kit (Amaxa/Lonza, Basel, Switzerland). Referring to the transduction experiments, human
PSCs were also either transfected as non-dissociated colonies (regular transfection) or as single
cells in suspension (reverse transfection after TrypLE Select or Accutase-treatment, includ-
ing 10 µM ROCK inhibitor and/or 2 µM thiazovivin incubation as indicated). Transfections
were carried out using the FuGENE HD and the Lipofectamine 2000 (Invitrogen) transfection
reagents according to the manufacturers’ instructions. The exact amounts of plasmid DNA
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and transfection reagent in OptiMEM used per 12-well will be stated in the results section.
Incubation of the DNA/transfection reagent complex was either carried out in defined N2B27
medium devoid of antibiotics ON or in OptiMEM followed by replacement with N2B27
medium following two hours incubation as indicated.
2.4.6 Cellular reprogramming by means of episomal plasmid nucleo-fection
Direct reprogramming of different lines of AFCs (P5-P10) by episomal plasmid nucleofection
was conducted on the basis of the protocol published by Yu et al. (2009) which was adapted to
meet the conditions of the VPE-1001 Human MSC Nucleofector Kit (Lonza, Basel, Switzer-
land). For each nucleofection sample, the most potential combinations of episomal plasmids
(Yu et al., 2009) were mixed in 1.5 ml reaction tubes (Sarstedt, Nümbrecht, Germany) as fol-
lows:
Combination 3.19 ‘ET2K’ ‘EN2K’ ‘M2L’
µg per 1.0× 106 cells per nucleofection 3.00 3.00 2.00
µg per 0.5× 106 cells per nucleofection 1.50 1.50 1.00
µg per 0.4× 106 cells per nucleofection 1.20 1.20 0.80
Combination 4.4 ‘6F EN2L’ ‘ET2K’
µg per 1.0× 106 cells per nucleofection 7.30 3.20
µg per 0.5× 106 cells per nucleofection 3.65 1.60
µg per 0.4× 106 cells per nucleofection 2.92 1.28
Combination 4.6 ‘4F EN2L’ ‘ET2K’ ‘EM2K’
µg per 1.0× 106 cells per nucleofection 4.20 3.20 4.60
µg per 0.5× 106 cells per nucleofection 2.10 1.60 2.30
µg per 0.4× 106 cells per nucleofection 1.68 1.28 1.84
100 µl cell suspension, prepared to contain 0.4 or 0.5× 106 cells in Human MSC Nucleofector
Solution, was added to the mixture of plasmid DNA, thoroughly mixed and electroporated
using the nucleofector programs C-17 and U-23. The cells of one nucleofection sample were
seeded into 2 to 5 wells of a 6-well plate, which had been pre-coated with Matrigel and con-
tained a layer of MEF feeder cells, and maintained in DeCoppi medium for the following 3
to 4 d. At this point medium was switched to UM either free of further supplements or con-
taining 0.25 mM β-aminopropionitrile (BAPN, Sigma) or 2 µM thiazovivin for an unlimited
period of time or a combination of 2 µM thiazovivin, 2 µM SB431542 and 0.5 µM PD0325901
(Stemgent) for five days. 10 d later, AFCs were maintained in CM with or without treatment
until human ESC-like colonies emerged, which could be picked. 2 µg per 0.5× 106 nucleo-
fected cells of the pmaxGFP vector provided with the nucleofection kit was used as positive
control (equivalent to the amount of ‘M2L’ in combination 3.19).
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2.4.7 Cellular reprogramming by means of mRNA transfection
2.4.7.1 In vitro mRNA synthesis
The five plasmids each encoding one of the reprogramming factor genes (POU5F1, SOX2,
KLF4, c-MYC or Lin28A, Addgene, Table A.2) and a GFP-encoding plasmid (pGEM4Z-EGFP-
A64, kindly provided by Prof. Dr. E. Gilboa, Duke University Medical Center, Durham, NC,
USA, previously described by Nair et al. (1998), Table A.2) were purified using columns and
buffers provided with the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) to serve
as template for a T7-driven in vitro transcription (IVT) producing the respective mRNAs. To
this end, approximately 12 µg plasmid were first linearized using 40 U of the restriction en-
zyme Xba I (all of the OSKM-encoding plasmids) or 20 U Spe I (GFP-encoding plasmid) in
40 µl total reaction volume at 37 ◦C ON and then column-purified again. The linearized DNA
was in vitro transcribed using the mMessage mMachine T7 Kit (Ambion) according to the man-
ufacturer’s instructions to synthesize capped mRNA. The template DNA was then degraded
by TURBO DNase. Next, poly(A) tails were added to the mRNAs using the poly(A) tailing
kit provided by Ambion. Because the GFP-encoding plasmid contained a poly(T) sequence
at the end of the coding sequence the produced GFP mRNA already contained a poly(A) tail
after the IVT and, thus, was not included in the tailing reaction. All mRNAs were precipitated
by incubation with LiCl at −20 ◦C for 2 h, pelleted by centrifugation at 18000× g and 4 ◦C
for 15 min and then washed with 70 % ethanol before repeated centrifugation. Finally, the
mRNA pellets were resuspended in 20 µl nuclease-free water (Ambion) and quantified by Nan-
oDrop measurement. RNasin Plus RNase Inhibitor (1 U/mg, Promega, Madison, WI, USA)
was added to each of the mRNA stock solution prior to aliquoting and storage at −80 ◦C.
The in vitro synthesis of mRNA was carried out by our collaboration partner Geertrui Tav-
ernier from the Research Group on Nanomedicines at Ghent University, Ghent, Belgium.
Predictions of the minimum free energy secondary structures of the reprogramming factor-
encoding mRNAs were obtained from the RNAfold WebServer at http://rna.tbi.univie.ac.at/
cgi-bin/RNAfold.cgi (Gruber et al., 2008). The FASTA format files for each of the mRNA
sequences of POU5F1 (NM_002701.4), SOX2 (NM_003106.3), KLF4 (NM_004235.4), c-MYC
(NM_002467.4) and LIN28A (NM_024674.4) provided by the National Center for Biotech-
nology Information (NCBI, http://www.ncbi.nlm.nih.gov/) were used as input. The queries
were run based on default parameter settings.
2.4.7.2 General mRNA transfection procedure
HFF1, BJ or AFCs were seeded into 6-well plates at a density of approximately 180,000 cells/
well the day before transfection. Cells were transfected with a total of 4 µg mRNA per 6-well.
For distinct applications, such as FACS and microscopic analysis, cells were seeded into 12
and 24-well plates instead. In these cases, the number of cells and amount of mRNAs to be
transfected was scaled down accordingly. The mRNAs were either synthesized as herein de-
scribed or commercially purchased as modified mRNAs from Stemgent (San Diego, CA, USA).
GFP-encoding mRNA was used as positive control. mRNA concentrations were adjusted to
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1 µg/µl with water and the required cocktails were mixed. Next, those 4 µg to be transfected
were pre-diluted with 46 µl OptiMEM and complexed with 4µl Lipofectamine RNAiMAX
(Invitrogen), which had been pre-diluted in 46 µl OptiMEM simultaneously. The transfection
mixture was incubated for 10 min at RT. Ad interim, medium was aspirated from the relevant
wells. Following the incubation the RNA/Lipofectamine complex was further diluted with
900 µl OptiMEM and incubated with the cells at 37 ◦C. After 2 h, the transfection solution
was replaced by fresh growth medium. Cells were harvested for RNA isolation, subjected to
FACS analysis or fixed for immunofluorescence staining at indicated time points.
All HFF1 and BJ mRNA transfection experiments were conducted in close cooperation with
Geertrui Tavernier.
2.4.7.3 Quantification of GFP expression followingmRNA transfection
HFF1 cells were plated in 12-well plates (90,000 cells /well) and transfected with 2 µg of GFP-
encoding mRNA per well as described above. To assess the number of GFP-positive cells,
culture medium was removed from the wells and the cells were washed with PBS. Images
were taken 24 post-transfection with a confocal microscope LSM 510 (Zeiss, Oberkochen,
Germany). Alternatively, the cells were detached with trypsin (0.05%, Life Technologies), cen-
trifuged (340× g for 4 min) and re-suspended in 100-200 µl FACSFlow (BD Biosciences). The
samples were kept on ice until GFP expression was evaluated by a Beckman Coulter Flow
Cytometer FC500 (BD Biosciences), equipped with a 488 nm laser.
These assays were performed with the aid of Geertrui Tavernier.
2.4.7.4 Detection of OSKML protein expression following mRNA trans-fection
HFF1 cells were plated in 24-well plates (45,000 cells /well) and transfected with 1 µg of
mRNAs encoding one of the reprogramming factors (OSKML) or with a 1:1:1:1:1 cocktail
of the same mRNAs per well as described above. Following transfection, cells were fixed and
reprogramming factor protein expression assessed by the above described immunofluorescent
protein labeling procedure at indicated time points.
These stainings were performed with the aid of Geertrui Tavernier.
2.4.7.5 mRNA-mediated iPSC generation
To attempt direct reprogramming by delivery of reprogramming factor-encoding mRNAs,
AFCs, and for optimization of the protocol also HFF1 or BJ cells, were transfected up to nine
times daily or on alternate days with a total of 4 µg per 6-well of an mRNA cocktail composed
of
Mix 1: 1:1:1:1 POU5F1, SOX2, KLF4 and c-MYC-mRNA,
Mix 2: 1:1:1:1:1 POU5F1, SOX2, KLF4, c-MYC and LIN28A-mRNA or
Mix 3: 3:2:1:1:1 POU5F1, SOX2, KLF4, c-MYC and LIN28A-mRNA
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on a layer of MEF feeder cells or, alternatively, without a layer of feeder MEF feeder cells.
Following the last transfection, cells were passaged onto layers of MEF feeder cells in Matrigel-
coated 6-well plates. Medium was then switched from DC medium or DMEM/10 %FBS to
UM for a period of 10 d before the cells were maintained in CM. Alternatively, transfections
were carried out on Matrigel-coated plates in NutriStem XF/FF Culture Medium (Stemgent).
Cells were monitored for morphological changes towards human ESC-like colonies. Medium
was replaced every other day. If indicated, treatments of the cells with one or combinations of
chemical substances were included in the post-transfection culture period as follows:
• 2 µM SB431542
• 0.5 µM PD0325901
• 500 µM ethyl 3,4-dihydroxybenzoate (EDHB) (Sigma)
• 2 µM thiazovivin
As a control, HFF1 cells mRNA-mediated reprogramming was conducted according to the
Stemgent protocol using the modified mRNAs (Stemgent mRNA Reprogramming Factors
Set: hOSKML, Cat. No. 00-0067) and medium (Stemgent Pluriton mRNA Reprogramming
Medium, Cat. No. 00-0070) provided, yet including the following modifications: HFF1 fore-
skin fibroblasts were employed as target cells for reprogramming. HFF1 cells were also mi-
totically inactivated to serve as feeder cells. Per transfection and 6-well of cells at suggested
densities, 25 µl of the mRNA cocktail containing OSKML mRNAs at the recommended ra-
tio were diluted in 25 µl OptiMEM and mixed with 2 µl LF RNAiMAX pre-diluted with
48 µl OptiMEM. The resulting 100 µl transfection solution were incubated for 10 min, sub-
sequently further diluted with 900 µl OptiMEM and added to the cells after removal of the
growth medium. After 2 h of incubation the transfection mix was substituted by the appropri-
ate equilibrated growth medium. B18R treatments were not performed.
2.4.7.6 Determination of cell viability following mRNA transfections
HFF1 cells were plated in 12-well plates (90,000 cells /well) and transfected daily with 2 µg of
a 1:1:1:1 cocktail of in vitro synthesized mRNAs encoding the reprogramming factors OSKM
as described above. Cell viability was evaluated 24 h after each transfection by an MTT assay
(Roche, Vilvoorde, Belgium) performed according to the manufacturer’s instructions.
This cytotoxicity assay was carried out by our collaboration partner Geertrui Tavernier.
2.4.7.7 Analysis of the immune response to diﬀerent cellular repro-gramming approaches
Approximately 180,000 HFF1 cells were plated per 6-well and maintained in DMEM/10 %
FBS for 24 h. As described for AFCs in the context of cellular reprogramming above, HFF1
cells were
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• transfected once or twice with ‘Mix 1’ of the mRNA reprogramming factor cocktails or
the equivalent total amount of GFP-encoding mRNA;
• infected once with a 1:1:1:1 cocktail of retroviruses encoding four reprogramming fac-
tors (OSKM) or a GFP-encoding retrovirus equivalent to the amount of a single repro-
gramming factor (no change of infectious medium until cell harvest);
• transfected once with a 1:1:1:1:1 cocktail of hsa-miR-302a, hsa-miR-302b, hsa-miR-302c,
hsa-miR-302d and hsa-miR-367 mimics (100 pmol total, Ambion) or the equivalent total
amount of a non-target (scrambled) miRNA (Ambion).
All cells were harvested 24 h post-transduction/transfection for RNA isolation and the regula-
tion of immune response-associated genes was assessed by qRT-PCR.
To determine the immunemodulatory effect of different substances following OSKM
mRNA transfection, cells were pre-incubated with these substances 1 h prior to transfection,
during the incubation of the complexed mRNA with the cells and 24 h post-transfection at
the following concentrations:
• 200 ng/ml B18R (eBioscience/biocompare)
• 5, 50 and 100 µM chloroquine (Sigma)
• 50, 100 and 500 nM trichostatin A (Sigma)
• 20 µM pepinh-TRIF (InvivoGen, San Diego, CA, USA)
• 20 µM pepinh-MYD (InvivoGen)
2.4.8 Cellular reprogramming by means of miRNA transfection
For reprogramming attempts by miRNA transfection, two recently published protocols (An-
okye-Danso et al., 2011; Miyoshi et al., 2011) were combined as follows: Per 6-well to be
transfected, 7.5 µl LF RNAiMAX were diluted in 250 µl OptiMEM. At the same time a
1:1:1:1:1 cocktail of hsa-miR-302a, hsa-miR-302b, hsa-miR-302c, hsa-miR-302d and hsa-miR-367
mimics (100 pmol total, Ambion) was diluted in 250 µl OptiMEM. The miRNA mix was added
to the transfection reagent solution, gently mixed and incubated at RT for 30 min. Thereafter,
the complexed miRNAs were transferred into the 6-wells containing approximately 200,000
AFCs each in 1.5 ml fresh DC medium lacking antibiotics. Four subsequent transfections were
carried out (d1, d4, d6, d8 after plating at d0) before AFCs were passaged onto layers of MEF
feeder cells in Matrigel-coated 6-well plates and maintained in UM, supplemented with 2 µM
thiazovivin. To monitor the morphology of cells further, medium was switched to MEF-CM
containing 2 µM thiazovivin after 10 d.
3
Virus-mediated generation of amnioticfluid-derived iPSCs
3.1 Introduction
In the first part of this project, distinct subpopulations of human amniotic fluid cells (AFCs)
will be sorted and used as starting material to render efficient cellular reprogramming possible.
Implementation of the originally published retrovirus-mediated reprogramming protocol by
Yamanaka et al. (Takahashi et al., 2007) should further enable reliable induction of pluripo-
tency in human AFCs. Once amniotic fluid-derived induced pluripotent stem cells (AFiPSCs)
are established these will be characterized in depth using the parental cells and human embry-
onic stem cells (ESCs) as references to monitor the de-differentiation and verify their potential
to self-renew and the complete induction of pluripotency. The newly generated AFiPSCs will
subsequently be utilized together with human ESCs to investigate the role of the pluripotency-
associated gene USP44 in maintaining self-renewal.
3.2 Results
3.2.1 Expansion and senescence of primary human AFCs
One of the major limitations of primary cell lines is their relatively early arrest of proliferation
when compared to ESCs, cancer or transformed cell lines. This phenomenon is commonly
known as replicative or cellular senescence (Hayflick and Moorhead, 1961; Hayflick, 1965)
and was associated with the lacking ability of somatic cells to maintain full telomere length
throughout the life cycle when compared to immortal cells (Mishiev et al., 1979; Allsopp et al.,
1992; Counter et al., 1994). Primary human AFCs, maintained and expanded for the purpose
of this PhD project, senesced at a maximum of 17 passages (P17) (Wolfrum et al., 2010). At this
stage, AFCs stopped dividing and senescence was further indicated by their enlarged, flattened
morphology and verified by positive staining for the senescence-associated beta-galactosidase
(Figure 3.1) (Wolfrum et al., 2010).
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Figure 3.1: Morphology of early passage and senescent bulk primary AFCs. (A) Early passage,
proliferative human AFCs (line 101, P5). (B, C) The same line of AFCs after proliferation
arrested at P17; the morphology of senescent AFCs is depicted without and with staining for
the senescence-associated beta-galactosidase, respectively. Taken from Wolfrum et al. (2010).
3.2.2 Quantification and sorting stem cell-like subpopulations frombulk primary human AFCs by FACS
Bulk AFCs contain subpopulations of cells that possess stem cell-like properties, such as
CD117-positive cells (De Coppi et al., 2007). We hypothesized that the use of these stem
cell-like cells as target cells for cellular reprogramming experiments would be inherently more
efficient compared to routinely employed fibroblast cells. To test this hypothesis we sought to
enrich stem cell-like sub-populations from bulk AFC samples for subsequent reprogramming
experiments. Accordingly, CD117-expressing AFCs were detected by immunofluorescent la-
beling for flow cytometric quantification and sorting of bulk AFCs. This revealed about 3 %
CD117-positive cells within bulk primary AFCs, which is comparable to the previously re-
ported 1 % (De Coppi et al., 2007) Figure 3.2. However, sorting of this subpopulation from
bulk AFC samples was not successful as the staining and sorting procedure severely affected
the cellular integrity of generally very large and seemingly fragile AFCs. This resulted in an
extremely low yield of intact, sorted cells, which could not be sufficiently re-expanded for
cellular reprogramming attempts before the onset of cellular senescence.
3.2.3 Sorting stem cell-like subpopulations from bulk primary humanAFCs by MACS
Magnetic activated cell sorting (MACS), which entails labeling of cell surface markers by spe-
cific antibodies coupled with magnetic beads and sorting of the cells in a magnetic field, was
employed as potentially less harmful, alternative technique to sort stem cell-like cells of bulk
AFCs. The outcome of this sorting approach, however, was comparable to that obtained by
FACS. Sorting, for example, of as many as 18.3× 106 cells at P9 resulted in approximately 1.6 %
CD117-posititve cells (2.9× 105 cells). However, only 1.3× 105 of these were intact as deter-
mined by the trypan blue exclusion method. Of these, in turn, only a limited number of cells
were able to attach. Based on their morphology, these cells appeared to be stressed Figure 3.3
and after protracted re-expansion, no CD117-expression was detectable by immunofluores-
cence microscopy in this subpopulation when applying the same anti human CD117 antibody
as used for FACS quantification and sorting. In this instance, the CD117-positive fraction was
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Figure 3.2: FACS-based quantification of the CD117-positive subpopulation in bulk primary
AFCs. CD117-positive cells in bulk primary AFCs (line 101, P15) were labeled by an APC-
conjugated antibody prior to FACS analysis. Results are given as average, n= 2.
Figure 3.3: Morphology of human AFCs prior to and following MACS of CD117-postive
cells. Upper panel: Unsorted human AFCs (line 101, P9) prior to CD117 MACS (left) and the
resulting CD117-positive fraction one day after plating (P10, right). Lower panel: The same
CD117-positive subpopulation after steady re-expansion, prior to repeated sorting at P13 (left)
and the resulting CD117-positive fraction one day after plating (P14, right).
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repeatedly sorted (3.5× 106 AFCs at P13), which yielded approximately 2.7 % CD117-positive
cells, 1.1× 104 of which were intact. Plating of these cells revealed extensive cell debris and an
even smaller fraction of cells attached Figure 3.3. In conclusion, none of the singularly nor
re-sorted CD117-positive subpopulations fully recovered before the onset of senescence. As a
result of this, a subpopulation of AFCs with confirmed stem cell-like characteristics eligible
for reprogramming could not be established by MACS.
3.2.4 Cellular reprogramming of human AFCs by means of retroviraltransduction
As sorting of stem cell-like sub-populations from AFC samples was not practicable, we sought
to derive iPSCs from bulk AFCs instead assuming that stem cell-like cells within the hetero-
geneous mixture of cells would facilitate efficient cellular reprogramming in any case. To this
end, we employed the original, robust protocol published by Takahashi et al. (2007).
3.2.4.1 Retroviral particle production
Retroviral vectors, like most other plasmids used in the course of this PhD project, were ampli-
fied, extracted and identified by restriction digest using adequate enzymes (Table A.2) followed
by gel electrophoresis as shown in Figure 3.4 (A). Retroviruses encoding either the reprogram-
ming factors OCT4, SOX2, KLF4, c-MYC (OSKM) or GFP were produced upon transfection
of these vectors into packaging Phoenix amphotropic (PA) cells (Figure 3.4 (B)). The viral titer
was determined using the GFP retrovirus as a reporter (Figure 3.4 (C)).
3.2.4.2 Retrovirus-mediated iPSC generation
The retroviruses were then utilized to deliver a 1:1:1:1 cocktail of the reprogramming factors
OSKM into bulk primary AFCs (line 101) of a proliferative phase (P5). Subsequently, trans-
duced AFCs were maintained under human ESC conditions (Takahashi et al., 2007). Putative
AFiPSC aggregates appeared about seven days post-transduction (Figure 3.5 (A)), which was
approximately two weeks earlier than what we and others observed for fibroblast-derived iP-
SCs (Takahashi et al., 2007; Prigione et al., 2010; Wolfrum et al., 2010). Unlike the parental
cells, mature AFiPSCs exhibited high nucleus/cytoplasm ratios, grew as sharp edged, densely
packed colonies (Figure 3.5 (B, C)) and were indistinguishable from human ESCs (lines H1
or H9) in terms of morphology (Figure 3.5 (D)) and proliferation rate (Wolfrum et al., 2010).
Approximately 45 putative AFiPSC colonies resulting from reprogramming of approximately
0.4× 106 AFCs according to the protocol outlined in the Material and Methods section were
initially picked (equivalent to ≈ 0.011 %). Of these, five clonal AFiPSC lines were expanded
for a minimum of 25 passages and characterized. Two of the AFiPSC lines underwent the
complete set of characterization assays (Wolfrum et al., 2010).
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Figure 3.4: Preparation of retroviruses for cellular reprogramming. (A) Gel electrophoresis of
reprogramming factor-encoding plasmids after amplification, extraction and restriction digest
using suitable restriction enzymes. The numbers at the bottom indicate the size of the expected
DNA fragments. (B) Packaging PA cells 18 h after transfection of the GFP-encoding transfer
vector. (C) Representative fluorescent images, which were used to determine the number of
transducing units per milliliter retroviral supernatant. HFF1 cells were transduced with serial
dilutions of the GFP-encoding retrovirus, fixed and cell nuclei counterstained with DAPI to
quantify the number of total cells and the number of GFP-positive cells in each sample.
3.2.4.3 Characterization of AFiPSCs
Human iPSCs closely resemble human ESCs, the gold standard of human pluripotent stem
cells (PSCs), with respect to morphology and self-renewal. To verify pluripotency, iPSCs have
to pass a number of tests (Maherali and Hochedlinger, 2008). Besides the demonstration of
their genetic origin from the parental cell line and karyotypic stability post-transduction of
integrating retroviruses, these assays are mainly aimed at highlighting the expression of ESC-
specific both intracellular and cell surface markers and the pluripotent differentiation potential,
i.e. the ability of iPSCs to differentiate into derivatives of all three embryonic germ layers (Ma-
herali and Hochedlinger, 2008). To this end, spontaneous differentiation is initiated, as done
for human ESCs, by so-called embryoid body formation in vitro (Itskovitz-Eldor et al., 2000)
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Figure 3.5: Morphology of early and mature AFiPSC and human ESC colonies. (A) Image of
one of the first putative AF-derived iPSC aggregates as they appeared approximately seven days
post-retroviral transduction of the parental AFC line. (B) Mature, undifferentiated AFiPSC
colony. Scale bar= 400µm. (C) Typical morphology of AFiPSC colonies cultivated on a layer
of MEF feeder cells. (D) H1 human ESCs during routine maintenance on a MEF feeder cell
layer. Modified from Wolfrum et al. (2010).
and by injection of iPSCs into immune-compromised mice in vivo (Thomson et al., 1998). The
latter test, the teratoma formation assay, is the most stringent pluripotency test for human iP-
SCs as chimera contribution, germline transmission and tetraploid complementation—routine
assays performed for murine iPSCs—are not feasible in humans (Maherali and Hochedlinger,
2008). We extended this range of standard tests by a trophoblast differentiation assay and
genome-wide gene expression profiling to get a more detailed comparison of the retrovirus-
derived AFiPSCs with human ESCs, H1 and H9, and iPSCs of other somatic cell origin.
DNA Fingerprinting
To verify the origin of the AFiPSCs, genomic DNA was isolated from various cell lines to
amplify genomic regions containing highly variable numbers of tandem tetranucleotide re-
peats (variable number tandem repeats, VNTRs). By separation on an agarose gel variations
of VNTR allele lengths resulted in cell line-specific patterns of amplified genomic DNA and
confirmed genetic relatedness of all five AFiPSC lines to the parental AFC line (Figure 3.6)
(Wolfrum et al., 2010). Simultaneously, contamination of all AFiPSC lines with the human
ESC lines, H1 and H9, could be excluded (Wolfrum et al., 2010).
Karyotypic stability
The retroviruses used to reprogram AFCs are well known to integrate into the host cell
genome inducing mutations which cause unpredictable effects such as tumorigenicity of the
target cells (Takahashi et al., 2007). Furthermore, iPSCs have been shown to harbor different
kinds of mutations and chromosomal aberrations (Mayshar et al., 2010; Pasi et al., 2011; Gore
et al., 2011; Prigione et al., 2011b,a). Hence, AFiPSC lines 4, 5, 10 and 41 were karyotyped
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Figure 3.6: Gel electrophoresis of fingerprinting PCR products. Genomic DNA was isolated
from all samples (ESC lines H1 and H9, different AFiPSC lines, the parental AFC line 101
and MEFs), amplified using PCR primer sets that flank different genomic regions containing
VNTRs (D7S796, D10S1214, D21S2055) and the PCR products resolved on a 3 % agarose gel.
NTC, non-template control. Modified from Wolfrum et al. (2010).
Figure 3.7: AFiPSC karyogram. Different AFiPSC lines were karyotyped but only one repre-
sentative image of the analyses is depicted. mar, minimal altered region.
to ensure the viral transduction did not induce chromosomal abnormalities. This revealed
that all of the tested AFiPSC lines exhibited a normal karyotype several passages after their
generation (Figure 3.7). No minimal altered regions were detected in any sample (Wolfrum
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et al., 2010).
Expression of human ESC markers
The AFiPSC lines were further characterized and their human pluripotent stem cell (PSC)
qualities assessed. Human ESCs, lines H1 and H9, served as a reference throughout the project.
AFiPSCs resembled human ESCs not only in terms of morphology but also with respect to
activation of the early pluripotency marker alkaline phosphatase (AP, Figure 3.8 (A)) and ex-
pression of markers of the undifferentiated ESC state, including OCT4, SOX2, NANOG,
SSEA4, TRA-1-60, TRA-1-81 as determined by immunocytochemistry (Figure 3.8 (B)) (Wol-
frum et al., 2010). Cadherin-1 (CDH1, E-cadherin) expression within AFiPSC colonies verified
the epithelial nature of AFiPSCs, a crucial feature of human ESCs. This was further supported
by the absence of vimentin (VIM), a type III intermediate filament expressed in mesenchymal
cells (Eastham et al., 2007), within the boundaries of AFiPSC colonies. The presence of vi-
mentin at the periphery of the colonies, however, indicated spontaneous differentiation of
AFiPSCs maintained on Matrigel-coated dishes in MEF-CM, a common observation in hu-
man ESC cultures (Zwaka and Thomson, 2005; Xu et al., 2005).
Pluripotency and in vitro and in vivo differentiation
To evaluate the success of cellular reprogramming of human AFCs, pluripotency of AFiPSCs
was assessed in greater detail. First, the expression of several self-renewal and pluripotency-
associated genes (Adewumi et al., 2007; Babaie et al., 2007; Chavez et al., 2009) was analyzed
on the mRNA level employing microarray-based transcriptome-profiling and quantitative real-
time polymerase chain reaction (qRT-PCR). NanoDrop measurements at 260 and 280 nm and
260 and 230 nm and agarose gel electrophoresis were routinely performed quality controls to
ensure integrity of the isolated total RNA whenever gene expression levels were determined in
the course of this PhD project. In a few cases, RNA quality was additionally assessed employ-
ing the technology of Agilent RNA 6000 Nano microfluidic chips. Representative results of
such RNA quality examinations by agarose gel electrophoresis and microfluidic chip analysis
are exemplarily shown in Figure 3.9 (A, B). The presence of sharp 18 S and 28 S ribosomal
RNA bands and peaks with a ratio of intensities of approximately 1:2 is indicative of the iso-
lated RNA being intact. Using such quality-checked total RNA, the majority of self-renewal
and pluripotency-associated genes determined in AFiPSCs in comparison to primary AFCs
was significantly up-regulated as demonstrated by microarray-based transcriptional analysis
(Figure 3.9 (C)) (Wolfrum et al., 2010). qRT-PCR validation, performed for a selection of
these pluripotency-associated genes, confirmed the array-derived data (Figure 3.9 (D)) (Wol-
frum et al., 2010).
Next, embryoid body formation and plating of the resulting aggregates is routinely per-
formed to efficiently differentiate human ESCs into different lineages in vitro (Itskovitz-Eldor
et al., 2000). Another option to assess spontaneous differentiation of human ESCs in vivo
entails their sub-cutaneous injection into immuno-deficient mice. As a result pluripotent cells
differentiate into derivatives representative of all three embryonic germ layers (Thomson et al.,
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Figure 3.8: Detection of human ESC marker expression in AFiPSCs. (A) AF-derived iPSC
lines were stained for AP at P1 and analyzed by light microscopy. (B) The presence of intra-
cellular (OCT4, SOX2, NANOG) and surface ESC markers (SSEA4, TRA-1-60, TRA-1-81,
CDH1) as well as expression of the mesenchymal cell-specific intermediate filament (VIM)
was assessed in AFiPSCs by immunofluorescent labeling. Scale bars= 200µm. Modified from
Wolfrum et al. (2010).
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Figure 3.9: Regulation of pluripotency-associated genes in AFiPSCs. (A) Representative images
of agarose gel electrophoresis and ethidium bromide staining of isolated total RNA samples.
(B) Electropherogram (fluorescence units [FU] over migration time [s]) resulting from the
Agilent RNA 6000 Nano Kit-based assessment of RNA integrity. (C) Heatmap depicting
microarray-derived expression levels of pluripotency-associated genes in human ESC lines
H1 and H9, different AFiPSC lines and the corresponding AFCs. The heatmap is colored by
LOG2 average expression values according to the color key below. Genes, which are signif-
icantly up-regulated in the group of AFiPSCs compared with the parental AFCs are tagged
with asterisks (padj< 0.05 (∗), < 0.01 (∗∗), < 0.001 (∗ ∗ ∗)). (D) qRT-PCR confirmation of the
microarray data. Bars and error bars represent average LOG2 ratios (AFiPSCs or H1 relative
to AFCs, respectively) and SD. n= 3 technical replicates per cell line. Modified from Wolfrum
et al. (2010).
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Figure 3.10: Pluripotent capabilities of AFiPSCs. (A) Upper panel: Embryoid body (EB) for-
mation was induced in AFiPSCs in vitro. EB morphology is depicted in suspension (d10)
and after plating onto gelatinized dishes (d12). Lower panels: The outgrowth of adherent EBs
was analyzed by immunofluorescence-based detection of different germ layer marker proteins
(AFP, α-fetoprotein; SMA, smooth muscle actin; NES, nestin; TUJ1, class III β-tubulin). Scale
bars = 200µm. (B) In vivo teratoma formation of AFiPSCs upon injection into NOD scid
gamma mice. Representative images of histological structures corresponding to endo-, ecto-
and mesodermal lineages are depicted. Taken from Wolfrum et al. (2010).
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1998). When conducted with AFiPSCs both of these assays confirmed pluripotency of the
amniotic fluid-derived iPSCs (Figure 3.10) (Wolfrum et al., 2010). Markers or histological
structures representing endoderm-, mesoderm- and ectoderm-derived lineages were detected
in both assays (Wolfrum et al., 2010).
Trophoblast differentiation
Besides their ability to differentiate into derivatives of the three embryonic germ layers, hu-
man ESCs can also develop into the trophoblast lineage in vitro (Thomson et al., 1998; Xu,
2006; Greber et al., 2008; Schulz et al., 2008; Vallier et al., 2009b). To test if AFiPSCs share
this quality, we stimulated two AFiPSC lines with 100 ng/ml BMP2 or BMP4 for five days.
This induced a morphological change from densely packed ESC-like AFiPSC colonies to-
wards clusters of loosely arranged, enlarged cells with typical cobblestone-like appearance
(Figure 3.11 (A)), a characteristic feature of trophoblast differentiation of human ESCs (Xu,
2006; Schulz et al., 2008). Accordingly, gene expression profiling and qRT-PCR demonstrated
down-regulation of the key pluripotency markers POU5F1 and NANOG and up-regulation
of the trophoblast markers CDX2, KRT7, HAND1, FOXF1, GATA3 and ID2 (Figure 3.11 (B))
(Wolfrum et al., 2010). Treatments with BMP2 and BMP4 induced similar effects, however,
BMP4 was more efficient (Wolfrum et al., 2010). The ultimate hallmark of ESCs differentiating
into the trophoblast lineage is the secretion of human chorionic gonadotropin, hCG, a hor-
mone secreted by trophoblastic cells of the placenta in vivo (Thomson et al., 1998; Xu, 2006).
This protein was detectable by immunofluorescent labeling following treatment of AFiPSCs
with a combination of 10 ng/ml BMP4 and 10µM SB431542 over a period of seven days (Fig-
ure 3.11 (C)) providing further evidence of the ability of AFiPSCs to derive trophoblast cells
(Wolfrum et al., 2010).
Comparative global gene expression analyses of AFCs, AFiPSCs and ESCs
Microarray-based genome-wide gene expression profiling is a high-throughput technology that
facilitates the simultaneous measurement of gene expression levels of thousands of genes in one
sample. As such it is powerful tool to assess a broad range of gene expression changes associated
with distinct treatments of the samples and to demonstrate the correlation of different samples
on mRNA level on a global scale. Transcriptomes of primary AFCs (line 101), the correspond-
ing AFiPSCs and the ESC lines H1 and H9 were profiled employing the Illumina BeadStudio
platform to further investigate their relatedness with regard to global gene expression. Hierar-
chical clustering on the basis of Pearson’s correlation and linear correlation coefficient analysis
of detected gene expression signals revealed distinguishable transcriptomes when AFiPSCs and
their parental AFCs at P6 (average linear R2≈ 0.67) and P17 (average linear R2≈ 0.50) were
analyzed (Figure 3.12 (A, B)) (Wolfrum et al., 2010). In contrast, transcriptomes of AFiPSCs
and ESCs were similar, though not identical (average linear R2≈ 0.94) (Wolfrum et al., 2010).
This analysis was also conducted for replicate samples of HFF1-derived FiPSCs generated
in our laboratory in comparison to the ESC lines H1 and H9 (Prigione et al., 2010). The
resulting average linear correlation coefficient of R2≈ 0.87, in contrast to R2≈ 0.94 for AFiP-
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Figure 3.11: Trophoblast differentiation of AFiPSCs. (A) Changes in AFiPSC morphology
upon treatment with 100 ng/ml BMP2 over five days. Scale bars= 20µm. (B) Bar plot depict-
ing qRT-PCR- and microarray-derived expression changes of pluripotency- and trophoblast-
associated genes upon treatment of AFiPSCs with 100 ng/ml BMP2 or BMP4 for five days.
Bars and error bars represent average LOG2 ratios (BMP-treated AFiPSCs relative to corre-
sponding untreated controls) and SD. Microarray: n= 1, qRT-PCR: n= 3 technical replicates
per line and treatment. (C) Phase contrast and images of immunofluorescently labeled human
chorion gonadotropin (hCG) in AFiPSCs following seven days of treatment with a combina-
tion of 10 ng/ml BMP4 and 10µM SB431542. Scale bars= 100µm. Modified from Wolfrum
et al. (2010).
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Figure 3.12: Comparative transcriptome analysis of human AFCs, AFiPSCs and ESCs, lines
H1 and H9. Total RNA was amplified, labeled and analyzed using the Illumina platform. (A)
Hierarchical clustering by means of Pearson’s correlation after exclusion of all those genes,
which were not expressed in any of the analyzed samples. (B) Table listing linear correlation
coefficients (R2) between indicated samples. (C) Venn diagram summarizing distinct and over-
lapping gene expression in the different samples. Taken from Wolfrum et al. (2010).
SCs versus human ESCs, emphasizing variable gene expression patterns between iPSCs of
different somatic origin (Wolfrum et al., 2010). A Venn diagram highlighted overlapping and
distinct gene expression patterns in AFCs versus AFiPSCs and ESCs (Figure 3.12 (C)). In this
context we identified gene signatures representative of cellular housekeeping functions (6934
genes, e.g., GAPDH, ACTB, PGK1, LDHA), self-renewal and pluripotency (1299 genes, e.g.,
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POU5F1, SOX2, NANOG, LIN28), a donor cell memory (350 genes, e.g., KRT7, RGS7), ESC-
specificity (257 genes, e.g., PRDM14, GSC, WNT3A), donor cell (AFCs)-specificity (665 genes,
e.g., OXTR, HHAT, RGS5, NF2, CD59, TNFSF10, NT5E) and an iPSC (AFiPSC)-specific gene
expression signature (555 genes, e.g., CNTFR, SIX6). The complete gene lists are presented in
Wolfrum et al. (2010), Table S3).
Analysis of a common ESC-like core transcriptional regulatory network in AFiPSCs and
FiPSCs
To narrow down the self-renewal and pluripotency signature gene list obtained from the
Venn diagram comprising the transcriptomes of AFCs, AFiPSCs and ESCs (1299 genes, Fig-
ure 3.12 (C)), we compared the same ESC samples with FiPSCs and their respective parental
fibroblast line HFF1 (Fibs) (Figure 3.13 (A), the entire gene lists are presented in Wolfrum et al.
(2010), Table S5). The HFF1 and FiPSC data sets were independently generated in our lab-
oratory as previously described (Prigione et al., 2010). The resulting, equivalent self-renewal
and pluripotency gene signature, in turn, was utilized to detect the overlap between the two
separate analyses (AFiPSCs/ESCs: 1299 genes in the self-renewal/pluripotency signature, FiP-
SCs/ESCs: 922 genes in the self-renewal/pluripotency signature). This overlap comprised
525 genes, which were expressed in all pluripotent cell types (AFiPSCs, FiPSCs and ESCs),
highlighting their role in maintaining self-renewal and pluripotency (Figure 3.13 (B), the cor-
responding gene list is presented in Wolfrum et al. (2010), Table S6). We sought to gain further
insight into the TRN that induces and maintains pluripotency in AFiPSCs and FiPSCs and to
define distinct functions of the 525 core self-renewal and pluripotency-associated genes of the
undifferentiated pluripotent stem cell state. To this end, we next identified the overlap of these
525 genes with genes, the promoters of which are bound by either OCT4 alone or by OCT4,
SOX2 and NANOG simultaneously as reported for human ESCs by ChIP-on-chip analyses
(Boyer et al., 2005; Jung et al., 2010). This highlighted a subset of pluripotency-associated genes,
which are part of an ESC-specific transcriptional regulatory network, comprising, for exam-
ple, POU5F1, SOX2, NANOG, DPPA4, LEFTY2 and CDH1 (Figure 3.13 (C)) (Wolfrum et al.,
2010). However, this list also contained genes, which are rather known to play essential roles
in differentiation processes of human ESCs such as EOMES or HAND1 (Greber et al., 2008).
Therefore, we sought to clarify and emphasize the role of these heatmap-listed genes. For this
purpose we further combined the heatmap data in Figure 3.13 (C) with gene expression data
derived from siRNA-mediated OCT4 (POU5F1) knock down experiments in ESCs (Babaie
et al., 2007). This resulted in a separation of these genes into three groups: (i) those genes,
which follow the expression behaviour of OCT4 upon loss of pluripotency due to OCT4
knock down, (ii) those genes, which are inversely regulated and (iii) those genes, which are not
significantly affected by the knock down of OCT4 (Figure 3.13 (C)) (Wolfrum et al., 2010).
The LARGE Principle of Cellular Reprogramming
The reprogramming experiment presented herein and other iPSC studies (Marchetto et al.,
2009; Ghosh et al., 2010) demonstrate the conversion of the parental cells’ transcriptome to-
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Figure 3.13: Identification of an overlapping ESC-like core TRN in AFiPSCs and FiPSCs. (A)
Venn diagram summarizing distinct and overlapping global gene expression in HFF1 fibrob-
lasts (Fibs), HFF1-derived iPSCs (FiPSCs) and ESCs (data obtained from Prigione et al. (2010)).
(B) Venn diagram comparing the two self-renewal and pluripotency-associated gene signatures
derived from the two previous Venn diagram analyses (AFCs versus AFiPSCs and ESCs (Fig
R12C); Fibs versus FiPSCs and ESCs (Figure R13A)) to identify a set of core self-renewal and
pluripotency-associated genes. (C) Heatmap depicting microarray-derived LOG2 average gene
expression values of a subset of the 525 core self-renewal and pluripotency-associated genes
(refer to B), the promoters of which have been shown to be bound by either OCT4 alone or
the combination of OCT4, SOX2 and NANOG (OSN, table on the right) as determined by
ChIP-chip analyses (Boyer et al., 2005; Jung et al., 2010). The heatmap is colored according to
the color key below. Genes were clustered with respect to their expression patterns across the
different samples using the Euclidean distance measure. The table on the right also highlights
gene expression changes upon siRNA-mediated OCT4 knock down (OCT4 kd) in ESCs (H1)
including the respective differential expression p-values (p-val) (Babaie et al., 2007). Modified
from Wolfrum et al. (2010).
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wards a distinct ESC-like state, irrespective of the cell source. Throughout this process, the
expression of a subset of genes expressed in the parental cells is Lost (L), whereas the expres-
sion of another group of genes is Acquired (A). Yet, the expression of a third subset of genes,
detectable in the parental cells, is Retained (R) in the corresponding iPSCs. We refer to this
concept as the LARGE (Lost, Acquired, Retained Gene Expression) Principle of Cellular Re-
programming (Figure 3.14 (A)) (Wolfrum et al., 2010). To illustrate the LARGE principle we
utilized transcription factor gene expression data as transcription factors usually affect gene
expression levels of several downstream targets and, thus, are likely to play an essential role
in this concept (Wolfrum et al., 2010). For each of the lost (genes expressed in donor cells,
but not in iPSCs), acquired (genes expressed in iPSCs, but not in the donor cells) and retained
(genes expressed in donor cells and iPSCs simultaneously, excluding genes of the house keeping
gene signature) gene sets derived from the Venn diagram analyses of AFCs/AFiPSCs/ESCs
and Fibs/FiPSCs/ESCs (Figure 3.12 (C) and Figure 3.13 (A), Tables S3 and S5 published in
Wolfrum et al. (2010)), we arbitrarily picked out genes associated with the Gene Ontology
term for transcription factor activity (GO0003700) (Ashburner et al., 2000). Expression data
of those 12 transcription factors with the lowest (Lost), highest (Acquired) or least varying
(Retained) change, when comparing AFiPSCs or FiPSCs with the corresponding parental
cells, were presented in heatmaps (Figure 3.14 (B)) (Wolfrum et al., 2010). This way of illus-
trating the LARGE principle of cellular reprogramming highlights several key findings: For
example, the list of lost genes included, e.g., HOXB7, HOXA9, HOXA10, PAX8, DSCR1 and
MYC, for AFiPSCs and, e.g., EMX2, FOXF2, FOXF1, MYC and KLF4 for FiPSCs (Wolfrum
et al., 2010). The acquired gene expression set can be further divided into two groups on
the basis of present or absent overlaps between the two analyses for AFiPSCs and FiPSCs:
those, which are universally acquired self-renewal genes present in both, AFiPSCs and FiP-
SCs, or, more generally, in all pluripotent iPSCs (e.g., POU5F1, SOX2, NANOG), and those
acquired gene expressions, which are rather iPSC type-dependent (e.g. SIX6, EGR2 (AFiP-
SCs) or PKNOX2, HOXD4, HOXD10 (FiPSCs); DLX5 (AFiPSCs and FiPSCs)) (Wolfrum
et al., 2010). The retained gene expression sets included genes like PKNOX2 (AFiPSCs), HM-
BOX1 and MGA (FiPSCs) or RAXL1 (AFiPSCs and FiPSCs) (Wolfrum et al., 2010). Moreover,
some general aspects were highlighted in Figure 3.14: i. The list of the most (or least) differen-
tially expressed lost, acquired and retained transcription factors overlapped only partly when
comparing AFCs turning into AFiPSCs with fibroblasts developing into FiPSCs. ii. The mag-
nitude of gene expression changes or the stability of gene expression retention of lost, acquired
or retained gene subsets, respectively, was not equal among all clonal AFiPSC lines (e.g., DLX1,
ZNF218, PKNOX2). The same was observed for clonally-derived FiPSC lines (DLX1, NME2).
iii. In many cases, gene expression levels observed for both (the majority of) AFiPSC lines
and FiPSC lines were distinct from those detected in human ESCs H1 and H9 (e.g. LHX2,
DLX5, DLX1, ZNF218 etc. (AFiPSCs) and PRRX1, NFE2, MLLT1, HOXD1, DLX5, DLX1 etc.
(FiPSCs)).
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Figure 3.14: The LARGE Principle of Cellular Reprogramming. (A) Schematic representation
of the LARGE Principle of Cellular Reprogramming. (B) Transcription factor gene expres-
sion data were extracted from the transcriptome data of AFCs, AFiPSCs, ESCs, Fibs and
FiPSCs and ranked according to the most effectively down-regulated (the set of lost genes),
up-regulated (the set of acquired genes) or the least varying (the set of retained genes) gene
expression levels when comparing each donor cell line with the corresponding group of iPSCs.
The heatmap depicts LOG2 average expression values of the top 12 or 24 lost, acquired and
retained genes for each of the donor cell lines, the respective iPSCs and ESCs as a reference.
The heatmap is colored according to the color key below. Significantly up- or down-regulated
gene expression in donor versus iPSCs is indicated by asterisks (padj< 0.05 (∗), < 0.01 (∗∗),
< 0.001 (∗ ∗ ∗)). Taken from Wolfrum et al. (2010).
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Expression of senescence-associated genes in primary AFCs and AFiPSCs
Finally, to investigate if reprogramming by-passes the senescence observed in primary AFC
cultures (Figure 3.1), we analyzed the expression of senescence and telomere-associated genes
in young, proliferating primary AFCs at P6 and senescent AFCs at P17 in comparison to the
corresponding, theoretically indefinitely self-renewing AFiPSC lines around P20. H1 and H9
ESCs (P56, P55, respectively) were included for comparison. To this end we derived a list of
116 senescence-associated genes (Table B.1) (Wolfrum et al., 2010) from the Gene Ontology
database (Ashburner et al., 2000), including those described by Vaziri et al. (2010). Of those,
we identified 64 genes as significantly differentially expressed in AFCs at P17 compared to the
union of all AFiPSC lines (Figure 3.15) (Wolfrum et al., 2010). Amongst those, telomere-
associated genes and genes involved in cell cycle regulation, e.g., MAD2L2, PARP1, RPA3,
DKC1, MSH6, CHEK1, PLK1, POU2F1, CDC2, BLM, WRN, DNMT1, DNMT3B, LMNB1,
and CDT1, were down-regulated in primary AFCs compared to AFiPSCs and ESCs (Wol-
frum et al., 2010). In contrast, PIN1, LMNA, GADD45A, CBX6, NOX4, ENG, HIST2H2BE,
CDKN2A, CDKN1A, GDF15 and SERPINE1, among others, were up-regulated in primary
AFCs compared to AFiPSCs and ESCs (Wolfrum et al., 2010).
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Figure 3.15: Heatmap of senescence-associated gene expression in AFCs, AFiPSCs and ESCs,
lines H1 and H9. The heatmap depicts LOG2 average genes expression values of signifi-
cantly differentially expressed senescence-associated genes resulting from the comparison of
the union of AFiPSCs around P20 with the parental AFC line 101 after the onset of senescence
at P17 (≥ 1.5 fold up- or down-regulattion, padj < 0.05). The heatmap is colored according to
the color key below. Genes were clustered with respect to their expression patterns across the
different samples using the Euclidean distance measure. Taken from Wolfrum et al. (2010).
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3.2.5 shRNA-mediated USP44 knock down in AFiPSCs and ESCs
Recently, we have investigated the key transcriptional regulatory network, which governs the
human pluripotent stem cell phenotype, by OCT4 ChIP-on-chip analysis (Jung et al., 2010).
As one of the key findings of this study, it has been demonstrated that the ubiquitin-specific
protease 44 (USP44), a deubiquitinating enzyme, harbors an evolutionary conserved OCT4
binding site and that USP44 is positively regulated by OCT4 in both human ESCs and embry-
onal carcinoma (EC) cells. To date, USP44 has been reported to play a key role in regulating
the cell cycle, i.e. in the control of the spindle checkpoint as it prevents the premature onset
of the anaphase (Stegmeier et al., 2007). However, the direct role of USP44 in promoting self-
renewal and pluripotency in these cell types is yet unknown. Genetic engineering of human
PSCs, i.e. knock-down, knock-out and knock-in of distinct genes to investigate their specific
function in the maintenance of self-renewal and differentiation potency, developmental pro-
cesses or diseases, is an essential part of stem cell biology (Thomson et al., 1998; Menendez
et al., 2005; Maury et al., 2011). Referring to previous knock down experiments carried out
in our laboratory (Babaie et al., 2007; Greber et al., 2007b), we sought to utilize the retroviral-
derived AFiPSC lines along with human ESCs to investigate the functional role of USP44 in
maintaining pluripotency and self-renewal in different human PSC types. We aimed to knock
down USP44 by RNA interference in human AF-derived iPSC lines and the ESC line H1.
To this end, we aspired to deliver constructs encoding short hairpin RNAs (shRNAs) against
USP44 by lentiviral transduction or by chemical transfection. However, as genetic manipula-
tion of human ESCs is still a major technical challenge (Zwaka and Thomson, 2003; Braam
et al., 2008; Giudice and Trounson, 2008; Zafarana et al., 2009; Ma et al., 2010; Maury et al.,
2011), the transduction and transfection protocol first required optimization by the use of
several GFP-encoding reporter constructs.
3.2.5.1 Lentiviral particle production
Lentiviral particles encoding different shRNAs against USP44 or TurboGFP (TGFP) were
produced in HEK 293 cells and subsequently used to infect HEK and HFF1 cells to verify
their ability to transduce human cell lines. For this purpose, the TGFP-encoding lentivirus
was used as a positive transduction control as the green fluorescent signal observed in target
cells upon lentiviral transduction demonstrated functionality of both freshly prepared and
concentrated, frozen lentiviruses (Figure 3.16).
3.2.5.2 Lentiviral transduction of human PSCs
Having verified the ability of the lentiviruses to infect human cell lines, the TGFP-control
virus was used to establish human PSC transduction. On the basis of the protocol recently
published by Du and Zhang (2010), we first dissociated H1 ESCs and infected single cells in
suspension with the TGFP-encoding lentiviral particles. As a result, H1 ESCs massively dif-
ferentiated and no green fluorescent signal was detectable (Figure 3.17) even up to six days
post-transduction.
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Figure 3.16: GFP expression in HEK 293 and HFF1 fibroblast cells upon transduc-
tion with TGFP-encoding lentiviruses. (A) Maps of the lentiviral shRNA, non-target
shRNA or TGFP-encoding lentiviral vectors. Obtained from http://www.sigmaaldrich.com/
life-science/functional-genomics-and-rnai/shrna/library-information/vector-map.html. (B)
Representative images of cells transduced with 50µl fresh lentiviral particles 72 h post-
transduction are shown. Scale bars= 200µm.
Figure 3.17: GFP expression in H1 ESCs upon TrypLE Select-mediated dissociation and trans-
duction with TGFP-encoding lentiviruses. Images were acquired 72 h post-transduction. Scale
bars= 200µm.
As the ability to maintain human PSCs in the undifferentiated state is crucial for inves-
tigating the role of USP44 in supporting self-renewal and pluripotency, we next tested if we
were generally able to recover undifferentiated human PSCs upon dissociation of the colonies
to single cells without transducing them. Thus, as in the lentiviral transduction protocol, we
pre-incubated H1 ESCs with ROCK Inhibitor prior to TrypLE Select-mediated dissociation
of the colonies and re-plating of the single cells in growth medium devoid of lentivirus, yet,
containing a combination of ROCK Inhibitor and thiazovivin or thiazovivin alone to pro-
mote the recovery of undifferentiated human PSC colonies. The absence of tightly packed
ESC colonies about one week after dissociation and the presence of spindle- or cobblestone-
shaped cells suggested substantial differentiation of H1 ESCs after dissociation and re-plating
(Figure 3.18, upper panel). However, after nearly two weeks of cultivation tightly packed
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Figure 3.18: Morphology and OCT4 expression in H1 ESCs cultivated with different sup-
plements following TrypLE Select-mediated dissociation. Images of the cellular morphology
were acquired at several time-points after dissociation as indicated. Cells were fixed and ana-
lyzed for OCT4 expression by immunofluorescent protein labeling 13 days after dissociation.
Scale bars= 200µm.
colonies of putatively undifferentiated ESCs re-emerged in very few cases (Figure 3.18, up-
per panel, d12). Such colonies expressed the key pluripotency factor OCT4 as determined by
immunofluorescent protein labeling.
Nevertheless, the presence of such OCT4-positive colonies was rather exceptional. Presum-
ably, these colonies have grown out of small cell clusters that could not be properly dissociated
even after pro-longed TrypLE Select-treatment (indicated by arrow in the upper panel of Fig-
ure 3.18).
As the treatment of human PSCs with ROCK inhibitor and thiazovivin did not markedly
improve the yield of undifferentiated human PSCs after single cell dissociation even with-
out lentiviral transduction, we tested if it was possible to homogeneously transduce non-
dissociated or only partly dissociated colonies of ESCs or AFiPSCs as suggested by the
MISSION RNAi human ESC transduction protocol (Sigma). We transduced un-dissociated
colonies (with and without centrifugation to enhance the transduction efficiency) and colonies
that have been manually dissociated into smaller pieces and Dispase-treated, as during routine
passaging of human PSCs. Still, no TGFP expression was detectable in the vast majority of
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samples two to five days post-transduction. The few green fluorescent signals observed were
the result of TGFP expression in differentiated human PSCs as clearly recognizable from the
spindle shaped morphology and the long cell protrusions (Figure 3.19).
Figure 3.19: GFP expression in un-dissociated or partly dissociated AFiPSCs and ESCs
after transduction of TGFP-encoding lentiviruses. Colonies of human PSCs were either
not split or manually dissociated and Dispase-treated prior to the incubation with TGFP-
encoding lentivirus. Images were acquired 48 h post-transduction (un-dissociated AFiPSC41),
72 h post-transduction (H1 ESCs) or 96 h post-transduction (Dispase-split AFiPSC41). Scale
bars= 200µm.
3.2.5.3 Transfection of human PSCs with lentiviral plasmids
Due to the unaccountable, unsuccessful expression of transgenes in undifferentiated human
PSCs following lentiviral transduction, we sought to deliver the USP44-targeting shRNAs
by plasmid transfection. Hence, the human ESC line H1 and AFiPSC line 41 were trans-
fected with the same USP44 shRNA-encoding vectors and, for optimization purposes, with
the TGFP-encoding control vector or two other positive reporter constructs encoding either
OCT4 promoter-driven EGFP or maxGFP. Various modifications were successively included
in the transfection protocol as follows: First, human PSCs were transfected with the OCT4
promoter-driven EGFP vector to determine if undifferentiated human PSCs can express the
desired transgene. These transfections were carried out following dissociation to single cells by
TrypLE Select or the putatively more gentle dissociation solution of Accutase (reverse trans-
fection including incubation with thiazovivin to promote the recovery of undifferentiated
human PSCs) or following no dissociation. Simultaneously, transfection efficiencies in growth
medium and OptiMEM were compared. As already observed for the lentiviral transduction,
Chapter 3. Virus-mediated generation of amniotic fluid-derived iPSCs 66
the few green fluorescent cells mainly had the morphology of differentiated cells, which, re-
ferring to their ability to express this OCT4 promoter-driven EGFP, however, must still have
contained sufficient levels of remnant OCT4. With respect to intact human PSC colonies the
only transgene expressing cells were those on the periphery of the colonies, whereas those cells
in the center of the tightly packed human PSC colonies were never observed to emit green
fluorescence (Figure 3.20). In view of the vimentin expression of putatively differentiated cells
Figure 3.20: GFP expression in un-dissociated or to the single cell level dissociated AFiP-
SCs and H1 ESCs following transfection of a vector encoding OCT4 promoter-driven EGFP.
Cells were either not dissociated prior to transfection (TF, 100µl OptiMEM, 2µg DNA, 6µl
FuGENE HD per 12-well) or TrypLE select-treated and transfected as single cells (reverse
transfection, RevTF, 100µl OptiMEM, 4µg DNA, 12µl FuGENE HD in N2B27 defined
medium containing thiazovivin). Incubation of complexed DNA was carried out in defined
N2B27 medium ON or in OptiMEM for 2 h as indicated. Images were acquired at the indicated
time points. Scale bars= 200µm.
on the periphery of AFiPSC colonies shown earlier (Figure 3.8), this finding is, once more,
indicative, that the only transgene expressing cells are presumably not undifferentiated but
rather differentiated PSCs.
Irrespective of these findings, we next, attempted to deliver the TGFP-encoding equivalent
of the shRNA lentiviral vectors into AFiPSCs and H1 ESCs. In order to also target those cells,
which are normally difficult to reach due to the high cell density in the center of human PSC
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colonies, transfections were carried out following TrypLE Select-mediated dissociation to sin-
gle cells, also including thiazovivin-treatment. Again, no TGFP expression could be observed
in both cell lines (Figure 3.21).
Figure 3.21: GFP expression in TrypLE Select-dissociated AFiPSCs and H1 ESCs following
transfection of a lentiviral vector encoding TGFP. The reverse transfections were carried out
using 100µl OptiMEM, 2µg DNA, 6µl FuGENE HD in N2B27 defined medium containing
thiazovivin. Images were acquired three (AFiPSC41) or five days (H1) post-transfection. Scale
bars= 200µm.
To potentially improve the transfection efficiency, we compared FuGENE HD transfec-
tion reagent with Lipofectamine 2000. To this end, after having conducted several preliminary
tests, we finally reverse transfected AFiPSCs with different GFP-encoding vectors using both
transfection reagents upon pre-incubation with ROCK Inhibitor and dissociation of the
colonies to single cells by Accutase-treatment, followed by further incubation with ROCK
inhibitor and thiazovivin. In parallel, un-dissociated AFiPSC colonies were transfected with
different GFP-encoding plasmids as this had only been done using FuGENE HD before.
Although a transfection efficiency gradient could be observed from Lipofectamine 2000/
pmaxGFP over FuGENE HD/pmaxGFP and Lipofectamine 2000/TGFP to FuGENE HD/
TGFP, the overall transfection efficiency was repeatedly low (Figure 3.22). Both in case of the
dissociated as well as the un-dissociated AFiPSCs the only transgene expressing cells (if any
were observable) were those which had already differentiated as evident from the shape of the
green fluorescent cells.
In conclusion, the lack of GFP expression in the core of densely packed, undifferentiated
human PSC colonies in all of the experiments carried out demonstrated that none of the vector
types used and neither the lentiviral nor the transfection-based delivery method facilitated an
efficient transgene expression in undifferentiated human PSC colonies. This was observed for
both un-dissociated and dissociated colonies of human ESCs as well as for AF-derived iPSCs,
irrespective of the use of supplements, i.e. ROCK Inhibitor and thiazovivin, to enhance the
viability of single human PSCs. In conclusion, the attempt to investigate the functional role
of USP44 in human PSCs requires extensive optimization and could not be pursued further
in the course of this PhD project.
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Figure 3.22: GFP expression in AFiPSC line 41 following comparative transfections of dif-
ferent GFP-encoding reporter constructs using Lipofectamine 2000 and FuGENE HD. (A)
AFiPSCs were pre-incubated with ROCK Inhibitor, dissociated by incubation with Accutase
and reverse transfected using 200µl OptiMEM, 1µg DNA and 2µl Lipofectamine 2000 or
100µl OptiMEM, 1µg DNA and 3µl FuGENE HD in N2B27 defined medium including
ROCK inhibitor and thiazovivin. (B) Un-dissociated AFiPSC colonies were transfected with
200µl OptiMEM, 1µg DNA and 2µl Lipofectamine 2000. Images were acquired four days
post-transfection. Scale bars= 200µm.
3.3 Discussion
The very first goal of this project was to sort stem cell-like subpopulations of human AFCs to
obtain a suitable source of cells, which could subsequently be reprogrammed more efficiently
to iPSCs than other terminally differentiated somatic cells. This was based on the fact that nu-
merous research reports have highlighted the expression of several stem cell markers, mainly
neuronal stem or progenitor cell markers, mesenchymal stem cell or pluripotent stem cell
markers, which facilitate the selection of cells with stem cell properties by different protocols
(In ’t Anker et al., 2003; Prusa et al., 2004; Tsai et al., 2004; Karlmark et al., 2005; Bossolasco
et al., 2006; Tsai et al., 2006; Chiavegato et al., 2007; De Coppi et al., 2007; Kim et al., 2007;
Sessarego et al., 2008; Trovato et al., 2009; You et al., 2009). However, the implementation of
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the most noted protocol (De Coppi et al., 2007) was not practicable in our setting. This was
due to the change in human AFC morphology, which was observed approximately at P4 to
P5. This morphological change involved a major increase in cell size, starting from a heteroge-
neous population of small ovoid to squamous epithelioid cells that turned into a homogeneous
population of large, flat, seemingly fragile fibroblast-like cells. Although the variety of cells
present in samples of human amniotic fluid have been investigated intensively (reviewed by
Gosden (1983)), the particular morphological change observed here has, to the best of my
knowledge, not been described in detail to date. Determination if this shift of morphology
was indeed a true morphological change of all cells in the culture or if it was rather due to
selection processes during the in vitro propagation and whether it was to some extent already
associated with the relatively early onset of senescence was beyond the scope of this project. It
has been shown, however, that MACS and FACS-based protocols involving human AFCs are
successful if performed early after isolation, preferably within the first two passages of culture
(Chiavegato et al., 2007; De Coppi et al., 2007; Moschidou et al.). The samples obtained for
this project were delivered as frozen aliquots at approximately P2, which required re-expansion
before being used in experimental settings. The morphological change occurred during the
phase of re-expansion and hampered efficient sorting strategies and, hence, the establishment
of stem-cell like subpopulations with verifiable marker expression for down-stream applica-
tions.
Provided that sufficient amounts of early passage human AFCs for MACS and FACS-based
sorting approaches were available, other surface markers should be considered for the selection
of stem cell-like cells for direct reprogramming. In a collaborative project, we have recently
shown that proportions of AFCs found in earlier stages of gestation, i.e. the first trimester,
express human ESC surface markers such as SSEA4 and AP, SSEA3, TRA-1-60 and TRA-1-81
at single cell level (Moschidou et al.). These stem cell-like cells resemble a subpopulation of
AFCs, which are probably closer to PSCs than the CD117-positive fraction (De Coppi et al.,
2007; Moschidou et al.). The potential of other human ESC markers such as CD133 (Kaufman
et al., 2001) and PODXL (Adewumi et al., 2007), an early marker of pluripotency during iP-
SCs generation (Mah et al., 2011), for more routinely available second trimester AFCs requires
further investigation.
The technical difficulties associated with sorting bulk primary AFCs changed the starting
point of this project. However, it did not affect the progress of the project as the use of bulk
primary human AFCs, which included putative stem cell-like cells, as starting material for
cellular reprogramming was still expected to be highly efficient.
3.3.1 Ground state pluripotency of AFiPSCs
Next, as demonstrated in this first part of this thesis, bulk primary AFCs can be converted into
an ESC-like phenotype by retroviral transduction of the Yamanaka cocktail of transcription
factors (OSKM). The fact that no enriched stem cell-like AFC samples were available as target
cells for cellular reprogramming did not derogate from efficient and especially rapid induction
of pluripotency when compared to the generation of iPSCs from skin fibroblast cells (Taka-
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hashi et al., 2007; Prigione et al., 2010; Wolfrum et al., 2010). This is in agreement with recent
reports, which have been published while this project was on-going: Whereas the experiments
described here and elsewhere (Li et al., 2009a; Galende et al., 2010; Anchan et al., 2011) were
based on the retroviral transduction of the original cocktail of four reprogramming factors
(OCT4 SOX2, KLF2, c-MYC), others have meanwhile accomplished to convert human AFCs
into iPSCs by lentiviral or retroviral transduction of just two (OCT4, SOX2) (Ye et al., 2009)
or even one reprogramming factor (OCT4), in combination with small chemical compounds
(NaB, PS48, A-83-01, PD0325901, CHIR99021 and Parnate) (Zhu et al., 2010), or upon pre-
selection of CD34-positive cells (Liu et al., 2012). These findings emphasize that human AFCs
acquire the PSC state more easily than fully differentiated somatic cells.
The AFiPSCs generated in the course of this project were positive for all tested human ESC
and pluripotency-associated markers. Immunofluorescence-mediated detection of cadherin-1
(E-cadherin), in contrast to vimentin, indicated the uniform epithelial nature of AFiPSCs.
These cells passed both the embryoid body formation and teratoma formation assays verify-
ing complete induction of pluripotency in these cells. It has further been demonstrated that
AFiPSCs, like ESCs, have the ability to form derivatives of the extraembryonic trophoblast
lineage. Generally, the acquisition of key ESC characteristics during cellular reprogramming
enhanced the restricted differentiation potential of human AFCs and should, thus, proof ben-
eficial for the application of AFiPSCs in basic and applied research. Although the teratoma
formation potential of AFiPSCs, a common feature of iPSCs and ESCs, impedes their poten-
tial use in cell replacement therapies, it must be assumed that ways will be found to exploit
the full differentiation potential of iPSCs while circumventing tumor formation risks. This
could for instance be achieved, by developing highly efficient differentiation protocols, which
result in pure terminally differentiated cell types, or accurate sorting strategies to separate
fully differentiated cells of interest from potential tumorigenic stem cells. Recent progress has
been made in this respect and the realization of the first clinical trials for human ESC-derived
therapeutics is leading the way (Drews et al., b; Schwartz et al., 2012b).
3.3.2 Cellular reprogramming by-passes senescence of bulk primaryAFCs
Furthermore, cellular reprogramming by-passes senescence of bulk primary AFCs. Acquisi-
tion of the ability to propagate indefinitely should also increase the value of AFiPSCs for
down-stream applications. The data obtained in the course of this project suggest, that the phe-
notypically rejuvenated appearance of AFiPSCs is based on a gene expression profile, which
averts or at least markedly delays the onset of senescence. Opposing expression of a large
number of senescence-associated genes has been highlighted for primary AFCs and AFiP-
SCs and ESCs. More specifically, high expression levels of various cell cycle and telomere
elongation-associated genes such as MAD2L2, PARP1, RPA3, DKC1, MSH6, CHEK1, PLK1,
POU2F1, CDC2, LMNB1 and CDT1 as well as TERT itself were detected in AFiPSCs in
contrast to primary AFCs (Wolfrum et al., 2010). The p53/p21 pathway is known to play
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an essential role in inducing and maintaining senescence (Brown et al., 1997). In line with
this, mRNA levels of several p53 target genes, which are known to be highly expressed in
senescent cells (Chang et al., 2000; Young and Smith, 2001; Huang and Vassilev, 2009), e.g.,
CDKN1A (p21), GDF15, and SERPINE1, were strikingly elevated in primary AFCs compared
to AFiPSCs and ESCs (Wolfrum et al., 2010). In contrast, DNMT1 and DNMT3B were ex-
pressed at low levels in bulk primary AFCs and significantly up-regulated in AFiPSCs. These
DNA-methyltransferases normally establish and maintain CpG methylation patterns during
embryonal development. They are also known, however, to repress transcription of CDKN1A
in opposition to and potentially independent of p53 (Young and Smith, 2001; Zheng et al.,
2006; Wolfrum et al., 2010). Hence, it could be speculated that the high expression levels of
the DNMTs in AFiPSCs may repress CDKN1A and, thus, senescence in these cells (Wolfrum
et al., 2010). Although from the results of the microarray-based transcriptome analysis there
is strong evidence that senescence of primary human AFCs is indeed by-passed upon the ac-
tivation of a self-renewal and pluripotency program, further studies are required to assess the
actual ability of AFiPSCs to restore telomere restriction fragment length to an ESC level, a
subject of controversial discussion in the iPSC field (Suhr et al., 2009; Agarwal et al., 2010;
Vaziri et al., 2010; Wolfrum et al., 2010).
3.3.3 The LARGE Principle of Cellular Reprogramming and ESC-specific gene expression signatures
The extensive comparative transcriptome analyses of AFiPSCs, ESCs (H1, H9) and FiPSCs
and the corresponding parental cell lines has highlighted mechanistic and functional aspects
of cellular reprogramming. The data obtained from the whole genome gene expression analy-
ses was used to devise the LARGE (Lost, Acquired and Retained Gene Expression) Principle
of Cellular Reprogramming, i.e. to identify genes, the expression of which was either Lost
(L), Acquired (A) or Retained (R) upon the induction of pluripotency in different iPSC types
(Wolfrum et al., 2010). In the following paragraphs, some of these gene expression patterns,
including several signature genes, will be discussed in greater detail.
The donor cell (AFC)-specific gene signature contains putative immune-suppressive fac-
tors such as CD59, TNFSF10, and NT5E (CD73) (Longhi et al., 2006; Hasegawa et al., 2008;
Falschlehner et al., 2009), which are thought to contribute to the immune-privileged charac-
teristics of primary AFCs (Walther et al., 2009). Expression of these genes is lost upon the
induction of pluripotency. Further investigations will have to elucidate whether this affects
potential therapeutic applications of AFiPSCs in comparison to primary AFCs (Wolfrum
et al., 2010). Interestingly, active gene expression of MYC (AFiPSCs and FiPSCs) and KLF4
(FiPSCs) was also lost upon reprogramming. This strengthens the idea that the main function
of KLF4 and c-MYC is to increase a balanced cellular proliferation, thereby accelerating or
enhancing the efficiency of reprogramming processes, while their expression appears to be
dispensable in PSCs (Evans and Liu, 2008; Zhao and Daley, 2008; Nandan and Yang, 2009;
Wolfrum et al., 2010).
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Among the expressed genes, which are universally acquired during reprogramming pro-
cesses, independent of the original cell source, are key pluripotency-associated factors, namely
POU5F1, SOX2 and NANOG (Boyer et al., 2005; Jung et al., 2010). These factors interact to
establish a core TRN, which is crucial for maintaining self-renewal and pluripotency (Boyer
et al., 2005; Jung et al., 2010). At the same time, however, expression of genes which are known
to play a role in differentiation and development such as EOMES and HAND1 are acquired
(Adjaye et al., 2005; Babaie et al., 2007; Jung et al., 2010; Wolfrum et al., 2010). It has been
demonstrated that these genes are direct targets of OCT4, SOX2 and NANOG (Boyer et al.,
2005). For instance, these genes are negatively regulated by OCT4 as they are up-regulated
upon OCT4 knock down (Babaie et al., 2007). Yet, the data set presented herein revealed low
level expression of some of these developmental-related genes in all our pluripotent cell types,
which is in line with ESC and iPSC-related microarray data deposited in repositories such
as Amazonia! (Le Carrour et al., 2010; Wolfrum et al., 2010). These observations could be
ascribed to spontaneously differentiating cells present in ESC and iPSC cultures as shown
earlier and also by others (Zwaka and Thomson, 2005; Xu et al., 2005) or artefacts of distinct
cell culture conditions. Investigations to detect distinct epigenetic marks on the promoters of
these genes could potentially enable further insight into expression patterns of these genes in
pluripotent cells and link it to the concept of bivalent chromatin structures, which mark poised
stem cell genes (Bernstein et al., 2006). Further genes implicated in developmental processes,
which were found to be acquired in a cell type-dependent manner during cellular reprogram-
ming, included, for example, SIX6, EGR2, HOXD4, HOXD10, PKNOX2 and DLX5 (Imoto
et al., 2001; Panganiban and Rubenstein, 2002; Nunes et al., 2003; Sarnat and Flores-Sarnat,
2005; Schmitt et al., 2009; Wolfrum et al., 2010). The list of Retained genes in both, AFiPSCs
and FiPSCs, also included transcription factors such as RAXL1 which is another gene involved
in the regulation of developmental processes (Wang et al., 2004). Persistent gene expression has
been described to contribute to differences between iPSCs of different origin and ESCs (Ghosh
et al., 2010). It may account for variable differentiation behaviours of iPSCs, irrespective of
the reprogramming technique that was applied to generate them (Hu et al., 2010b,a). The im-
pact of such actively expressed, developmental genes on the maintenance of pluripotency and
self-renewal and on spontaneous or directed differentiation processes of distinct iPSC types,
thus, deserves further investigation.
The expression of some of the distinct signature genes could be attributed to viral integra-
tions into the target cells’ genomes. The group-wise analysis of several AFiPSCs or FiPSCs
lines versus the parental cell lines and ESCs, however, renders clone-specific viral integrations
as a cause for these observations improbable. It could rather be speculated that these gene
expression patterns result from an incomplete conversion of chromatin modifications in iP-
SCs, which could account for a cell type-specific epigenetic memory (Marchetto et al., 2009;
Ghosh et al., 2010; Wolfrum et al., 2010) although the existence of such a memory is a subject
of debate (reviewed by Drews et al. (b,a)). This is further supported by the identification of
ESC-specific genes signatures in the comparison of the different iPSCs with ESCs, including,
for example, PRDM14, WNT3A and GSC. While PRDM14 has been shown to promote the
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undifferentiated ESC state (Tsuneyoshi et al., 2008), the role of WNT3A in maintaining the
self-renewal and pluripotency has long been a matter of debate (Sato et al., 2004; Davidson
et al., 2012). At the same time, both WNT3A and GSC, are primitive streak/mesendoderm
markers known to regulate developmental processes (Greber et al., 2008). Regardless of the
exact molecular function of these factors in the pluripotent state, the fact that these genes dis-
tinguish the transcriptomes of AFiPSCs and FiPSCs from those of ESCs indicates incomplete
reprogramming and underscores differences between ESCs and iPSCs on mRNA level that
persist upon the acquisition of the ESC phenotype in both iPSC types. Follow-up studies
should be designed to identify functional consequences of this observation (Wolfrum et al.,
2010). The partially inconsistent gene expression patterns observed in the LARGE heatmap
(Figure 3.14), in contrast, have presumably been caused by viral integrations. In order to verify
this hypothesis and to identify actual effects of viral integrations on the genome of the iPSCs,
it will be inevitable to generate iPSCs without genetic modifications and to perform compar-
ative transcriptome and functional analyses of viral and non-viral-derived iPSCs (Wolfrum
et al., 2010).
3.3.4 Genetic modification of human PSCs to knock down USP44 re-mains a technical challenge
The attempt to investigate the role of the pluripotency-associated gene USP44 in maintain-
ing self-renewal and differentiation potential in retrovirus-derived AFiPSCs and ESCs by
shRNA-mediated knockdown was not successful. As demonstrated by the use of several re-
porter constructs, neither lentiviral transduction nor plasmid transfection in combination
with different strategies of sample preparations facilitated sufficient transgene expression in
undifferentiated PSCs. Instead, most of the genetic manipulation strategies induced severe loss
of cell viability and/or massive differentiation. Although difficulties were to be expected, as
genetic manipulation of human ESCs remains a technical challenge (Zwaka and Thomson,
2003; Xia et al., 2007; Braam et al., 2008; Giudice and Trounson, 2008; Zafarana et al., 2009;
Ma et al., 2010; Maury et al., 2011), this result was yet surprising. After all numerous reports
have described successful interference of gene expression in human ESCs employing different
approaches such as transient or stable chemical transfection of shRNAs or siRNAs or shRNA
or siRNA-encoding constructs (Hay et al., 2004; Matin et al., 2004; Hyslop et al., 2005; Babaie
et al., 2007; Vallier et al., 2009a; Adachi et al., 2010; Ma et al., 2010), nucleofection of siRNAs
or of shRNA or siRNA-encoding vectors (Fong et al., 2008; Hohenstein et al., 2008), virus-
mediated expression of shRNAs or siRNAs (Zaehres et al., 2005; Tulpule et al., 2010; Wang
et al., 2012b)electroporation of inducible shRNA-encoding vectors (Zafarana et al., 2009) and
homologous recombination upon electroporation [(Zwaka and Thomson, 2003). Cao et al.
compared the different gene transfer methods (lipofection, electroporation, nucleofection and
lentiviral transduction) in human ESCs and found that lentiviral transduction resulted in the
highest efficiency while only barely affecting cell viability [Cao+F 2010 (19551446)]. Like-
wise, efficient genetic modification by lentiviral transduction has been demonstrated by others
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(Gropp et al., 2003; Ma et al., 2003; Gropp and Reubinoff, 2006; Wang et al., 2012b). Lipo-
fection has been shown to be generally less efficient (Cao et al., 2010). However, lipid-based
transfection of nucleic acids is known to have a low toxicity on human ESCs (Maury et al.,
2011) and of different transfection reagents FuGENE HD, one of the chemicals used in this
project, was shown to facilitate efficient and stable transgene expression (Liu et al., 2009). Based
on the highly similar phenotypes it seems plausible to convey these findings from human ESCs
to iPSCs, for which many corresponding studies remain to be done. In view of these findings
it appears unclear at first glance, why our attempts failed. Although the initial experiments
were based on a protocol published by an established group in the field (Du and Zhang, 2010),
different factors, by themselves or in combination, may have caused the poor outcome.
First of all, as anticipated, transduction or transfection of non-dissociated human PSCs
only led to transgene expression in the periphery of the colonies and rendered manipulation
of the cells in the center of the colonies impossible. It is not clear, however, if this was due to
the limited access of the transduction/transfection reagent to single cells in the densely packed
center of the colonies or if this was rather due to differences in the uptake of these reagents
between undifferentiated PSCs in the middle of the colony and potential spontaneously differ-
entiating cells at the boundaries. To by-pass this problem and to obtain uniform cultures of
transgene-carrying cells by subcloning, the human PSCs were dissociated prior transduction
or transfection. This, in turn, brought about another basic problem associated with (genetic)
manipulation of human ESCs that certainly contributed to the negative outcome of the exper-
iments described herein—the low cloning efficiency, i.e. the lack of human ESCs, or human
PSCs in general, to survive as single cells and to re-grow into mature colonies of undifferen-
tiated cells once dissociated to single cell level (Amit et al., 2000; Thomson et al., 1998). In
avoidance of decreased cell viability during the transduction/transfection procedure we disso-
ciated the cells with different putatively gentle reagents such as Accutase (Bajpai et al., 2008)
and TrypLE Select (Du and Zhang, 2010) and incubated the cells with Rock inhibitor Y-27632
and thiazovivin, which have been highlighted to diminish dissociation-induced apoptosis of
human PSCs (Watanabe et al., 2007; Lin et al., 2009). Unexpectedly, none of these treatments
enhanced transduction or transfection. Incubation with neurotrophins is an alternative small
molecule approach believed to improve manipulation of human PSCs (Pyle et al., 2006). Fur-
ther investigations are required, however, to reveal if neurotrophins indeed would have had
a positive effect on the transduction and transfection efficiencies. Not even the attempt to
manipulate human PSCs as small clumps as a compromise between no dissociation of human
PSCs and dissociation to the single cell level, which is routinely applied when human PSCs are
genetically modified (Maury et al., 2011), ameliorated gene delivery. As this way of handling
PSCs limits the induction of apoptosis this finding supports the hypothesis that undifferen-
tiated PSCs may have means to impede the entrance of transduction or transfection reagents
into the cells.
Another critical factor that substantially determines the success of transgene expression in
distinct cell lines is the choice of the promoter. The different shRNAs employed in this project
were under the control of the human U6 promoter, which was shown to efficiently drive RNA
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polymerase III transcription to generate the encoded shRNAs (Zaehres et al., 2005; Tulpule
et al., 2010). TurboGFP expression from the corresponding reporter construct, however, was
mediated by the ubiquitous cytomegalovirus (CMV) promoter (Figure 3.16). Transgenes un-
der the control of this promoter, in contrast, were reported to be more effectively ‘suppressed’
upon lentiviral transduction into human ESCs than other ubiquitously active promoters,
namely the cytomegalovirus immediate-early enhancer/chicken β-actin hybrid (CAG), phos-
phoglycerate kinase (PGK) and human elongation factor-1α (EF1α) promoters (Xia et al.,
2007). Concerning the transient transfection of CMV-driven genes, published data have been
controversial. While one group demonstrated generally weak CMV promoter activity follow-
ing nucleofection in human ESCs (Chan et al., 2008), another group reported robust transient
transcriptional activity of the CMV promoter upon transgene delivery by various chemical
methods but inability to select stably transfected cells (Liu et al., 2009). Likewise another study
demonstrated highly efficient CMV-driven enhanced GFP expression in human ESCs after
chemical transfection followed by a significant decrease (Lebkowski et al., 2001). Yet others
have shown that CMV is a suitable promoter for transient transgene expression by nucle-
ofection in human ESCs (Hohenstein et al., 2008). This is also supported by the fact that
the pmaxGFP reporter construct, a CMV-driven enhanced GFP-encoding vector by Amaxa
(Lonza), is commonly used as a positive nucleofection control in various cell lines, including
human ESCs (Fong et al., 2008; Hohenstein et al., 2008). Hence, although the CMV promoter-
driven TGFP reporter construct does not appear to be the superior vector for the optimization
experiments, the poor outcome of the transduction and transfection experiments cannot solely
be attributed to its constrained strength in human PSCs. Especially since the OCT4 promoter-
driven GFP vector was not any more efficient.
In summary, referring to the recent progress with respect to genetic manipulation of hu-
man ESCs and considering the various possibilities of incorporating different human PSC
handling techniques and applying putatively supportive reagents, a successful knock down of
the USP44 gene expression levels appeared achievable. After all, however, it was most likely
the combination of the low cloning efficiency of human PSCs together with the generally low
transduction and even lower transfection efficiencies in human PSCs that caused the exper-
iments to fail. Hence, implementation of the USP44 knock down strategy still seems to be
feasible but requires major optimization efforts.
4
Non-viral generation of amnioticfluid-derived iPSCs
4.1 Introduction
To generate human iPSCs suitable for clinical purposes it is essential to establish cellular repro-
gramming protocols, which allow for an induction of pluripotency in somatic cells without
modification of the target cell genome. In order to pursue the main goal of this PhD project
further, the non-viral, integration-free generation of iPSCs from human AFCs to complement
the retroviral-derived AFiPSCs, we next aimed at the implementation and optimization of
published non-integrating reprogramming methods. As sorting of stem cell-like subpopula-
tions was not feasible due to the reasons described earlier, the same bulk primary human AFCs
were used as a starting point for non-viral reprogramming experiments.
4.2 Results
4.2.1 Cellular reprogramming by means of episomal plasmid nucleo-fection
We attempted to reprogram AFCs by transfection of episomal plasmids as published by (Yu
et al., 2009). According to their findings and a recent follow-up publication, the oriP/EBNA1
(Epstein-Barr nuclear antigen-1)-based episomal vectors do not integrate into the host cell
genome but rather persist in the cells as stably extra-chromosomally replicating episomes,
thus facilitating a sufficient expression of the reprogramming factors to induce pluripotency.
Without drug-selection and with pro-longed maintenance of the cells in culture, however, the
episomes are lost, which results in fully established iPSC lines free of residual vector or trans-
gene sequences (Yu et al., 2009; Cheng et al., 2012).
Different lines of human AFCs (P5-P10), including the parental cell line from which the
retrovirally derived AFiPSCs were obtained, were electroporated with a combination of re-
programming factor-encoding episomal plasmids (Figure 4.1 (A)) and subsequently maintained
under human ESC conditions. To potentially achieve a higher reprogramming efficiency, trans-
fected cells were partly treated with BAPN (Tang et al., 1983) or thiazovivin, alone or in
combination with SB431542 and PD0325901 (Lin et al., 2009).
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Figure 4.1: Nucleofection of human AFCs with reprogramming factors-encoding episomal
plasmids. (A) Maps of the episomal plasmids used to electroporate different lines of human
AFCs. The three depicted combinations of vectors and distinct amounts were used accord-
ing to the protocol by Yu et al. (2009). (B) From left to right: Bulk primary human AFCs
(line 102, P5) prior to nucleofection. Floating cells indicate extensive cell death one day post-
electroporation. The same nucleofected AFCs on a layer of mitotically inactivated MEF feeder
cells one day post-nucleofection after removal of the majority of dead cells; the moderate cell
density indicates that only a few electroporated cells attached onto the culture dish. (C) Sin-
gle positive nucleofection control cells express maxGFP. (D) From left to right: Granulated
colony of nucleofected AFCs approximately four weeks post-nucleofection. The only auspi-
cious ESC-like, potential iPSC colony that emerged as a result of all nucleofection experiments
one day prior to picking around seven weeks post-nucleofection; the colony contains large
parts of differentiated cells (black arrows) next to undifferentiated cells (white arrows). Undif-
ferentiated piece of the same colony one day after picking.
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The electroporation procedure induced extensive loss of cell viability, resulting in a low
density of nucleofected AFCs among MEF feeder cells as highlighted by the observation of
single GFP-expressing cells in the positive control (Figure 4.1 (B, C)). Of the approximately
7.5× 106 human AFCs that were nucleofected with the reprogramming factor-encoding epi-
somal plasmids in different experiments, three colonies with granulated morphology (one
in UM/CM without chemicals, one in UM/CM containing thiazovivin and one in UM/CM
containing BAPN) appeared, yet, never developed further into human ESC-like colonies. Over-
all, only one putative iPSC colonies emerged approximately five weeks post-nucleofection
(in UM/CM containing BAPN) (Figure 4.1 (D), approximately 5.5× 10−5 % efficiency). This
colony had the typical ESC morphology, i.e. sharp-edged, dense colonies of cells with high
nucleus to cytoplasm ratio, but proliferated markedly slower. Expansion of this potential iPSC
colony turned out to be extremely difficult: By the time, the colony appeared ready for pick-
ing or splitting, essential parts of it had already spontaneously differentiated (Figure 4.1 (D)).
Upon passaging further differentiation re-occurred in substantial proportions of the colony.
Hence, no net expansion was achieved overall and this colony was lost after approximately
three passages, before any characterization experiments could be performed.
4.2.2 Cellular reprogramming by means of mRNA transfection
After repeated failure of the episomal plasmid based technology to induce pluripotency in
somatic cells without introducing genomic modifications in the target cells, we next pro-
ceeded to RNA-mediated nuclear reprogramming methods. Among the different non-viral,
putatively non-integrating reprogramming techniques available at this time, the focus of this
project was on the novel, highly promising mRNA reprogramming approach. Although an
mRNA-mediated cellular reprogramming protocol had recently already been published by
Warren et al. (2010), the lack of follow-up publications implies there are major hurdles to
overcome before this approach becomes reproducible and routinely applicable for successful
cellular reprogramming (Wang and Na, 2011). We therefore sought to develop a modified
mRNA reprogramming approach building upon the experience and knowledge about in vitro
mRNA synthesis and transfection of our collaboration partners of the Research Group on
Nanomedicines at Ghent University, Ghent, Belgium, and our experience on cellular repro-
gramming and the culture of human PSCs. As the access to human AFCs was limited, we
made use of BJ and HFF1 fibroblasts to optimize the mRNA transfection protocols. However,
the actual experiments attempting to reprogram somatic cells were also conducted using bulk
human AFCs.
4.2.2.1 In vitro mRNA synthesis
First, mRNAs encoding each of the reprogramming factor genes POU5F1 (transcript vari-
ant 1, encoding the OCT4A protein isoform), SOX2, KLF4, c-MYC and LIN28A and the green
fluorescent reporter protein (GFP) were produced starting from the commercially bought plas-
mids. Representative images of intermediates generated in the synthesis process are depicted
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in Figure 4.2. First, from each reprogramming factor-encoding plasmid an open reading frame
Figure 4.2: In vitro synthesis of mRNAs encoding single reprogramming factors—agarose gel
electrophoresis of intermediates. (A) Exemplary images of the fragments resulting from the
XbaI-mediated restriction digest of the KLF4- and c-MYC-encoding plasmids. (B) Comparison
of in vitro transcribed POU5F1- and SOX2-encoding mRNAs prior to and after the poly(A)-
tailing reaction (+/−p(A)). (C) Purified in vitro transcribed, poly(A)-tailed mRNAs derived
from the plasmids encoding either one of the five reprogramming factors or the reporter GFP.
Expected gene product sizes (excluding the poly A tail) are indicated at the bottom.
containing fragment was released by restriction enzyme digest and used as template for the
in vitro transcription reaction (Figure 4.2 (A)). The appearance of a band shift and smear fol-
lowing the poly(A)-tailing reaction indicates successful polyadenylation of the 3’-termini of
in vitro synthesized, capped mRNAs (Figure 4.2 (B)). Hence, functionality and stability of
these mRNAs upon transfection could be assumed. An image of purified in vitro transcribed
mRNAs including caps and poly(A)-tails of all five reprogramming factors is also shown in
Figure 4.2 (C).
4.2.2.2 Quantification of protein expression following mRNA transfec-tion
Next, the in vitro synthesized GFP-encoding mRNA was used as a reporter to determine
the transfection efficiency of our mRNA transfection protocol. Per 12-well, HFF1 cells were
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transfected with 2µg GFP-encoding mRNA complexed with Lipofectamine RNAiMAX, as
described in the ‘Materials and Methods’ chapter. The resulting GFP expression was assessed
by flow cytometry and microscopic analysis. As depicted in Figure 4.3 this revealed that ap-
proximately 85% of cells expressed GFP with a very high intensity per cell (Drews et al., 2012).
Figure 4.3: GFP expression in mRNA-transfected HFF1 cells. 4µg GFP-encoding mRNA
and 4µl Lipofectamine, both pre-diluted in 46µl of OptiMEM, were mixed and incubated
for 10 min at RT. Then, 900µl of OptiMEM were added and this solution was divided over
two 12-wells of HFF1 cells and incubated for 2 h, after which the complexes were removed
and regular growth medium added. (A) FACS analysis of 10,000 cells for GFP expression
24 h post-transfection (black line: untreated control; green line: GFP-positive cells). (B) Mi-
croscopic image of HFF1 cells simultaneously lipofected with GFP-encoding mRNA. Scale
bar= 200µm. Modified from Drews et al. (2012).
4.2.2.3 Immunofluorescence-based detection of the reprogrammingfactor proteins following mRNA transfection
As proof of principle and to additionally assess the quality and localization of protein ex-
pression from the mRNAs delivered by single reprogramming factor transfection (OSKML),
HFF1 cells were fixed at different time points post-transfection and protein expression de-
tected using fluorescence dye-labeled antibodies against each of the reprogramming factors.
As highlighted in Figure 4.4 (A), protein expression was already detectable (OCT4, SOX2,
LIN28) or increased above endogenous background levels (KLF4, c-MYC) 4 h after a single
factor mRNA transfection when compared to mock-transfected control cells. The peak of
expression was observed 10 to 24 h post-transfection (Drews et al., 2012). In case of SOX2 and
LIN28, the fluorescent signal was strong even 48 h after transfection, whereas for OCT4, KLF4
and c-MYC it was nearly decreased to background levels, yet still detectable, at this time point.
When HFF1 cells were transfected with the same total amount of mRNA as a 1:1:1:1:1 cock-
tail of the different reprogramming factors instead of single factors and fixed and stained 24 h
post-transfection, the fluorescent signal observed following antibody labeling was markedly re-
duced when compared to the single factor transfection but still detectable (Figure 4.4 (B)). The
expected nuclear localization of the transcription factors OCT4, SOX2, KLF4 and c-MYC
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as well as the pre-dominantly cytoplasmic localization of the RNA-binding protein LIN28
(Balzer and Moss, 2007) was verified (Drews et al., 2012).
4.2.2.4 mRNA-mediated iPSC generation
Having demonstrated functionality of the in vitro synthesized mRNAs upon transfection,
next, a total of about 17× 106 HFF1, BJ and AFCs (9.6× 106 HFF1 cells, P5-P10; 6.4× 106
BJ cells, P5-P10; 1.2× 106 AFCs, line 101, P10) were employed for reprogramming experi-
ments. To establish our own mRNA-based reprogramming protocol modifications of several
parameters were tested including the use of different reprogramming factor-encoding mRNA
cocktails (1:1:1:1 of OSKM, 1:1:1:1:1 of OSKML or 3:2:1:1:1 of OSKML), transfections on
MEF feeder cells or without MEF feeder cells, with and without Matrigel, different media
including and excluding small molecule treatments (thiazovivin, SB431542, PD0325901 (Lin
et al., 2009), EDHB (Prigione et al.)) to enhance cellular reprogramming and switching from
somatic to human PSC conditions at different time points. Despite the different approaches,
no morphological changes and no formation of granulated colonies or colonies with human
ESC-like morphology were observed. Instead, with increasing numbers of transfections, which
were performed to ensure expression of the reprogramming factors over a sufficient period
of time, cells increasingly died and lifted off the plate. To determine the effect of the trans-
fection protocol on cell viability an MTT assay was performed 24 h after daily transfections
with Lipofectamine RNAiMAX complexes carrying mRNAs encoding the Yamanaka factors.
This demonstrated, the number of transfected cells decreased starting after the second trans-
fection (Figure 4.5 (A)) (Drews et al., 2012). After seven consecutive transfections no viable
Figure 4.5: Loss of cell viability upon repeated transfection of reprogramming factor-encoding
mRNAs into somatic cells. (A) Cytotoxicity of reprogramming factor-encoding mRNA trans-
fections in HFF1 cells. Per 12-well, cells were transfected daily with 2µg of equal amounts of
mRNAs encoding POU5F1, SOX2, KLF4 and c-MYC by complexing with 2µl Lipofectamine
as described in Materials and methods. Seven consecutive transfections were performed. MTT
assay was done 24 h post every transfection. Graphs represent means and SD. n≥ 2. Taken
from Drews et al. (2012). (B) Images of HFF1 and BJ fibroblasts as well as human AFCs
(AF101) acquired prior to (upper panel) and after (lower panel) a minimum of five subsequent
transfections to deliver four or five reprogramming factors exemplarily illustrate the markedly
decreased numbers of viable cells, which were observed for all cell types in either fibroblast,
AFC or ESC conditions. TFs, transfections.
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cells remained. A severe loss of cell viability during the reprogramming experiments was also
observed for all other cell lines (Figure 4.5 (B)). Generally, however, BJs seemed to be more
susceptible to cell death than HFF1 cells and AFCs and HFF1 cells were similarly vulnerable.
Maintenance of the target cells in defined human ESC culturing medium NutriStem
instead of MEF-CM prior to and after each transfection was the only modification of the re-
programming protocol that slightly increased cell viability upon repeated transfections. This
enabled a series of as many as nine consecutive transfections (day 1 and day 2 and every other
day henceforth) before low cell viability prohibited any further transfections. However, even
this period of 16 days in total, including permanent transfections, were insufficient to trig-
ger any phenotypic changes in the target cells. The addition of small molecules, e.g. EDHB,
which promotes reprogramming through indirect stabilization of HIF1α and the resulting
influence on the cellular energy metabolism (Prigione et al.), or a combination of EDHB with
thiazovivin, SB and PD, which were already shown to enhance the induction of pluripotency
(Lin et al., 2009), and maintenance of the target cells on MEF feeder cells under human ESC
conditions after the transfection series could not alleviate the loss of cell viability and did not
evidently enhance the cellular reprogramming process. In fact, implementation of the mRNA
reprogramming protocol by Stemgent using mRNAs and reagents provided in the kit, yet
excluding the B18R treatment, lead to the same outcome.
Comparative global gene expression analysis of reprogramming factor mRNA-transfected
and mock-transfected human neonatal of fibroblasts
As all the different attempts to induce pluripotency by repeatedly transfecting mRNAs of
the reprogramming factors into fibroblasts and AFCs failed due to progressive cell death
we sought to investigate this further. It is known that transfection of poly(A) tailed mRNA
into human dermal fibroblast cells induces interferon response (Rautsi et al., 2007; Angel
and Yanik, 2010). To get a more detailed insight into which pathways are involved, we first
analyzed the transcriptome of reprogramming factor (OSKML) mRNAs-transfected HFF1
and BJ neonatal fibroblasts against mock-transfected (Lipofectamine-treated) control cells 24 h
post-transfection. To enable profound interpretation of the data, the transcriptome profiles
were also compared to gene expression data from untreated, wildtype HFF1 and BJ fibroblast
cells, human ESCs (lines H1 and H9) and fibroblast-derived human iPSCs (FiPSCs, retroviral
derived from HFF1 and BJ cells) generated and maintained in our laboratory as previously
described (Prigione et al., 2010, 2011b).
A global view at the transcriptome data by hierarchical clustering revealed a clear sep-
aration of fibroblasts transfected with mRNAs encoding the reprogramming factors from
wild-type and mock-transfected fibroblasts as well as from human FiPSCs and ESCs (Fig-
ure 4.6 (A)) (Drews et al., 2012). Linear correlation coefficient analysis demonstrated that
mRNA-transfected fibroblasts shared decreasing numbers of expressed genes with mock-
transfected fibroblasts (R2≈ 0.84), wild-type fibroblasts (R2≈ 0.73), FiPSCs (R2≈ 0.60) and
ESCs (R2≈ 0.56) (Drews et al., 2012). Interestingly, the transcriptomes of mock-transfected
and wild-type fibroblasts are more closely related to those of FiPSCs and ESCs (R2≈ 0.71)
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than those of reprogramming factor-transfected fibroblasts from FiPSCs and ESCs (R2≈ 0.58)
(Figure 4.6 (B)) (Drews et al., 2012). This emphasizes that the overall gene expression profile
of reprogramming factor mRNA-transfected fibroblasts is indeed different from the origi-
nal donor cells on one hand and the PSC lines on the other hand. Importantly, a general
switch of the global gene expression pattern from the fibroblast-transcriptome towards the
transcriptome of a pluripotent cell (down-regulation of fibroblast genes, up-regulation of
pluripotency-associated genes) was not apparent as early as 24 h after transfection of the re-
programming factor-encoding mRNAs, despite the high expression levels of the exogenously
delivered reprogramming factors themselves (Drews et al., 2012). This is consistent with our
previous findings in retrovirus-transduced fibroblasts (Mah et al., 2011).
Nevertheless, we sought to investigate whether potential pluripotency-associated genes are
up-regulated as early as 24 h after transfection of the reprogramming factors. To this end we
generated a Venn diagram on the basis of ‘expressed’ genes in mock-transfected control cells,
reprogramming factor-transfected fibroblasts and the union of FiPSCs and ESCs, i.e. the over-
lap of genes present in these two pluripotent cell types, which is presented in (Figure 4.6 (C))
(Drews et al., 2012). The resulting list of 148 putative pluripotency-associated genes, overlap-
ping in reprogramming factor-transfected fibroblasts and the union of FiPSCs and ESCs, is
given in Table B.2 (Drews et al., 2012). This list is enriched for genes encoding cellular mem-
brane and transmembrane proteins and genes associated with cell-cell signaling including, for
example, SYT1, CXCR7, CEACAM1, BST2 and CXCL6 (Table B.3) (Drews et al., 2012).
To get an insight into the gene expression changes directly induced by transfection with
reprogramming factor-encoding mRNAs, we conducted a differential gene expression analysis
comparing reprogramming factor-transfected fibroblast cells with mock-transfected control
cells. As a result, a total of 662 genes were significantly up-regulated in mRNA-transfected
fibroblast cells when compared to the mock-transfected, Lipofectamine-treated control fibrob-
last cells (≥ 1.5 fold increase in expression level, padj< 0.05, the top 100 up-regulated genes
are presented in Table B.4, the complete list of 662 genes can be obtained from Drews et al.
(2012), Supplementary Table S3). These included IFNB1, CCL5, ISG20, OAS1, MDA5 (IFIH1),
RIG-I (DDX58), IRF7, MYD88, ADAR and TRIF (TICAM1), which were strongly up-regulated,
e.g., IFNB1= 967, CCL5¯ 441, OAS1= 184, MDA5= 72, RIG-I = 47 fold up-regulation in trans-
fected over mock-transfected cells (Drews et al., 2012). In contrast, 331 genes were observed
as significantly down-regulated when comparing mRNA- with mock-transfected fibroblasts
(≥ 1.5 fold decrease in expression level, padj< 0.05, the top 100 down-regulated genes are pre-
sented in Table B.5, the complete list of 331 genes can be obtained from Drews et al. (2012),
Supplementary Table S4). Examples of down-regulated genes included CCNB1, CCNB2 CCNF,
CDC20 and BAX (Drews et al., 2012). The total of 993 significantly differentially expressed
genes is depicted in Figure 4.6 (D) including gene expression data of all other groups of sam-
ples for comparison (Drews et al., 2012). To better comprehend the role of these differentially
expressed genes and to associate these genes with signaling pathways, the two gene lists were
functionally annotated using the DAVID database (Dennis et al., 2003; Huang da et al., 2009).
As shown in Table 4.1, the three most highly enriched clusters of up-regulated genes, which
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altogether comprise 129 of the 662 up-regulated genes, represent the response to bacteria
or bacterial structures or drugs (cluster 1, including, e.g., IFNB1, CCL2, CCL5, IL10, IL12,
MYD88 and TICAM1 (TRIF )), innate immune response/innate immunity (cluster 2, includ-
ing, e.g., DDX58 (RIG-I), TRIM25, MYD88 and TICAM1 (TRIF )) and regulation of apoptosis
(cluster 3, including, e.g. GADD45A, PYCARD, CASP7, TNFRSF10A, TNFSF10 (TRAIL) and
NOD1) (Drews et al., 2012). The corresponding list of significantly enriched KEGG path-
ways includes the Jak-STAT signaling pathway, the RIG-I-like receptor signaling pathway, the
cytosolic DNA-sensing pathway, the Toll-like receptor signaling pathway and apoptosis (Ta-
ble 4.1, Figure B.2) (Drews et al., 2012). The initiation of apoptosis upon mRNA transfection is
further supported by the fact that the list of down-regulated genes is highly enriched for gene
clusters associated with cell cycle (cluster 1, including, e.g., BAX, CDKN3, CCNB1, CCNF,
CDC20 and CDKN1B), cytoskeleton (cluster 2) and chromosome condensation (cluster 3) (Ta-
ble 4.2, 114 of 331 down-regulated genes in the three most highly enriched clusters) suggesting
that proliferation is actively inhibited in mRNA-transfected cells (Drews et al., 2012). Accord-
ingly, the list of down-regulated genes is significantly enriched for cell cycle and p53 signaling
pathways as defined by KEGG (Kanehisa and Goto, 2000) (Table 4.2, Figure B.2) (Drews et al.,
2012).
Table 4.1: KEGG pathway enrichment analysis and functional annotation clustering of
the 662 significantly up-regulated genes in mRNA-transfected fibroblasts versus mock-
transfected controls. Modified from Drews et al. (2012).
Category Term Count % PValue
KEGG_PATHWAY hsa04630:Jak-STAT signaling pathway 23 3.66 6.06E-07
KEGG_PATHWAY hsa04622:RIG-I-like receptor signaling
pathway
14 2.23 8.16E-06
KEGG_PATHWAY hsa03050:Proteasome 11 1.75 2.37E-05






KEGG_PATHWAY hsa05322:Systemic lupus erythematosus 14 2.23 2.96E-04
KEGG_PATHWAY hsa04620:Toll-like receptor signaling
pathway
13 2.07 1.25E-03




KEGG_PATHWAY hsa05120:Epithelial cell signaling in
Helicobacter pylori infection
8 1.27 2.66E-02
Annotation Cluster 1 Enrichment Score: 6.1334533046512645
GOTERM_BP_FAT GO:0002237∼response to molecule of
bacterial origin
18 2.86 7.93E-09
Continued on next page
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GOTERM_BP_FAT GO:0009617∼response to bacterium 25 3.97 1.03E-07
GOTERM_BP_FAT GO:0042493∼response to drug 17 2.70 4.80E-03
Annotation Cluster 2 Enrichment Score: 5.714405417076349
SP_PIR_KEYWORDS immune response 28 4.45 4.98E-09
GOTERM_BP_FAT GO:0045087∼innate immune response 17 2.70 3.38E-05
SP_PIR_KEYWORDS innate immunity 12 1.91 4.27E-05
Annotation Cluster 3 Enrichment Score: 5.231835180839759
GOTERM_BP_FAT GO:0008219∼cell death 55 8.74 1.74E-07
GOTERM_BP_FAT GO:0016265∼death 55 8.74 2.14E-07
GOTERM_BP_FAT GO:0012501∼programmed cell death 49 7.79 2.40E-07
GOTERM_BP_FAT GO:0006915∼apoptosis 48 7.63 3.80E-07
GOTERM_BP_FAT GO:0042981∼regulation of apoptosis 58 9.22 5.32E-07
GOTERM_BP_FAT GO:0043067∼regulation of programmed
cell death
58 9.22 7.13E-07
GOTERM_BP_FAT GO:0043065∼positive regulation of
apoptosis
38 6.04 7.16E-07
GOTERM_BP_FAT GO:0010941∼regulation of cell death 58 9.22 8.23E-07
GOTERM_BP_FAT GO:0043068∼positive regulation of
programmed cell death
38 6.04 8.48E-07
GOTERM_BP_FAT GO:0010942∼positive regulation of cell
death
38 6.04 9.44E-07
SP_PIR_KEYWORDS Apoptosis 32 5.09 3.00E-06
GOTERM_BP_FAT GO:0006916∼anti-apoptosis 22 3.50 1.57E-05
GOTERM_BP_FAT GO:0006917∼induction of apoptosis 25 3.97 5.24E-04
GOTERM_BP_FAT GO:0012502∼induction of programmed
cell death
25 3.97 5.46E-04
GOTERM_BP_FAT GO:0043066∼negative regulation of
apoptosis
26 4.13 9.67E-04
GOTERM_BP_FAT GO:0043069∼negative regulation of
programmed cell death
26 4.13 1.17E-03
GOTERM_BP_FAT GO:0060548∼negative regulation of cell
death
26 4.13 1.22E-03
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Table 4.2: KEGG pathway enrichment analysis and functional annotation clustering of
the 331 significantly down-regulated genes in mRNA-transfected fibroblasts versus mock-
transfected controls. Modified from Drews et al. (2012).
Category Term Count % PValue
KEGG_PATHWAY hsa04110:Cell cycle 11 3.62 4.09E-05
KEGG_PATHWAY hsa04114:Oocyte meiosis 10 3.29 8.55E-05




KEGG_PATHWAY hsa04115:p53 signaling pathway 5 1.64 2.74E-02
Annotation Cluster 1 Enrichment Score: 23.110790902697754
GOTERM_BP_FAT GO:0022402∼cell cycle process 58 19.08 2.49E-28
GOTERM_BP_FAT GO:0007049∼cell cycle 65 21.38 6.46E-27
GOTERM_BP_FAT GO:0022403∼cell cycle phase 48 15.79 1.64E-25
SP_PIR_KEYWORDS cell cycle 48 15.79 6.64E-25
SP_PIR_KEYWORDS cell division 38 12.50 1.40E-24
GOTERM_BP_FAT GO:0000279∼M phase 42 13.82 7.83E-24
GOTERM_BP_FAT GO:0000278∼mitotic cell cycle 44 14.47 9.38E-24
GOTERM_BP_FAT GO:0048285∼organelle fission 36 11.84 2.06E-23
SP_PIR_KEYWORDS mitosis 32 10.53 2.86E-23
GOTERM_BP_FAT GO:0007067∼mitosis 35 11.51 6.37E-23
GOTERM_BP_FAT GO:0000280∼nuclear division 35 11.51 6.37E-23
GOTERM_BP_FAT GO:0000087∼M phase of mitotic cell
cycle
35 11.51 1.16E-22
GOTERM_BP_FAT GO:0051301∼cell division 39 12.83 1.23E-22
GOTERM_CC_FAT GO:0005819∼spindle 29 9.54 6.83E-22
GOTERM_CC_FAT GO:0015630∼microtubule cytoskeleton 47 15.46 5.17E-20
Annotation Cluster 2 Enrichment Score: 8.063492575694381
GOTERM_CC_FAT GO:0005819∼spindle 29 9.54 6.83E-22
GOTERM_CC_FAT GO:0015630∼microtubule cytoskeleton 47 15.46 5.17E-20







SP_PIR_KEYWORDS cytoskeleton 35 11.51 4.41E-10
GOTERM_BP_FAT GO:0007017∼microtubule-based process 23 7.57 4.85E-10
GOTERM_CC_FAT GO:0005856∼cytoskeleton 56 18.42 7.49E-10
Continued on next page
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GOTERM_CC_FAT GO:0005874∼microtubule 21 6.91 3.95E-08
GOTERM_CC_FAT GO:0005813∼centrosome 19 6.25 4.54E-08
SP_PIR_KEYWORDS microtubule 18 5.92 1.49E-07
SP_PIR_KEYWORDS motor protein 11 3.62 4.40E-05
UP_SEQ_FEATURE domain:Kinesin-motor 7 2.30 5.42E-05




GOTERM_MF_FAT GO:0003777∼microtubule motor activity 8 2.63 2.28E-04




SMART SM00129:KISc 6 1.97 4.97E-04




SP_PIR_KEYWORDS centromere 12 3.95 9.49E-12
SP_PIR_KEYWORDS kinetochore 13 4.28 2.27E-10




GOTERM_CC_FAT GO:0005694∼chromosome 28 9.21 1.62E-08




GOTERM_CC_FAT GO:0000776∼kinetochore 10 3.29 5.67E-06
SP_PIR_KEYWORDS chromosomal protein 10 3.29 4.72E-04
According to the Interferome database (Samarajiwa et al., 2009), 249 of the 662 up-regulated
genes and 40 of the 331 down-regulated genes are so-called interferon-regulated genes (IRGs),
i.e. they are transcriptionally regulated by distinct interferons, in this case mainly type I
interferons, such as IFNB1, and to a lesser extent type II and III interferons (Table B.6
and Table B.7) (Drews et al., 2012). This emphasizes the key role type I interferons play
in the regulation of innate immunity. Thus, the immune response observed upon mRNA
transfection of fibroblast cells may be referred to as innate interferon response (Angel and
Yanik, 2010; Drews et al., 2012).
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Analysis of innate immune response-associated transcript levels in human neonatal
fibroblasts following mRNA transfection
Next, the increased expression levels of immune-related genes observed for the microarray-
derived transcriptome data were verified by qRT-PCR. On that account we chose to assess
the expression of a set of innate immune response-related genes from the microarray-derived
data, which were already strongly affected during retroviral reprogramming experiments (Mah
et al., 2011). The encoded proteins are known to be relevant at distinct levels of the antiviral
innate immune response, as already partly mentioned above. They are either directly involved
in the recognition and binding of exogenous, putatively pathogenic, nucleic acids (RIG-I
(DDX58) (Pichlmair et al., 2006; Binder et al., 2011), PKR (EIF2AK2) (Baglioni et al., 1981;
McAllister and Samuel, 2009), OAS1 (Baglioni et al., 1981; Kristiansen et al., 2010) and IFIT1
(Pichlmair et al., 2011)), key regulators of transcription during the innate immune response
(IFNB1 (Yoneyama and Fujita, 2010)), intra- or extracellular transducers of the stimulus (IL12A
(CLMF, NKSF1) (Tahara and Lotze, 1995; Katashiba et al., 2011), IRF7 (Kawai et al., 2004;
Yoneyama and Fujita, 2010), STAT2 (Uddin et al., 1995), CCL5 (RANTES) (Schall et al., 1990;
Genin et al., 2000)) or viral restriction factors (ISG20 (Espert et al., 2003; Zhou et al., 2011),
TRIM5 (Rold and Aiken, 2008; Pertel et al., 2011). Interestingly, all of these genes have been
shown to be regulated by interferons as determined with the help of the Interferome data
base (Table B.6) (Drews et al., 2012). As shown in Figure 4.7, qRT-PCR demonstrated the
up-regulation of all 11 genes under investigation in both BJ and HFF1 neonatal fibroblasts
24 h post- transfection of a mix of reprogramming factor-encoding mRNAs when compared
to mock-transfected control cells (Drews et al., 2012).
Figure 4.7: qRT-PCR of innate immune response-associated transcripts in mRNA-transfected
human fibroblasts. BJ and HFF1 cells were transfected with a 1:1:1:1:1 cocktail of
reprogramming factors OSKML-encoding mRNAs (4µg per 6-well) and harvested 24 h later
for RNA isolation. Bars and error bars represent average LOG2 ratios of transfected fibroblasts
over mock-transfected controls and SD. n= 3 technical replicates per cell line. Taken from
Drews et al. (2012).
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Analysis of the innate immune response to different cellular reprogramming approaches
in human neonatal fibroblasts
In a next step, we were interested in a comparison of the magnitude of this innate immune
response induced by reprogramming experiments based on different delivery protocols.
We further intended to determine the immune response triggered by transfection of the
commercially available modified mRNAs, which were used for cellular reprogramming by
Warren et al. (2010) to ensure that the immunogenic effects observed for the in-house produced,
unmodified mRNA was not solely due to the alterations in the in vitro synthesis of mRNAs
but rather a general mRNA-mediated effect. To this end gene expression levels of the same set
of innate immune response-associated genes were assessed after
• retroviral transduction of a 1:1:1:1 cocktail of the reprogramming factors OSKM, one
transfection of a 1:1:1:1 cocktail of the reprogramming factors OSKM using the in-house
synthesized, unmodified mRNA,
• two subsequent transfections (day1, day2) of a 1:1:1:1 cocktail of the reprogramming
factors OSKM using the in-house synthesized, unmodified mRNA,
• one transfection of a 1:1:1:1 cocktail of the reprogramming factors OSKM using
commercially bought, modified mRNA or
• one transfection of a mix of pluripotency-promoting miRNAs (miR-302s/367).
(Concerning the series of retroviral and miRNA tests, the experimental setup was based on
either our own or published reprogramming experiments (Wolfrum et al., 2010; Anokye-
Danso et al., 2011; Miyoshi et al., 2011). The functionality of the modified mRNA from
Stemgent was assessed prior to the experiments (Figure B.3).
To verify successful delivery and functionality of the in-house synthesized transfected/
transduced factors and, thus, to enable feasibility of comparing the resulting data, protein
expression of one of the reprogramming factors (SOX2) was monitored by detection with
immunofluorescence dye-labeled antibodies whenever reprogramming factors were directly
delivered to the cells as either retroviruses or mRNAs (Figure B.4 (A – C)). For the miRNA
approach, expression levels of PODXL were assessed by qRT-PCR instead (Figure B.4 (D)).
This gene was chosen on the basis of our recent finding that PODXL, a surface marker
expressed in human ESCs, iPSCs and embryonal carcinoma cells (Tan et al., 2009), is up-
regulated as early as 24 h post-transduction of OSKM-encoding retroviruses during cellular
reprogramming (Mah et al., 2011).
Despite the fact that only the absolute quantities of gene expression levels resulting from
the different mRNA transfection approaches can be directly compared, Figure 4.8 highlights
that the magnitude of up-regulation of the innate interferon response genes was notably
different in the methods under investigation: Of all the cellular reprogramming techniques
applied herein, the transfection of our unmodified reprogramming factor mRNA, although
capped and poly(A)-tailed, shows the strongest up-regulation of immune-associated genes
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Figure 4.8: Expression levels of innate immune response-associated genes and introduced
reprogramming factor genes in HFF1 cells upon delivery of reprogramming factors by diverse
methods. HFF1 cells were transfected with a 1:1:1:1 cocktail of mRNAs encoding POU5F1,
SOX2, KLF4 and c-MYC. Transfections were carried out once or twice (‘1 mRNA’, ‘2 mRNA’,
respectively; 4µg total per 6-well per transfection). The mRNAs were either synthesized in
our laboratory (‘mRNA’) or commercially bought (‘modified mRNA’). Alternatively, HFF1
cells were transduced once with a 1:1:1:1 combination of retroviruses encoding POU5F1,
SOX2, KLF4 and c-MYC or transfected once with a 1:1:1:1:1 mix composed of the human
miRNA mimics miR-302a, miR-302b, miR-302c, miR-302d and miR-367 (100 pmol total
per 6-well). All samples were harvested for RNA isolation 24 h after the last transfection/
transduction. (A) Levels of innate immune response-associated transcripts. (B) Expression
levels of the reprogramming factor genes. Bars and error bars represent average LOG2 ratios of
transfected/transduced fibroblasts over mock-transfected/-transduced controls and SD. n= 6
for ‘1 mRNA’; n= 4 for ‘2 mRNA’; n = 3 for ‘Retrovirus’, ‘modified mRNA’ and ‘miRNA’.
Modified from Drews et al. (2012).
(Drews et al., 2012). Interestingly, the second transfection with the same mRNA cocktail
24 h after the first one, slightly increases the expression levels of only a few genes such as
PKR, IL12A, ISG20, yet, does not have a strong overall augmenting immunogenic effect.
This suggests that the cellular immune response is almost maximally up-regulated already
after the first round of transfection (Drews et al., 2012). In contrast, transcript levels of the
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reprogramming factors were slightly increased after the second transfection when compared
to those levels determined after the first transfection (Drews et al., 2012). Regarding the
corresponding immunofluorescent detection of reprogramming factor proteins, which were
performed as transfection controls, however, SOX2 expression was negligible after the second
round of mRNA transfection (Figure B.4 (C)) (Drews et al., 2012).
Transfection of the commercially available modified mRNAs from Stemgent, which, in
contrast to our mRNA, contained pseudouridine and 5-methylcytidine-modified nucleotides
and was phosphatase-treated, resulted in markedly reduced expression levels of almost all
immune response-associated genes compared to transfection with our unmodified mRNA
as expected (Drews et al., 2012). However, transfection of modified mRNAs was unable to
prevent the up-regulation of innate interferon response. Transcript levels of most of the
immune response-associated genes were still high compared to mock-transfected controls.
At the same time, the number of reprogramming factor transcripts in the cell were notably
less when compared to the transfections with the same amount of our in vitro synthesized,
unmodified mRNAs (Figure 4.8) (Drews et al., 2012).
Expression levels of both immune response-associated and reprogramming factor genes of
cells transduced with a retroviral reprogramming factor cocktail were similar to those detected
upon transfection of commercially available, modified mRNAs (Drews et al., 2012). Finally, an
up-regulation of the endogenous reprogramming factor-encoding genes by miRNAs could not
be observed as early as 24 h post-transfection as anticipated (Drews et al., 2012). In contrast,
PODXL transcript levels were elevated when compared to cells transfected with scramble
miRNAs 24 h post-transfection although the magnitude of up-regulation was less compared
to the single and double transfections of unmodified RNAs and the cocktail of retroviruses
(Figure B.4 (D)). Interestingly, transfection of the pluripotency-promoting miRNAs did not
trigger any immune response (Figure 4.8) (Drews et al., 2012).
Next, for the in-house synthesized, unmodified mRNA, the retroviruses and the miRNAs
we checked whether the immune response is dependent on the specific factors by substituting
the reprogramming factors with GFP-encoding mRNAs or retroviruses or a scrambled
control, respectively.
Logically, GFP transfection did not induce a marked alteration of reprogramming factor
transcript levels despite normal variation (Figure 4.9) (Drews et al., 2012). Yet, the immune
response gene expression levels followed the exact same pattern and the absolute transcript
quantities were similar when compared to those observed for all respective delivery techniques.
This was also observed in the case of retroviral transduction of GFP, in which, for practical
reasons, the amount of GFP-encoding particles were equivalent to only one quarter of the
total amount of viral transduction units used for the mix of reprogramming factors (Drews
et al., 2012).
Effect of immune modulators on the innate immune response in human neonatal
fibroblasts upon transfection of reprogramming factor-encoding mRNAs
Knowing that the main roadblock in our mRNA reprogramming experiments is the vigorous
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Figure 4.9: Expression levels of immune response-associated genes and reprogramming factor
genes in HFF1 cells upon delivery of control genes by diverse methods. Repetition of the
HFF1 transfection/transduction experiments as described in Figure 4.8. Yet, this time, the
total amount of mRNAs and miRNAs used for reprogramming were substituted with the same
amount of GFP-encoding mRNA (‘1 mRNA’, ‘2 mRNA’; 4µg total per 6-well per transfection)
or a scrambled miRNA (100 pmol total per 6-well). Similarly, cells were transduced with
a GFP-encoding retrovirus equivalent to the amount of retrovirus encoding one of the
reprogramming factors in the reprogramming OSKM cocktail. (A) Levels of innate immune
response-associated transcripts. (B) Expression levels of the reprogramming factor genes. Bars
and error bars represent average LOG2 ratios of transfected/transduced fibroblasts over mock-
transfected/-transduced controls and SD. n= 6 for ‘1 mRNA’; n= 4 for ‘2 mRNA’; n= 3 for
‘Retrovirus’ and ‘miRNA’. Modified from Drews et al. (2012).
activation of an innate interferon response, we next tried to identify substances that could
possibly suppress this immune reaction. Hence, we sought to determine the ability of different
immune modulators to prevent up-regulation of the different innate immune response-
associated genes by qRT-PCR.
The first molecule of choice to suppress the innate interferon response is B18R, a virus-
encoded decoy receptor specific for type I interferons of various species, which neutralizes
signaling via type I interferon receptors (INFAR1/2) (Colamonici et al., 1995; Symons et al.,
1995; Galligan et al., 2006). B18R was described to prevent transmembrane signaling and
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transcriptional regulation of the interferon regulated genes (Colamonici et al., 1995; Symons
et al., 1995). For this reason it was also used in the only mRNA-based reprogramming
protocol published so far (Warren et al., 2010). With this in mind, we applied it to our mRNA
transfection protocol. As shown in Figure 4.10 (A), in an initial experiment, this treatment did
not have any measurable effect on expression levels of the immune response-associated genes
after mRNA transfection even though all of these genes are known to be IRGs as determined
by the Interferome database (Table B.6) (Drews et al., 2012). However, as this result is in line
with our previous finding that B18R did not have any effect on the efficiency of retroviral
reprogramming (Mah et al., 2011) we did not pursue investigations using B18R further.
Chloroquine was originally synthesized as an antimalarial drug but pleiotropic functions
of this substance have been reported (Cooper and Magwere, 2008). For example, the lysosomo-
tropic substance chloroquine was used in specific transfection setups to increase efficiency
either by enhancing endosomal escape of nucleic acids to be delivered through endosomal
disruption and/or by delaying the traffic of endocytosed nucleic acids into lysosomes,
retarding their degradation (Wattiaux et al., 2000). Several immune-modulatory, anti-inflamma-
tory effects of chloroquine such as the ability to inhibit TNF-α and IL-1β and IL-6 production
in lipopolysaccharide-stimulated human monocytes or macrophages (Jang et al., 2006) were
discussed by Cooper and Magwere (2008). In the last decade Chloroquine has also been tested
as therapeutic against viral infections such as HIV retroviral infections (Savarino et al., 2003).
The observation that chloroquine can reduce type I interferon (INFA) production in CpG-
DNA-stimulated or viral ssRNA-stimulated plasmacytoid-derived dendritic cells (Diebold
et al., 2004; Katashiba et al., 2011) and IL12 production in ssRNA poly(U)-stimulated
monocyte-derived dendritic cells (Katashiba et al., 2011) intrigued us to examine the ability
of chloroquine to suppress the immune response following mRNA transfection in fibroblast
cells. Strong up-regulation of the adapter molecules MYD88 and IRF7 (Table B.4), which are
mediators of nucleic acid recognition signaling pathways triggered by mRNA transfection
(Yoneyama and Fujita, 2010), further encouraged us to test chloroquine. However, when
treating cells prior to, during and following mRNA transfections with 5µM, 50µM and
100µM of chloroquine (Diebold et al., 2004; Jang et al., 2006; Katashiba et al., 2011),
we primarily noticed strong concentration-dependant cytotoxic effects, which resulted in
decreased viability of cells treated with 50µM chloroquine and death of almost all cells treated
with 100µM chloroquine (Drews et al., 2012). Although a few of the innate interferon
response-associated gene expression levels (e.g., RIG-I, OAS1, CCL5, ISG20) were slightly
reduced upon chloroquine treatment when compared to controls (Figure 4.10 (B)), these
reductions were not sufficient to balance the cytotoxic effects of this molecule—especially with
the intention to use chloroquine in a protocol including numerous subsequent transfections
as required for the induction of pluripotency in somatic cells (Drews et al., 2012).
Trichostatin A (TSA) is a Streptomyces metabolite. It was first discovered as an antifungal
antibiotic, which was shown to inhibit mammalian histone deacetylases later on (Tsuji et al.,
1976; Yoshida et al., 1990). Interestingly, Huangfu et al. (2008) highlighted its potential to
enhance cellular reprogramming processes in mouse embryonic fibroblasts. Concerning its
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immune-modulatory capacity, it was reported to block un-methylated CpG oligonucleotide-
induced up-regulation of INFα, INFβ, IFNλ and INFω and other pro-inflammatory cytokines,
namely IL-6, TNF-α, and TRAIL in plasmacytoid dendritic cells, which was associated with
blocking nuclear translocation of the transcription factor IRF7 (Salvi et al., 2010). In view of
this, we next tested its potential in inhibiting innate interferon response following mRNA
transfection of HFF1 fibroblasts, which significantly up-regulated IRF7. No remarkable
effect on the transcript levels of the innate immune response gene test set was observed
(Figure 4.10 (C)) (Drews et al., 2012). Solely the expression levels of CCL5 and ISG20 in 500 nM
TSA-treated cells were reduced when compared to untreated, mRNA-transfected samples.
However, the absolute gene expression values were still much higher than those determined
for treated, mock-transfected controls (Drews et al., 2012).
Pepinh-TRIF and pepinh-MYD are two peptide inhibitors designed to contain domains
of the signaling adapter molecules TRIF and MYD88, which facilitate interaction with the
respective pattern-recognition receptors TLR3 or TLR7/8 (Loiarro et al., 2005; Toshchakov
et al., 2005). Competing with endogenous TRIF and MYD88 for association with the PRRs,
these two peptide inhibitors were shown to attenuate signaling to the nucleus, thereby
suppressing the up-regulation of innate immune response genes, the very first step in pathogen
defense. Especially since both TRIF and MYD88 were significantly up-regulated upon mRNA
transfection in fibroblast cells (Table B.4 and Table S3 of Drews et al. (2012)), pepinh-TRIF and
pepinh-MYD were promising candidates with respect to the modulation of the innate immune
response in mRNA-transfected fibroblasts despite the potential lack of TLR7/8 expression in
human neonatal foreskin fibroblasts. Treatment of HFF1 cells prior to, during and following
mRNA transfections with the suggested concentration of 20µM, however, did not lead to a
marked reduction of any of the immune response-associated transcript levels (Figure 4.10 (D))
(Drews et al., 2012).
4.2.3 Cellular reprogramming by means of miRNA transfection
From the preceding experiments it is known that transfections of miRNAs do not trigger an
innate immune response in the target cells. We therefore sought to exploit this circumstance by
using this novel approach to induce pluripotency in somatic cells. miRNA-mediated cellular
reprogramming is independent of the direct overexpression of the original reprogramming
factors OCT4, SOX2 and KLF4, c-MYC or NANOG, LIN28. Instead, it is based on the
delivery of miRNAs that are preferentially expressed in ESCs to support the pluripotent
phenotype (Anokye-Danso et al., 2011; Miyoshi et al., 2011). On the basis of these findings,
we performed a pilot experiment and transfected bulk human AFCs with a cocktail of
miRNA mimics of the miR-302/367 cluster and subsequently maintained them under human
PSC conditions. Yet, no morphological changes, no formation of colonies with granulated
or human ESC-like morphology was observed after treatment of about 1× 106 cells. The
experiments were terminated after approximately one month of culture. In contrast to
the techniques employing the original reprogramming factors, the mechanisms underlying
miRNA-mediated cellular reprogramming were even more elusive at this point. Thus, further
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investigations and optimization were required and are currently on-going in our laboratory to
establish the miRNA-mediated induction of pluripotency in somatic cells.
4.3 Discussion
The stem cell field is a competitive area of research that progresses at a breathtaking pace.
The groundbreaking development of iPSCs greatly contributed to that. In view of the fact
that human iPSCs offer enormous opportunities in regenerative medicine, the field has been
striving to generate clinical-grade iPSCs. Most importantly, this comprises the establishment
of reprogramming protocols that allow for the induction of pluripotency without genomic
alteration of the target cells. Various promising strategies have been reported to achieve this
goal including transduction of reprogramming factor-encoding adenoviruses (Zhou and Freed,
2009) or Sendai viruses (Fusaki et al., 2009), nucleofection of episomal plasmids (Yu et al.,
2009), treatment with recombinant reprogramming factor proteins (Kim et al., 2009a) and
transfection of reprogramming factor-encoding mRNAs (Warren et al., 2010) or human ESC-
specific miRNAs (Miyoshi et al., 2011). However, unlike the robust originally published
integrating virus-mediated reprogramming method published by Takahashi et al. (2007); Yu
et al. (2007), to date none of these methods have successfully been established as a standard
reprogramming protocol and the amount of time that has passed since the last reported
innovations increases.
4.3.1 Cellular reprogramming bymeans of episomal plasmids requiresfurther optimization
The first attempt to generate iPSCs from human AFCs by non-viral, non-integrating approaches
was based on nucleofection of episomal plasmids as initially published by Thomson and
colleagues for human newborn foreskin fibroblast cells (Yu et al., 2009). We employed the
most-effective plasmid combination to induce pluripotency in human AFCs. Surprisingly, not
a single mature, expandable iPSC colony was obtained during several rounds of nucleofection
although several millions of cells had been used as input. There are several possible factors that
may have contributed to the poor outcome of these experiments.
Generally, direct reprogramming of somatic cells into iPSCs is thought to depend on the
amount, balance and continuity of transgene expression (Yamanaka, 2009b). In the particular
case of episomal plasmid-mediated reprogramming meeting all these conditions is especially
intricate. First of all, in contrast to the original protocols of virus-mediated reprogramming
(Takahashi et al., 2007; Yu et al., 2007), a total of seven reprogramming factors is used (OCT4,
SOX2, KLF4, c-MYC, NANOG, LIN28 and SV40 large T antigen) (Yu et al., 2009). These
factors are encoded on different vectors, which are combined for nucleofection. Moreover,
two genes are regulated by a single promoter sequence and co-expression is mediated by the
internal ribosome entry site 2 (IRES2) (Figure 4.1). Taken together, this dramatically reduces
the chances of sufficient expression of each of the reprogramming factors and potentially
impairs an optimally stoichiometric balanced, well-orchestrated simultaneous expression of
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all transgenes particularly in conjunction with the extensive loss of cell viability induced by
electroporation. Without active selection it is further unclear, for how long the episomal
plasmids remain in the transfected cells to mediate adequate transgene expression (Yu et al.,
2009). In addition to that it is a matter of debate, whether all cells in one sample have an equal
opportunity to acquire the pluripotent state (stochastic model) or whether only certain cells
in one sample are more competent to become iPSCs (elite model) (Yamanaka, 2009b). For
human AFCs it is tempting to believe that the few putative stem cell-like subpopulations have
greater chances to become fully reprogrammed or that, at least, they require less time. Another
major drawback of the episomal plasmid-based approach is the enormous size of the episomal
plasmids ranging from 12852 bp to 19949 bp, which is likely to hamper efficient transgene
delivery. In summary it should become clearer, why reprogramming by means of episomal
plasmids is generally rather inefficient.
However, there might be other more specific factors, which may have additionally contribu-
ted to the poor experimental outcome. For example, one might expect the age of the cells,
which were used as starting material to be one critical factor. Especially for the one human
AFC line, which had already been used for retrovirus-mediated reprogramming, the cells
had partly been cultured to P10 prior to nucleofection. As described earlier, human AFCs
senesce relatively early (Wolfrum et al., 2010). It could be assumed that a limited proliferation
potential of higher passage human AFCs may have impeded this reprogramming approach.
Interestingly, however, the episomal plasmid-mediated cellular reprogramming includes the
SV40 large T antigen as ‘reprogramming factor’ as mentioned above (Yu et al., 2009). The
oncogene SV40 large T antigen is known to drive cells into the S-phase of cell cycle, thereby
inducing proliferation and transformation of cells (Ahuja et al., 2005). Hence, it could be
speculated that the SV40 large T antigen expression in the target cells should have balanced
potential proliferation deficits. This, together with the observation that the use of early passage
human AFCs did not facilitate reprogramming either, leads me to exclude the passage number
of the target cells to be a major influencing factor.
Nucleofection is usually performed employing cell line-specific nucleofection solutions
and electric impulse parameters (Yu et al., 2009). This is, however, impossible as for heteroge-
neous samples of human AFCs no particular kit is available. Referring to several reports, which
highlight the presence of MSC populations in human AFCs amongst others (In ’t Anker et al.,
2003; Tsai et al., 2004, 2006; Bossolasco et al., 2006; Kim et al., 2007; De Coppi et al., 2007;
Sessarego et al., 2008; You et al., 2009), it was assumed that the use of MSC-specific settings and
solutions would promote an efficient transgene delivery, while preventing exceedingly high
levels of cell death. It is unclear, however, if the use of a different nucleofection kit and other
nucleofection parameters, e.g. for neuronal or epithelial lineage cells, would have been more
advantageous.
We included several small molecules to possibly enhance the reprogramming process,
namely BAPN (0.25 mM) (Tang et al., 1983) or thiazovivin (2µM), alone or in combination
with ALK4/5/7 inhibitor SB431542 (2µM) and MEK inhibitor PD0325901 (0.5µM) (Lin
et al., 2009). In the case of heterogeneous human AFCs it cannot be exactly specified,
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which particular cell type the reprogramming process starts from (Gosden, 1983). It can be
anticipated, however, that at least a certain proportion of the cells is of mesenchymal origin
(In ’t Anker et al., 2003; Tsai et al., 2004, 2006; Bossolasco et al., 2006; Kim et al., 2007;
De Coppi et al., 2007; Sessarego et al., 2008; You et al., 2009). These will have to undergo the
process of mesenchymal to epithelial transition (MET) to become iPSCs of epithelial nature
(Wang et al., 2010). The combined TGFβ and MEK/ERK pathway inhibition by SB431542
and PD0325901 treatment is believed to enhance the generation of iPSCs from fibroblast
cells by promotion of MET (Lin et al., 2009). BAPN has not yet been implicated in direct
reprogramming. This chemical is rather known for its ability to inhibit the activity of all
lysyl oxidases (Pinnell and Martin, 1968; Lugassy et al., 2012). Activation of lysyl oxidases,
in turn, has been shown to be required for hypoxic repression of cadherin-1 (E-cadherin),
which induces epithelial to mesenchymal transition (EMT) and thereby mediates cellular
transformation and tumor progression (Schietke et al., 2010). In view of these findings, we
hypothesized that BAPN may enhance reprogramming of human AFCs by inhibiting lysyl
oxidases and, thus, blocking EMT and promoting MET. Interestingly, BAPN treatment was
applied in the case where the only potential iPSC colony was obtained, which, however,
proliferated markedly slower than other human PSC lines. This observation is especially
astonishing in view of the of the SV40 large T antigen transgene expression in those cells.
This ESC-like colony also spontaneously differentiated to a high degree so that it could not
successfully be established as iPSC line. It is unclear whether this could have been an undesired
side effect of the small molecule BAPN. Generally, however, with respect to the use of small
molecules in this study it can be concluded that neither BAPN nor any of the other chemicals
positively influenced the induction of pluripotency due to the poor overall outcome.
Unfortunately, the majority of episomal-based reprogramming experiments had been
conducted prior to two follow-up publications by Chou and co-workers. and Yu and
colleagues. While Chou et al. (2011) developed an improved OriP/EBNA episomal plasmid,
which encodes five reprogramming factors (OSKML) in a single poly-cistronic unit, to derive
iPSCs from human blood mononuclear cells, Yu et al. (2011) described the use of other
small molecules to greatly enhance the induction of pluripotency in skin fibroblasts, adipose
tissue-derived cells and cord blood cells by nucleofection of the original episomal plasmid
vectors. The combinations and amounts of nucleofected episomal plasmids varied only slightly.
Yet, besides TGFβ and MEK/ERK pathway inhibition by A-83-01 (0.5µM) and PD0325901
(0.5µM), which is similar to our treatment, they found simultaneous treatments with other
small molecules to increase the reprogramming efficiency. Hence, it can be anticipated that the
combined use of ROCK inhibitor HA-100 (10 µM), PD0325901 (0.5µM), CHIR99021 (3µM),
A-83-01 (0.5µM) and hLIF (1000 U/ml) as well as supplementation of MEF-conditioned
human ESC medium with 100 ng/ml FGF2, instead of the usual 4 ng/ml in unconditioned
medium and 8 ng/ml in MEF-CM (Yu et al., 2011) would have improved the experimental
outcome. In fact, it is currently being observed in our laboratory that the implementation of
this modified protocol (Yu et al., 2011) instead of the original one (Yu et al., 2009) enables a
more efficient induction of pluripotency in human foreskin fibroblasts and MSCs (Matthias
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Megges, Kalina Tosheva, Peggy Matz, unpublished data). A modification of the nucleofection
protocol to include the above mentioned small molecules and the improved episomal plasmid
is thus recommended for future experiments. Considering that episomal-derived iPSCs do not
harbor integration events as recently demonstrated by deep whole-genome sequencing (Cheng
et al., 2012), an optimization of the episomal plasmid-mediated reprogramming protocol
appears worthwhile.
4.3.2 mRNA-mediated induction of pluripotency is hampered by aninnate interferon response
The second attempt to generate iPSCs from human AFCs by non-viral, non-integrating
approaches was based on transfection of in vitro transcribed mRNAs encoding the originally
published reprogramming factors (Takahashi et al., 2007; Yu et al., 2007). This approach failed
due to severe loss of cell viability following continued transfection of mRNAs into human
AFCs and human foreskin fibroblasts. Thus, we examined the effect of the transfections on the
cells in greater detail using human foreskin fibroblast cells due to their increased availability.
The genome-wide gene expression analysis revealed that an overall transcriptome shift
towards pluripotent cells did not occur as early as 24 h post-transfection of a cocktail of
reprogramming factor-encoding mRNAs into human neonatal foreskin fibroblasts. Yet, we
could identify an overlap of 148 genes in reprogramming factor mRNA transfected fibroblast
cells and the union of pluripotent FiPSCs and ESCs. Their relevance as potential early
pluripotency-associated markers of reprogramming warrants further investigations.
As the main result of the microarray-based transcriptome analysis we highlighted the
strong innate immune reaction, an interferon-mediated response, to be the key roadblock
during reprogramming by means of frequent mRNA transfections, which is in line with other
reports (Angel and Yanik, 2010; Mah et al., 2011). According to the recent understanding,
purified, in vitro synthesized reprogramming factor-encoding mRNA triggers an immune
response via its recognition by pattern-recognition receptors (PRRs) upon transfection
similarly to microbial or viral infections (Yoneyama and Fujita, 2010; Angel and Yanik, 2010;
Drews et al., 2012). In principle, the endocytic uptake route of lipofected nucleic acids (Khalil
et al., 2006) suggests a primary role for TLR3 and TLR7/8 in the recognition of the transfected
mRNAs due to their endosomal location (Yoneyama and Fujita, 2010). TLR3 preferentially
detects double-stranded RNAs, whereas TLR7/8 mainly recognizes single-stranded RNAs
(Yoneyama and Fujita, 2010). As mRNAs usually form complex secondary structures (images
of predicted minimum free energy secondary structures of the reprogramming factor mRNAs
obtained from the RNAfold WebServer (Gruber et al., 2008) are depicted in Figure B.1)
and parameters such as pH vary along the endocytic pathway, it is generally difficult to
precisely predict, exactly which of these PRRs are specifically involved in the detection of
the different transfected mRNA molecules (Drews et al., 2012). It is further known that
TLR3 and TLR7/8 are preferentially expressed in immune cells (Yoneyama and Fujita, 2010).
Accordingly, the microarray data derived in this part of the PhD project point towards an
Chapter 4. Non-viral generation of amniotic fluid-derived iPSCs 102
up-regulated expression of TLR3 in fibroblasts upon mRNA transfection, whereas TLR7/8
receptors are not expressed in any of the samples under investigation. Without confirmation
of these data by the more sensitive qRT-PCR, however, this finding, taken by itself, does not
exclude latent, low level expression of TLR7/8 in human neonatal foreskin fibroblasts (Drews
et al., 2012).
Cytoplasmic receptors should also play an essential role in the recognition of mRNAs as
soon as they are accessible in the cytoplasm, e.g., after endosomal escape of the transfected
mRNAs (Wattiaux et al., 2000). RIG-I (DDX58) and MDA5 (IFIH1) are such cytoplasmic
PRRs and, according to the microarray data, expression of the corresponding genes is highly
up-regulated upon mRNA transfection (Table B.4) (Drews et al., 2012). An important role of
cytoplasmic receptors is supported by Kato et al, who reported that, indeed, infection of mouse
embryonic fibroblasts with several single-stranded RNA viruses was RIG-I- rather than TLR-
dependent (Kato et al., 2005). Yet, clarification as to which of the various possible receptors
or which combination of receptors is eventually responsible for the detection of so-called
pathogen-associated molecular pattern (PAMP) in this particular case of mRNA lipofection
requires further detailed investigations.
Regardless of this, our data emphasized that the PRR(s) involved subsequently triggered an
increased translation of type I interferons, like IFNB1, and pro-inflammatory cytokines such
as CCL2, CCL5, IL10 and IL12A (Drews et al., 2012). Especially the type I interferons, in turn,
provoked positive feedback regulation in an autocrine and paracrine fashion, which enhanced
different defense mechanisms against the putative pathogen attack in the same and neighboring
cells sensitizing them towards foreign nucleic acids (Angel and Yanik, 2010). This may explain
why the observed immune response was at its maximum already after the first transfection.
As a consequence of the interferon signaling, PRRs like RIG-I, MDA5, including those which
elicit antiviral/antimicrobial activities such as OAS1, PKR and ADAR, were significantly up-
regulated in mRNA transfected fibroblast cells along with a number of signaling molecules
(JUN (as part of the transcription factor AP-1), IRF7, MYD88, IRAK4 etc.) (Table B.4 and Table
S3 of Drews et al. (2012)). Concomitantly, interferon-responsive cell cycle-associated genes
were down-regulated and apoptosis-associated genes up-regulated (Drews et al., 2012). This is
in line with Johnston et al. (2005), who demonstrated induction of IFNB1, PKR, OAS1 as well
as cell death in human dermal fibroblasts stimulated with dsRNA. It must be assumed that,
along with the impaired cell viability, protein translation was blocked and the foreign nucleic
acids degraded as a result of these gene regulatory processes (Brown et al., 1976; Sen et al.,
1976; Clemens and Williams, 1978; Levin et al., 1981; Sadler and Williams, 2008) as further
supported by the humble signals detected for immunofluorescence-labeled SOX2 24 h after
the second consecutive transfection (Figure B.4). Hence, treatments with the small molecules
EDHB, SB431542, PD0325901 and thiazovivin to enhance the process of reprogramming in
these cells (Lin et al., 2009; Prigione et al.) were ineffectual, as an efficient expression of the
pluripotency-inducing transgenes was suppressed. This probably represents the key difference
between retroviral and mRNA-mediated reprogramming. We observed similar transgene
and immune response-associated gene expression levels in modified mRNA-transfected and
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retrovirally transduced fibroblasts 24 h after the introduction of the reprogramming factor-
encoding transgenes (Figure 4.8). Whereas this level of immune response induction still
mediates efficient induction of pluripotency in somatic cells when retroviruses are employed
(Wolfrum et al., 2010; Mah et al., 2011), it triggers severe loss of cell viability and failure of
the reprogramming experiment when the transgenes are delivered as mRNAs. It should be
emphasised, at this point, that the observed expression of retrovirally encoded reprogramming
factor genes should not have reached the maximum 24 h post-transduction as demonstrated
by the increase in immunofluorescent signal intensity of reprogramming factors proteins
from 24, to 72 h post-transduction in our recent publication (Mah et al., 2011). In contrast,
the exogenous expression levels measured for the modified mRNA-transfected cells were
presumably the highest possible. Hence, although the level of the immune response is the
similar in both cases, the different outcome of retrovirus versus mRNA-mediated induction of
pluripotency are most likely attributable to the consistent reprogramming factor expression
from integrated transgene sequences in retrovirally transduced cells (Mah et al., 2011) as
opposed to a loss of transgene expression due to a block of processing and active degradation
of consecutively delivered mRNAs in non-viral reprogramming (Brown et al., 1976; Sen et al.,
1976; Clemens and Williams, 1978; Levin et al., 1981; Sadler and Williams, 2008).
Hence, in order to facilitate efficient reprogramming of somatic cells by means of mRNA
transfection it will be inevitable to identify ways to suppress the innate immune response
triggered by the transgene delivery. Although B18R, chloroquine, TSA and pepinh-TRIF and
pepinh-MYD are known to interfere at distinct levels of innate immune response-associated
signaling pathways (Diebold et al., 2004; Loiarro et al., 2005; Toshchakov et al., 2005; Salvi
et al., 2010; Warren et al., 2010; Katashiba et al., 2011), we could not demonstrate a measurable
immune suppressing effect (Drews et al., 2012). For B18R this was especially surprising as its
putative immune suppressing capacity was highlighted for mRNA-mediated reprogramming
in human fibroblasts (Warren et al., 2010). With respect to chloroquine, it is likely that
its cytotoxic effect superimposed its immune suppressing capacity. Notwithstanding, it
remains unknown, why the different substances were ineffective. As most of their above
described immune modulatory effects were determined in cells directly involved in the
immune system such as macrophages or plasmacytoid-derived dendritic cells there appear
to be crucial differences in the signaling pathways, which induce the innate immune response
upon recognition of foreign nucleic acids, between immune and fibroblast cells. Functional
studies, on the basis of the data set presented herein, should bring further insights and enable
the identification of truly effective chemical immune suppressors which mediate efficient
induction of pluripotency in somatic cells by mRNAs. Furthermore, reprogramming factor-
encoding mRNAs could be co-expressed with siRNAs targeting innate immune response-
relevant genes (Angel and Yanik, 2010).
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4.3.3 Transfection of miRNAs resembles a promising reprogrammingapproach
One of the key results of the qRT-PCR analysis comparing immune response-associated
transcript levels among different reprogramming approaches was that miRNAs did not
markedly induce any of the tested genes. We are convinced that this observation was a result of
the length and structural characteristics of the miRNA mimics leading to their recognition as
endogenous Dicer products and to evade the immune system (Marques et al., 2006) rather than
unsuccessful delivery. In support of this, delivery of the miRNAs into the target cells resulted
in an up-regulation of the PODXL gene expression (Mah et al., 2011) although the magnitude
of up-regulation was less compared to the single and double transfections of unmodified
RNAs and the cocktail of retroviruses (Figure B.4). Also referring to recent reports on the
generation of iPSCs solely mediated by an overexpression of ESC-specific miRNAs in somatic
cells (Anokye-Danso et al., 2011; Miyoshi et al., 2011), we were encouraged to set up a pilot
experiment in which bulk human AFCs were transfected with a cocktail of miRNA mimics
to enable non-integrative reprogramming (Anokye-Danso et al., 2011; Miyoshi et al., 2011).
Unfortunately, this did not facilitate the generation of iPSCs. Yet, in view of the lack of
replicating experiments and the fact that these reports have not been reproduced to date this
outcome is not surprising. Generally, specific investigations to unveil the roles of miRNAs
in stabilizing the pluripotent state of ESCs and iPSCs constitute a rather new area of stem
cell research (Mallanna and Rizzino, 2010). The knowledge concerning specific functions and
targets of distinct miRNAs is still limited and most of it has resulted from studies in other
species including mouse. It has been anticipated that miRNAs contribute to the maintenance
of the TRN that governs the PSC state (Jaenisch and Young, 2008), the underlying mechanisms,
however, are only currently being unravelled. This was initiated by findings that expression of
the distinct miRNAs such as the miR-302/367 cluster is specific for undifferentiated human
ESCs (Lakshmipathy et al., 2007; Morin et al., 2008). Although meanwhile, the miR-302/367
cluster has been demonstrated to be directly regulated by the key pluripotency-associated
transcription factors OCT4, SOX2 and NANOG (Barroso-delJesus et al., 2008; Card et al.,
2008), details of how these and other ESC-specific miRNAs regulate the developmental
potential of human PSCs is yet unknown. Regulation of cell cycle progression and potential
induction of the TGFβ/Activin A/Nodal signaling pathway by the miR-302/367 cluster may
be involved (Card et al., 2008; Barroso-del Jesus et al., 2009). In contrast, miRNAs miR-145
and mature let-7, for example, were identified as highly expressed in differentiated cells instead
(Marson et al., 2008; Xu et al., 2009). Research focussing on the interplay of these antagonistic
miRNAs and the missing links to the pluripotency-associated TRN in the regulation of
‘stemness’ and differentiation is currently on-going. It is known, for instance, that introduction
of miRNAs of the let-7 family does not induce differentiation in ESCs but that inhibition of
let-7 family miRNAs enhances reprogramming (Melton et al., 2010). The fact that somatic cells
express miRNAs which putatively balance the transfected pluripotency-associated miRNAs
may partly explain why Anokye-Danso et al. (2011) were successful using a lentiviral approach,
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whereas we, in our initial experiment, were not. Integration of the miRNA-encoding cassette
into the host cell genome mediated a long-term expression at high levels. Although Miyoshi
et al. (2011) claimed the generation of iPSCs by transient lipofection of comparable total
concentrations of mature miRNAs, it should be tested, if higher concentrations of the miRNA
mimics or more than four subsequent transfections would have enabled the induction of
pluripotency in human AFCs. In parallel the combination of miRNAs employed by Miyoshi
et al. (2011) should be tested, namely miR-200c plus mir-302s and mir-369s family miRNAs.
As the field advances targets and down-stream effects of distinct miRNAs will be verified. This
will provide several options of improving this miRNA-mediated reprogramming approach,
including the establishment of suitable experimental controls, the incorporation of small
molecules other than thiazovivin (Li et al., 2009c; Lin et al., 2009; Zhu et al., 2010; Yu et al.,
2011; Wang and Adjaye, 2011) and combinations of other pluripotency-associated miRNAs
as well as inhibitors of somatic cell-specific miRNAs (Melton et al., 2010; Ebert et al., 2007).




A great deal of biomedical research concentrates on the development of systems to model
and, hence, understand and prevent diseases. For cases, where damage has already occurred
or the outbreak of a disease is unavoidable, regenerative medicine aims at designing adequate
therapeutics combining cell-based approaches, molecular medicines and biomaterials to treat
them (Mason and Dunnill, 2008). Different types of stem and progenitor cells in the human
body qualify for the development of cellular therapeutics, each accompanied by distinct
advantages and disadvantages. Due to their exceptional differentiation potential and capacity
to self-renew, human ESCs, for example, are valuable candidates (Thomson et al., 1998). The
ethical concerns associated with human ESCs, however, restrict their implementation into
regenerative medicine. With the development of iPSCs (Takahashi et al., 2007; Yu et al., 2007),
which resemble a true alternative to human ESCs, new perspectives have been opened in
the field. Human AFCs are another source of routinely available multipotent and putatively
immune-privileged fetal stem cells, which are inherently of great value for application in
regenerative medicine (Fauza, 2004; De Coppi et al., 2007; Walther et al., 2009).
We hypothesized the induction of pluripotency in human AFCs to be efficient and to
enhance the differentiation potential of human AFCs, while circumventing the early onset of
senescence putatively adding even greater value to these cells for regenerative therapies. Hence,
the objective of this study was to generate and comparatively characterize iPSCs from human
AFCs by viral and non-viral, non-integrative methods.
As demonstrated in the first part of this thesis and by others (Li et al., 2009a; Ye et al.,
2009; Galende et al., 2010; Zhu et al., 2010; Anchan et al., 2011; Liu et al., 2012), the induction
of pluripotency in human AFCs was, indeed, efficient and faster than reprogramming of
human neonatal foreskin fibroblast cells. This finding supports our hypothesis that stem
cell-like subpopulations within bulk primary human AFCs promote the de-differentiation
process, although the preferential contribution of the stem cell-like cells to the high overall
reprogramming efficiency of human AFCs has recently been argued by Anchan et al. (2011).
The induction of pluripotency by-passed the naturally occurring arrest of proliferation in
AFCs by reversing senescence-associated gene expression patterns. The resulting iPSCs closely
resembled human ESCs. Besides the fact that AFCs enable efficient generation of iPSCs,
another advantage of using such a ‘young’ cell type for reprogramming purposes is the reduced
risk of genetic lesions in the resulting PSCs (Maherali and Hochedlinger, 2008; Gore et al.,
2011; Prigione et al., 2011a). Moreover, the generation of AFiPSCs after amniocentesis would
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theoretically facilitate the production of autologous therapeutics, which could be available
around the time of birth. Interestingly, it has also been shown that human AFCs can be used
as autologous feeder cells at the same time to support the undifferentiated growth of human
iPSCs and ESCs (Anchan et al., 2011). The development of xeno-free culturing conditions
resembles another important step into developing clinical grade cellular therapeutics (Mallon
et al., 2006; Takahashi et al., 2009). One of the key obstacles of generating clinical grade human
iPSCs, however, is the lack efficient non-integrative reprogramming techniques (Maherali and
Hochedlinger, 2008). Despite the high reprogramming efficiency of human AFCs in robust
viral reprogramming approaches, the non-integrative generation of iPSCs from AFCs could
not be achieved in the course of this project.
The observed inefficiency of episomal and mRNA-mediated non-integrating reprogram-
ming approaches can be attributed to an insufficient transgene expression with respect to the
amount, stoichiometric balance and continuity (Yamanaka, 2009b). With regards to episomal
reprogramming, these aspects are most likely not fulfilled but the use of improved vectors
(Chou et al., 2011) and the additional support of small molecules to enhance the conversion
process (Yu et al., 2011) should be explored. For mRNA-mediated reprogramming pro-
longed transgene expression is inhibited by a severe induction of an innate immune response
(Angel and Yanik, 2010; Drews et al., 2012), which requires adequate suppression. Concerning
miRNA-mediated reprogramming the most effective conditions and benchmark data are yet to
be determined. The general difficulty of generating human iPSCs without genetic modification
is also resembled in the lack reproducing reports following the initial publications (Warren
et al., 2010; Anokye-Danso et al., 2011; Miyoshi et al., 2011; Yu et al., 2011). Hence, the
outcome of this project corresponds to the current status of the field: Further optimization of
non-integrative reprogramming methods remains to be done and will be inevitable to move
towards the establishment of clinical grade human iPSCs (Drews et al., 2012).
Based on the observations presented here and elsewhere (Li et al., 2009a; Ye et al., 2009;
Galende et al., 2010; Zhu et al., 2010; Anchan et al., 2011; Liu et al., 2012), human AFCs
still appear to be a suitable source of cells for the realization of non-viral reprogramming
techniques as the fast emergence of ESC-like colonies during reprogramming suggests that
AFCs require shorter periods of stoichiometricly balanced transgene expression at sufficient
levels. This notion is further supported by the observation that first trimester AFCs, i.e.
AFCs obtained during earlier stages of gestation, express human ESCs markers and enable the
induction of pluripotency without the use of genetic material (Moschidou et al.) In view of
this, the realization of the longed for derivation of iPSCs solely by small molecules (Yamanaka,
2009a; Solanki and Lee, 2010) appears to be feasible even if the more routinely available second
trimester AFCs may not exhibit the same human ESC characteristics as their first trimester
counterparts.
Alongside with the development of advanced reprogramming approaches, effective screening
techniques should be established to verify that despite the use of non-integrating genetic
material, indeed, no genetic modifications are induced in the course of the reprogramming
process as even small molecule enhancers of the de-differentiation process may be mutagenic
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or provoke undefined side-effects (Yamanaka, 2009a). Furthermore, basic guidelines and
definitions associated with the generation of clinical grade human iPSCs should be agreed
upon (Maherali and Hochedlinger, 2008). This, however, requires sufficient understanding
of the molecular biological events underlying cellular reprogramming. Employing human
ESCs as the reference for human PSCs will continue to be essential to decipher the molecular
differences between human ESCs and iPSCs, an important prerequisite to better understand
distinctions between human iPSCs derived from different individuals or different tissues of
origin. Such differences, which indicate the existence of an epigenetic memory, have been
observed in this and several other studies that have been reviewed and discussed in detail
elsewhere (Drews et al., b,a). The functional relevance of such distinct expression patterns,
described with the LARGE Principle of Reprogramming, especially in case of AFCs, AFiPSCs
and ESCs, will have to be investigated profoundly in order to estimate limitations and to
exploit the full potential associated with putative future utilization of amniotic fluid-derived
cells. Moreover, this kind of comparative transcriptome analysis should also be extended
to include iPSC lines derived by various reprogramming protocols. With respect to the
development of ‘advanced’ regenerative therapies in the context of genetically inherited human
disease, e.g. cellular therapeutics generated from genetically corrected patient iPSCs (Raya
et al., 2009; Zou et al., 2009; Kazuki et al., 2010; Howden et al., 2011; Sebastiano et al., 2011;
Yusa et al., 2011; Wang et al., 2012a), this project highlighted difficulties associated with the
genetic manipulation of human PSCs. This is in line with others (Zwaka and Thomson, 2003;
Xia et al., 2007; Braam et al., 2008; Giudice and Trounson, 2008; Zafarana et al., 2009; Ma
et al., 2010; Maury et al., 2011) and suggests that genetic manipulations should be done in
the parental cells prior to reprogramming. This finding further underlines that the excision
of transgene sequences upon the acquisition of pluripotency in somatic cells (Kaji et al.,
2009; Woltjen et al., 2009) is not the method of choice among the reprogramming approaches
proposed to produce footprint-free human iPSCs.
Taken together, amniotic fluid-derived human iPSCs have the potential to be clinically




The high efficiency observed for retrovirus-mediated reprogramming of human AFCs suggests
amniotic fluid to be a very suitable source of cells for the realization of less-effective
non-integrating reprogramming strategies. The identification of gene expression signatures
indicative of an epigenetic memory in these AFiPSCs, however, highlighted the necessity for
further functional investigations which should be extended to include AFiPSCs generated
by alternative reprogramming protocols in order to estimate limitations and to exploit the
full potential of AFiPSCs for future applications in basic and applied research. A need for
extensive optimization was further demonstrated by the incapability of genetically modifying
AFiPSCs, a prerequisite for potential gene therapy approaches. Concerning attempts to realize
non-viral, non-integrating reprogramming protocols with human AFCs, nucleofection of
episomal plasmids induced morphological changes but did not facilitate the establishment
of fully reprogrammed iPSC lines. This approach is still promising as an improved version
of the protocol has very recently enabled the derivation of iPSCs from other somatic cells
in our laboratory. In the context of mRNA-mediated reprogramming, the functionality of
the mRNA transfection protocol was demonstrated. The acquisition of a pluripotent state in
AFCs and human neonatal fibroblasts through mRNAs encoding the reprogramming factors
was impeded, however, by activation of an interferon-regulated innate immune response.
Subsequently, several anti-inflammatory compounds, namely B18R, chloroquine, TSA, pepinh-
TRIF, pepinh-MYD, were analysed for their capability of suppres-sing this immune response
but without a positive effect. Hence, although not yet successful, the profound analysis of the
innate interferon response associated with the transfection of mRNAs should provide a basis
for the development of new strategies to suppress this immune reaction in order to facilitate
efficient mRNA-mediated reprogramming in the future. The comparison of different delivery
methods with respect to the magnitude of the induced immune response revealed miRNAs to
be non-immunogenic, highlighting transfection of miRNAs as an especially promising tool
to realize non-integrative induction of pluripotency in human somatic cells despite the failure
of pilot experiments in AFCs. In conclusion, this work has emphasized the significance of
human AFCs as a starting cell source for direct reprogramming. Yet, concomitantly, obstacles
such as the technical difficulties associated with episomal plasmid-mediated reprogramming
and the immune response triggered by transfections of mRNAs were revealed. These aspects
need to be addressed in order to enable reliable induction of pluripotency in human AFCs
with putative relevance for regenerative medicine.
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Zusammenfassung (German abstract)
Die Entwicklung humaner induzierter pluripotenter Stammzellen (induced pluripotent stem
cells, iPSCs) aus somatischen Zellen eröffnet ungeahnte Möglichkeiten für Forschung und
Medizin. Der Verwendung von iPSCs zu therapeutischen Zwecken stehen derzeit jedoch
die mit der viralen Reprogrammierung einhergehenden Modifikationen des Genoms im
Wege. Das Streben nach alternativen, nicht-mutagenen Reprogrammierungsmethoden ist
aufgrund deren geringerer Effizienz eng an die Identifizierung von Zelltypen gekoppelt,
die sich einfacher in das Entwicklungsstadium embryonaler Stammzellen (embryonic stem
cells, ESCs) zurückversetzen lassen. Humane Fruchtwasserzellen (amniotic fluid cells, AFCs)
werden routinemäßig isoliert und weisen Stammzell-ähnliche Eigenschaften auf. Dadurch sind
AFCs vermutlich auch durch ineffizientere nicht-mutagenen Methoden zu reprogrammieren.
Ziel dieser Arbeit war es, mithilfe viraler und nicht-viraler Techniken aus AFCs iPSCs zu
generieren und diese vergleichend zu charakterisieren. Dabei sollten auch humane ESCs, als
Standard für pluripotente Stammzellen, sowie iPSCs aus Zellen anderer Gewebe (Fibroblasten-
iPSCs, FiPSCs) einbezogen werden. Die retrovirale Reprogrammierung führte schnell und
effizient zur Umwandlung humaner AFCs in iPSCs (AFiPSCs). Diese iPSCs glichen human
ESCs im Hinblick auf die Morphologie, Proliferation und die Expression von Stammzellmar-
kern. Ihre Fähigkeit, Zelltypen aller drei embryonalen Keimblätter zu bilden, konnte sowohl
in vitro als auch in vivo bestätigt werden. Als Ergebnis der Behandlung der AFiPSCs mit
BMP2 und BMP4 wurde darüber hinaus ihr Potential in Zelllinien des Trophoblasten zu
differenzieren demonstriert. Eine detaillierte Microaray-basierte Analyse des Transkriptoms
von ESCs, AFiPCs, FiPSCs sowie der jeweiligen parentalen Zellen bestätigte die Aktivität
eines transkriptionell regulatorischen Netzwerks in allen pluripotenten Stammzellen. Gleich-
zeitig wurden beispielsweise aber auch charakteristische Genexpressionsmuster in den ver-
schiedenen identifiziert, die nach der Reprogrammierung erhalten blieben. Diese und ähnliche
Befunde wurden im sogenannten “LARGE Principle of Cellular Reprogramming” zusammen-
gefasst. Eine genetische Manipulation der AFiPSCs zur Gen-Funktionsanalyse konnte nicht
realisiert werden. Versuche, humane AFCs durch nicht-virale, nicht-mutagene Methoden, wie
der Nukleofektion von episomalen Plasmiden oder der Transfektion von Reprogrammierungs-
faktoren-kodierenden mRNAs, zu reprogrammieren, scheiterten. Die ausführliche Untersu-
chung der Ursachen dafür ergab, dass die schwerwiegende Aktivierung einer Interferon-
regulierten Immunantwort die Reprogrammierung maßgeblich hemmte. Anschließende
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Versuche, diese Immunabwehr durch geeignete immunmodulatorische Substanzen zu unterbin-
den, blieben jedoch ohne Erfolg. Die im Laufe dieser Arbeit ermittelten Daten stellen dennoch
eine wichtige Grundlage für weiterführende Tests dar. Zusammenfassend konnte anhand
dieser Arbeit der Stellenwert humaner AFCs für die Generierung von iPSCs hervorgehoben
werden. Dabei wurden jedoch auch bestehende Hindernisse aufgezeigt, welche einer potentiel-
len Anwendung von AFiPSCs zu therapeutischen Zwecken noch im Wege stehen.
A
Supplementary Material and Methods
A.1 Composition and preparation of cell culture mediaand solutions
A.1.1 ‘DeCoppi medium’ for AFC culture
Components to make 500 ml:
315 ml α-MEM (Gibco)
75 ml ESC-qualified fetal bovine serum (ES-FBS, Gibco)
5 ml L-glutamine (200 mM, Lonza)
5 ml Penicillin/Streptomycin (PS, 10,000 U/ml each, Lonza)
90 ml Chang B (Trinova Biochem, Giessen, Germany)
Mix all components and filter (Corning, 0.22µm, PAS).
Supplement with 10 ml Chang C (Trinova Biochem).
A.1.2 BJ, HFF1, HEK293 and PA culture medium
Components to make 500 ml:
450 ml DMEM (high glucose, Gibco)
50 ml FBS (Biochrom)
A.1.3 MEF culture medium
Components to make 500 ml:
435 ml DMEM (high glucose)
50 ml FBS
5 ml L-glutamine
5 ml Non-essential amino acids (NEAA, 100×, Gibco)
5 ml PS
Mix all components and filter.
Preparation of human basic fibroblast growth factor (bFGF, FGF2)
Recombinant human basic fibroblast growth factor (bFGF, FGF2, Peprotech) was dissolved in
sterile-filtered PBS containing 0.2 % BSA (Fraction V, 99 % purity, Sigma) at a concentration
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of 8µg/ml. Aliquots were kept at -20 ◦C.
A.1.4 Unconditioned medium (UM) for human ESC culture
Components to make 500 ml:
385 ml Knockout DMEM (KO-DMEM, Gibco)




35µl of 0.14 M β-mercaptoethanol (Sigma), pre-diluted 1:10 in PBS, sterile-filtered
Mix all components and filter. Supplement with 4 ng/ml FGF2 right before use on human
PSCs.
A.1.5 Preparation ofMatrigel stock solution andMatrigel-coated labware
Growth factor-reduced Matrigel solution (BD) was thawed on ice at 4 ◦C ON, mixed with
KO-DMEM as suggested for the particular batch by the manufacturer, aliquoted and re-frozen.
Chilled pipettes and tubes were used whenever Matrigel was diluted. To coat plastic tissue
culture labware with Matrigel, aliquots of the stock solution were thawed again (preferably
at 4 ◦C), diluted 1:14 with cold KO-DMEM, dispensed into the required amount of wells or
flasks (1.5 ml per well of a six well plate) covering the entire bottom of each well. The plate
was sealed with PARAFILM M (Pechiney Plastic Packaging) and kept at 4 ◦C (10 d maximum).
A.1.6 Defined (N2B27) medium for human PSC culture
Components to make 50 ml:
47 ml DMEM/F12 (Gibco)
0.5 ml N2 Supplement (100×, Invitrogen)
1 ml B27 Supplement minus Vitamin A (50×, Invitrogen)




3.5µl of 0.14 M β-mercaptoethanol, pre-diluted 1:10 in PBS, sterile-filtered
Mix all components and filter.
A.1.7 Freezing media
AFCs: 10 % DMSO (Sigma) in ES-FBS
HFF1, BJ: 10 % DMSO, 50 % FBS in DMEM
HEK293, PA cells: 10 % DMSO, 40 % FBS in DMEM
MEFs: 10 % DMSO, 50 % FBS in DMEM
Human PSCs: 10 % DMSO, 50 % KO-SR in KO-DMEM
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A.2 Transformation protocol
Competent E.coli, e.g. JM109, cells were thawed on ice. 50µl bacterial suspension were mixed
with 1µg of plasmid DNA and incubated on ice for 5 min. The cells were heat shocked in
a 42 ◦C water bath for 50 s and put back on ice for 3 min, followed by a 30 min recovering
incubation in 1 ml LB medium lacking antibiotics shaking at 175 rpm at 37 ◦C. E.coli were
pelleted by centrifugation at 1500× g for 5 min. The supernatant was poured off and the
remaining drop of medium was used to resuspend the cells. Next, 50-100µl of this suspension
was spread onto LB/antibiotic agar plates and the cultures were incubated at 37 ◦C ON. Single
colonies were picked under sterile conditions 12-16 h later and expanded. To prepare glycerol
stocks, the cell suspension resulting from the expansion of a single picked colony, was mixed
with LB medium containing 30 % glycerol at a ratio of 1:1 and frozen at -80 ◦C for long-term
storage.
A.3 PCR, qRT-PCR and gel electrophoresis
A.3.1 10× B1 PCR buﬀer
500 mM Tris-HCl, pH= 8.8
200 mM (NH4)2SO4
15 mM MgCl2
0.1 % Tween 20
in ddH2O.
A.3.2 Fingerprinting PCR
Reaction master mix, 20µl per reaction:
ddH2O 15.75µl
10 X B1 buffer 2.5µl
25 mM dNTP mix (1:1:1:1) 0.25µl
1µM forward primer 0.5µl
1µM reverse primer 0.5µl
Pfu-Polymerase (10 U/µl) 0.1µl
Taq-Polymerase (10 U/µl) 0.4µl
template DNA (15 ng/µl) 5.0µl
→ 25µl/reaction
Fingerprinting PCR cycle protocol:
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(35 cycles) 1 min 94 ◦C
1 min 55 ◦C
1 min 72 ◦C
∞ 4 ◦C
If the first PCR reaction did not result in sufficient amplification products, the same PCR was
repeated including the following modifications:
ddH2O 8.25µl instead of 15.75µl
5 M Betaine 7.5µl
0.2 to 1.0µl of the first reaction mixture were adjusted to a volume of 5µl with ddH2O and
input as DNA template for re-amplification.
A.3.3 20× SB electrophoresis buﬀer
NaOH 8 g
Boric Acid 45 g
ad 1 l with ddH2O, adjust pH to 8.0.
A.3.4 qRT-PCR cycle protocol
Hold 50 ◦C 2 min
hold 95 ◦C 10 min
(40 cycles) 95 ◦C 15 sec
60 ◦C 1 min
95 ◦C 15 sec
60 ◦C 15 sec
95 ◦C 15 sec
A.4 Antibodies, plasmids, primers
Table A.1: List of antibodies used for the immunofluorescent protein labeling procedure.




mouse Invitrogen CD11705 1:20
OCT3/4 (C-10) mouse Santa Cruz
Biotechnology
sc-5279 1:100
SOX2 (Y-17) goat SCB sc-17320 1:100
GKLF (H-180) rabbit SCB sc-20691 1:100
Continued on next page
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Table A.1 – Continued from previous page
Human antigen Species raised in Company Catalog no. Dilution
c-MYC (N-262) rabbit SCB sc-764 1:100
LIN28 rabbit Proteintech 11724-1-AP 1:400
NANOG goat R&D Systems AF1997 1:100
SSEA4 mouse Millipore SCR001 1:100
TRA-1-60 mouse Millipore SCR001 1:100
TRA-1-81 mouse Millipore SCR001 1:100
E-CADHERIN
(CDH1)
mouse BD Biosciences 610181 1:80
VIMENTIN (VIM) mouse Sigma-Aldrich V6630 1:80








mouse DakoCytomation M0851 1:100
NESTIN (NES) mouse Millipore MAB5326 1:200
CLASS III BETA
TUBULIN (TUJ1)








donkey Invitrogen A11055 1:300
anti-goat IgG, Alexa
fluor 594
chicken Invitrogen A21468 1:300
anti-mouse IgG,
Alexa fluor 488
goat Invitrogen A11001 1:300
anti-mouse IgG,
Alexa fluor 594
goat Invitrogen A11005 1:300
anti-rabbit IgG,
Alexa fluor 488
donkey Invitrogen A21206 1:300
anti-rabbit IgG,
Alexa fluor 594
chicken Invitrogen A21442 1:300
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Table A.2: List of plasmids used for the production of viral particles, nucleofection, lipofection and in vitro transcription.









pMXs-hOCT3/4 17217, Addgene OCT4 JM109 LB medium Ampicillin (100µg/ml) XhoI
pMXs-hSOX2 17218, Addgene SOX2 JM109 LB medium Ampicillin (100µg/ml) NotI
pMXs-hKLF4 17219, Addgene KLF4 JM109 LB medium Ampicillin (100µg/ml) NotI
pMXs-hc-MYC 17220, Addgene c-MYC JM109 LB medium Ampicillin (100µg/ml) NotI

























n/a TB medium Carbenicillin (100µg/ml) —
Continued on next page
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n/a TB medium Carbenicillin (100µg/ml) —
pLKO.1-puro_TGFP SHC003, Sigma TurboGFP JM109 TB medium Carbenicillin (100µg/ml) —
phOCT4-EGFP Dr. W. Cui EGFP TOP10 LB medium Kanamycin (50µg/ml), —
Episomal plasmid-mediated reprogramming:
pEP4 E02S EN2L (‘4F
EN2L’)
20922 Addgene OCT4, SOX2,
NANOG, LIN28




20923 Addgene OCT4, SOX2, c-
MYC, KLF4
n/a LB medium Ampicillin (100µg/ml) BamHI,
EcoRI, NsiI
pEP4 E02S CK2M EN2L
(‘6F EN2L’)
20924 Addgene OCT4, SOX2,
KLF4, c-MYC,
NANOG, LIN28,
n/a LB medium Ampicillin (100µg/ml) BamHI, NsiI
pEP4 E02S EN2K
(‘EN2K’)
20925 Addgene OCT4, SOX2,
NANOG, KLF4
n/a LB medium Ampicillin (100µg/ml) BamHI,
EcoRI
pCEP4-M2L (‘M2L’) 20926 Addgene c-MYC, LIN28 n/a LB medium Ampicillin (100µg/ml) SpeI, HindIII
pEP4 E02S ET2K
(‘ET2K’)
20927 Addgene OCT4, SOX2,
SV40LT, KLF4
n/a LB medium Ampicillin (100µg/ml) BamHI,
EcoRI, NsiI
IVT, mRNA-mediated reprogramming:
pcDNA3.3_OCT4 26816, Addgene OCT4 DH5a LB medium Ampicillin (100µg/ml) —
pcDNA3.3_SOX2 26817, Addgene SOX2 DH5a LB medium Ampicillin (100µg/ml) —
Continued on next page
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pcDNA3.3_KLF4 26815, Addgene KLF4 DH5a LB medium Ampicillin (100µg/ml) —
pcDNA3.3_c-MYC 26818, Addgene c-MYC DH5a LB medium Ampicillin (100µg/ml) —
pcDNA3.3_LIN28A 26819, Addgene LIN28A DH5a LB medium Ampicillin (100µg/ml) —
pGEM4Z-EGFP-A64 Prof. Dr. E. Gilboa GFP KRX LB medium Ampicillin (100µg/ml) —




Table A.3: List of primers used for qRT-PCR and DNA fingerprinting analyses.
Gene Sequence forward primer (5‘-3’) Sequence reverse primer (5‘-3’) Amplicon length [bp]
qRT-PCR, housekeeping genes:
ACTB TCAAGATCATTGCTCCTCCTGAG ACATCTGCTGGAAGGTGGACA 87
GAPDH CTGGTAAAGTGGATATTGTTGCCAT TGGAATCATATTGGAACATGTAAACC 81
qRT-PCR, retrovirus-mediated reprogramming:
CDX2 TCACTACAGTCGCTACATCACCATC TTAACCTGCCTCTCAGAGAGCC 78
CER1 ACCACGATGCACTTGCCACT CCGTCTTCACCTTGCACTGG 94
DNMT3B GCTCACAGGGCCCGATACTT GCAGTCCTGCAGCTCGAGTTTA 93
DPPA4 TGGTGTCAGGTGGTGTGTGG CCAGGCTTGACCAGCATGAA 91
FGF4 CCCTTCTTCACCGATGAGTGC CATTCTTGCTCAGGGCGATG 109
FOXF1 AAAGGAGCCACGAAGCAAGC AGGCTGAAGCGAAGGAAGAGG 81
GATA3 ACTCCAGCCACATGCTGACC AGCATCGAGCAGGGCTCTAAC 117
GDF3 TTGGCACAAGTGGATCATTGC TTGGCACAAGTGGATCATTGC 96
HAND1 TCCCTTTTCCGCTTGCTCTC CATCGCCTACCTGATGGACG 114
ID2 AATCCTGCAGCACGTCATCG CTGGTGATGCAGGCTGACAA 85
KRT7 AGATCGCCACCTACCGCAAG ATTCACGGCTCCCACTCCAT 74
LEFTY1 AATGTGTCATTGTTTACTTGTCCTGTC CAGGTCTTAGGTCCAGAGTGGTG 76
NANOG CCTGTGATTTGTGGGCCTG GACAGTCTCCGTGTGAGGCAT 78
POU5F1 GTGGAGGAAGCTGACAACAA ATTCTCCAGGTTGCCTCTCA 120
SOX2 GTATCAGGAGTTGTCAAGGCAGAG TCCTAGTCTTAAAGAGGCAGCAAAC 78
TERT ACGGCGACATGGAGAACAAG GAGGTGTCACCAACAAGAAATCATC 90
qRT-PCR, non-viral reprogramming:
CCL5 CATATTCCTCGGACACCACA GAGCACTTGCCACTGGTGTA 100
c-MYC ACTCTGAGGAGGAACAAGAA TGGAGACGTGGCACCTCTT 159
IFIT1 AAAAGCCCACATTTGAGGTG GAAATTCCTGAAACCGACCA 168
Continued on next page
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Gene Sequence forward primer (5‘-3’) Sequence reverse primer (5‘-3’) Amplicon length [bp]
IFNB CATTACCTGAAGGCCAAGGA CAGCATCTGCTGGTTGAAGA 178
IL12A TGGCCCTGTGCCTTAGTAGT CAGAAGCTTTGCATTCATGG 80
IRF7 GGGTGTGTCTTCCCTGGATA GCTCCATAAGGAAGCACTCG 92
ISG20 CAGAACAGCCTGCTTGGAC CGGATTCTCTGGGAGATTTG 80
KLF4 GGGCCCAATTACCCATCCTT CTTTGGCTTGGGCTCCTCTG 114
LIN28A GTCTGGAATCCATCCGTGTC TCCTTTTGATCTGCGCTTCT 101
OAS1 CGATCCCAGGAGGTATCAGA TCCAGTCCTCTTCTGCCTGT 116
PKR TCGCTGGTATCACTCGTCTG GATTCTGAAGACCGCCAGAG 183
PODXL CAGCATCAACTACCCACCGATAC GATCCTCACACTTTGCCCAGTTAC 81
POU5F1 GTGGAGGAAGCTGACAACAA ATTCTCCAGGTTGCCTCTCA 120
RIG-I GTTGTCCCCATGCTGTTCTT GCAAGTCTTACATGGCAGCA 124
SOX2 AACCAGAAAAACAGCCCGGACCG GGTTCTCCTGGGCCATCTTGCG 94
STAT2 GACTGAAATCATCCGCCATT GGATTCGGGGATAGAGGAAG 83
TRIM5 GAGAAGCTCAGGGAGGTCAA CTCACAAAGCCAGCAAATGA 123
PCR, DNA fingerprinting:
D7S796 TTTTGGTATTGGCCATCCTA GAAAGGAACAGAGAGACAGGG —
D10S1214 ATTGCCCCAAAACTTTTTTG TTGAAGACCAGTCTGGGAAG —
D21S2055 AACAGAACCAATAGGCTATCTATC TACAGTAAATCACTTGGTAGGAGA —
B
Supporting Data
Table B.1: List of 116 senescence-associated genes derived from the Gene Ontology database
(Ashburner et al., 2000), including those described by Vaziri et al. (2010). These genes served as
input for the differential gene expression analysis between AFCs (P17) and the group of all AFiPSC
lines. Modified from (Wolfrum et al., 2010).
Symbol Definition
ACD Homo sapiens adrenocortical dysplasia homolog (mouse) (ACD), mRNA.
AKT1 Homo sapiens v-akt murine thymoma viral oncogene homolog 1 (AKT1),
transcript variant 3, mRNA.
ATM Homo sapiens ataxia telangiectasia mutated (includes complementation groups
A, C and D) (ATM), transcript variant 1, mRNA.
ATR Homo sapiens ataxia telangiectasia and Rad3 related (ATR), mRNA.
BCL2 Homo sapiens B-cell CLL/lymphoma 2 (BCL2),nuclear gene encoding
mitochondrial protein, transcript variant beta, mRNA.
BLM Homo sapiens Bloom syndrome (BLM), mRNA.
BRCA1 Homo sapiens breast cancer 1, early onset (BRCA1), transcript variant BRCA1-
delta11b, mRNA.
BRCA2 Homo sapiens breast cancer 2, early onset (BRCA2), mRNA.
C20ORF52 Homo sapiens chromosome 20 open reading frame 52 (C20orf52), mRNA.
CALR Homo sapiens calreticulin (CALR), mRNA.
CBX1 Homo sapiens chromobox homolog 1 (HP1 beta homolog Drosophila )
(CBX1), mRNA.
CBX5 Homo sapiens chromobox homolog 5 (HP1 alpha homolog, Drosophila)
(CBX5), mRNA.
CBX6 Homo sapiens chromobox homolog 6 (CBX6), mRNA.
CDC2 Homo sapiens cell division cycle 2, G1 to S and G2 to M (CDC2), transcript
variant 2, mRNA.
CDKN1A Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A),
transcript variant 2, mRNA.
CDKN2A Homo sapiens cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits
CDK4) (CDKN2A), transcript variant 4, mRNA.
CDT1 Homo sapiens chromatin licensing and DNA replication factor 1 (CDT1),
mRNA.
CHEK1 Homo sapiens CHK1 checkpoint homolog (S. pombe) (CHEK1), mRNA.
Continued on next page
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Symbol Definition
CHEK2 Homo sapiens CHK2 checkpoint homolog (S. pombe) (CHEK2), transcript
variant 1, mRNA.
DCLRE1C Homo sapiens DNA cross-link repair 1C (PSO2 homolog, S. cerevisiae)
(DCLRE1C), transcript variant c, mRNA.
DDIT3 Homo sapiens DNA-damage-inducible transcript 3 (DDIT3), mRNA.
DKC1 Homo sapiens dyskeratosis congenita 1, dyskerin (DKC1), mRNA.
DNAJA3 Homo sapiens DnaJ (Hsp40) homolog, subfamily A, member 3 (DNAJA3),
mRNA.
DNMT1 Homo sapiens DNA (cytosine-5-)-methyltransferase 1 (DNMT1), mRNA.
DNMT3B Homo sapiens DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B),
transcript variant 6, mRNA.
DOT1L Homo sapiens DOT1-like,histone H3 methyltransferase (S. cerevisiae)
(DOT1L), mRNA.
EMD Homo sapiens emerin (Emery-Dreifuss muscular dystrophy) (EMD), mRNA.
ENG Homo sapiens endoglin (Osler-Rendu-Weber syndrome 1) (ENG), mRNA.
EXO1 Homo sapiens exonuclease 1 (EXO1), transcript variant 3, mRNA.
FANCF Homo sapiens Fanconi anemia, complementation group F (FANCF), mRNA.
FEN1 Homo sapiens flap structure-specific endonuclease 1 (FEN1), mRNA.
FOXM1 Homo sapiens forkhead box M1 (FOXM1), transcript variant 1, mRNA.
GADD45A Homo sapiens growth arrest and DNA-damage-inducible, alpha (GADD45A),
mRNA.
GDF15 Homo sapiens growth differentiation factor 15 (GDF15), mRNA.
GMCL1 Homo sapiens germ cell-less homolog 1 (Drosophila) (GMCL1), mRNA.
H2AFX Homo sapiens H2A histone family, member X (H2AFX), mRNA.
HADH2 Homo sapiens hydroxyacyl-Coenzyme A dehydrogenase, type II (HADH2),
transcript variant 1, mRNA.
HELLS Homo sapiens helicase, lymphoid-specific (HELLS), mRNA.
HIST2H2AC Homo sapiens histone cluster 2, H2ac (HIST2H2AC), mRNA.
HIST2H2BE Homo sapiens histone cluster 2, H2be (HIST2H2BE), mRNA.
HRAS Homo sapiens v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS),
transcript variant 2, mRNA.
IGFBP6 Homo sapiens insulin-like growth factor binding protein 6 (IGFBP6), mRNA.
ILK Homo sapiens integrin-linked kinase (ILK), transcript variant 1, mRNA.
KRAS Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS),
transcript variant b, mRNA.
LBR Homo sapiens lamin B receptor (LBR), transcript variant 1, mRNA.
LIMS1 Homo sapiens LIM and senescent cell antigen-like domains 1 (LIMS1), mRNA.
LMNA Homo sapiens lamin A/C (LMNA), transcript variant 2, mRNA.
LMNB1 Homo sapiens lamin B1 (LMNB1), mRNA.
MAD2L2 Homo sapiens MAD2 mitotic arrest deficient-like 2 (yeast) (MAD2L2), mRNA.
MAP2K1 Homo sapiens mitogen-activated protein kinase kinase 1 (MAP2K1), mRNA.
MDC1 Homo sapiens mediator of DNA damage checkpoint 1 (MDC1), mRNA.
MDM2 Homo sapiens Mdm2, transformed 3T3 cell double minute 2, p53 binding
protein (mouse) (MDM2), transcript variant MDM2, mRNA.
Continued on next page
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Symbol Definition
MNT Homo sapiens MAX binding protein (MNT), mRNA.
MORC3 Homo sapiens MORC family CW-type zinc finger 3 (MORC3), mRNA.
MORF4 Homo sapiens mortality factor 4 (MORF4), mRNA.
MRE11A Homo sapiens MRE11 meiotic recombination 11 homolog A (S. cerevisiae)
(MRE11A), transcript variant 1, mRNA.
MSH2 Homo sapiens mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)
(MSH2), mRNA.
MSH6 Homo sapiens mutS homolog 6 (E. coli) (MSH6), mRNA.
MYC Homo sapiens v-myc myelocytomatosis viral oncogene homolog (avian)
(MYC), mRNA.
NCL Homo sapiens nucleolin (NCL), mRNA.
NHP2L1 Homo sapiens NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae)
(NHP2L1), transcript variant 1, mRNA.
NOLA1 Homo sapiens nucleolar protein family A, member 1 (H/ACA small nucleolar
RNPs) (NOLA1), transcript variant 2, mRNA.
NOX4 Homo sapiens NADPH oxidase 4 (NOX4), mRNA.
NPM1 Homo sapiens nucleophosmin (nucleolar phosphoprotein B23, numatrin)
(NPM1), transcript variant 2, mRNA.
NRAS Homo sapiens neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS),
mRNA.
NUP62 Homo sapiens nucleoporin 62kDa (NUP62), transcript variant 1, mRNA.
PARP1 Homo sapiens poly (ADP-ribose) polymerase family, member 1 (PARP1),
mRNA.
PCNA Homo sapiens proliferating cell nuclear antigen (PCNA), transcript variant 1,
mRNA.
PDCD4 Homo sapiens programmed cell death 4 (neoplastic transformation inhibitor)
(PDCD4), transcript variant 2, mRNA.
PIN1 Homo sapiens protein (peptidylprolyl cis/trans isomerase) NIMA-interacting 1
(PIN1), mRNA.
PLK1 Homo sapiens polo-like kinase 1 (Drosophila) (PLK1), mRNA.
PML Homo sapiens promyelocytic leukemia (PML), transcript variant 2, mRNA.
POT1 Homo sapiens POT1 protection of telomeres 1 homolog (S. pombe) (POT1),
transcript variant 2, transcribed RNA.
POU2F1 Homo sapiens POU class 2 homeobox 1 (POU2F1), mRNA.
PRELP Homo sapiens proline/arginine-rich end leucine-rich repeat protein (PRELP),
transcript variant 2, mRNA.
PRKCD Homo sapiens protein kinase C, delta (PRKCD), transcript variant 2, mRNA.
PRKDC Homo sapiens protein kinase, DNA-activated, catalytic polypeptide (PRKDC),
transcript variant 1, mRNA.
RAD9A Homo sapiens RAD9 homolog A (S. pombe) (RAD9A), mRNA.
RAI17 Homo sapiens zinc finger, MIZ-type containing 1 (ZMIZ1), mRNA.
RB1 Homo sapiens retinoblastoma 1 (including osteosarcoma) (RB1), mRNA.
RBL1 Homo sapiens retinoblastoma-like 1 (p107) (RBL1), transcript variant 1,
mRNA.
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RBL2 Homo sapiens retinoblastoma-like 2 (p130) (RBL2), mRNA.
RFC2 Homo sapiens replication factor C (activator 1) 2, 40kDa (RFC2), transcript
variant 1, mRNA.
RGN PREDICTED: Homo sapiens regucalcin (senescence marker protein-30),
transcript variant 1 (RGN), mRNA.
RIF1 Homo sapiens RAP1 interacting factor homolog (yeast) (RIF1), mRNA.
RPA1 Homo sapiens replication protein A1, 70kDa (RPA1), mRNA.
RPA2 Homo sapiens replication protein A2, 32kDa (RPA2), mRNA.
RPA3 Homo sapiens replication protein A3, 14kDa (RPA3), mRNA.
SERPINE1 Homo sapiens serpin peptidase inhibitor, clade E (nexin, plasminogen activator
inhibitor type 1), member 1 (SERPINE1), mRNA.
SIRT1 Homo sapiens sirtuin (silent mating type information regulation 2 homolog) 1
(S. cerevisiae) (SIRT1), mRNA.
SIRT6 Homo sapiens sirtuin (silent mating type information regulation 2 homolog) 6
(S. cerevisiae) (SIRT6), mRNA.
SMG1 Homo sapiens PI-3-kinase-related kinase SMG-1 (SMG1), mRNA.
SMG6 Homo sapiens Smg-6 homolog, nonsense mediated mRNA decay factor (C.
elegans) (SMG6), mRNA.
SNURF Homo sapiens SNRPN upstream reading frame (SNURF), transcript variant 1,
mRNA.
SOD1 Homo sapiens superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1
(adult)) (SOD1), mRNA.
SRF Homo sapiens serum response factor (c-fos serum response element-binding
transcription factor) (SRF), mRNA.
SUV39H1 Homo sapiens suppressor of variegation 3-9 homolog 1 (Drosophila)
(SUV39H1), mRNA.
SUV39H2 Homo sapiens suppressor of variegation 3-9 homolog 2 (Drosophila)
(SUV39H2), mRNA.
SUV420H1 Homo sapiens suppressor of variegation 4-20 homolog 1 (Drosophila)
(SUV420H1), transcript variant 1, mRNA.
SUV420H2 Homo sapiens suppressor of variegation 4-20 homolog 2 (Drosophila)
(SUV420H2), mRNA.
SYNE1 Homo sapiens spectrin repeat containing,nuclear envelope 1 (SYNE1),
transcript variant alpha, mRNA.
TBX2 Homo sapiens T-box 2 (TBX2), mRNA.
TBX3 Homo sapiens T-box 3 (ulnar mammary syndrome) (TBX3), transcript variant
2, mRNA.
TERF1 Homo sapiens telomeric repeat binding factor (NIMA-interacting) 1 (TERF1),
transcript variant 1, mRNA.
TERF2 Homo sapiens telomeric repeat binding factor 2 (TERF2), mRNA.
TERT Homo sapiens telomerase reverse transcriptase (TERT), transcript variant 1,
mRNA.
TINF2 Homo sapiens TERF1 (TRF1)-interacting nuclear factor 2 (TINF2), mRNA.
TNKS1BP1 Homo sapiens tankyrase 1 binding protein 1, 182kDa (TNKS1BP1), mRNA.
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TNKS2 Homo sapiens tankyrase, TRF1-interacting ankyrin-related ADP-ribose
polymerase 2 (TNKS2), mRNA.
TP53 Homo sapiens tumor protein p53 (Li-Fraumeni syndrome) (TP53), mRNA.
TP73L Homo sapiens tumor protein p73-like (TP73L), mRNA.
TPP1 Homo sapiens tripeptidyl peptidase I (TPP1), mRNA.
TRIOBP Homo sapiens TRIO and F-actin binding protein (TRIOBP), transcript variant
1, mRNA.
WRN Homo sapiens Werner syndrome (WRN), mRNA.
XPA Homo sapiens xeroderma pigmentosum, complementation group A (XPA),
mRNA.
ZNF146 Homo sapiens zinc finger protein 146 (ZNF146), mRNA.
Table B.2: List of 148 genes overlapping in reprogramming factor-transfected fibroblasts and the
union of FiPSCs and ESCs (reported in Figure 4.6 C). Modified from Drews et al. (2012).
Symbol Definition
ADRA1B Homo sapiens adrenergic, alpha-1B-, receptor (ADRA1B), mRNA.
ANKRD1 Homo sapiens ankyrin repeat domain 1 (cardiac muscle) (ANKRD1), mRNA.
ARHGAP17 Homo sapiens Rho GTPase activating protein 17 (ARHGAP17), transcript
variant 1, mRNA.
ARHGEF10L Homo sapiens Rho guanine nucleotide exchange factor (GEF) 10-like
(ARHGEF10L), transcript variant 1, mRNA.
ARL6IP4 Homo sapiens ADP-ribosylation-like factor 6 interacting protein 4 (ARL6IP4),
transcript variant 4, mRNA.
ARL9 Homo sapiens ADP-ribosylation factor-like 9 (ARL9), mRNA.
ASPHD2 Homo sapiens aspartate beta-hydroxylase domain containing 2 (ASPHD2),
mRNA.
ATP8B4 Homo sapiens ATPase, class I, type 8B, member 4 (ATP8B4), mRNA.
BBS7 Homo sapiens Bardet-Biedl syndrome 7 (BBS7), transcript variant 1, mRNA.
BCAP29 Homo sapiens B-cell receptor-associated protein 29 (BCAP29), transcript
variant 4, mRNA.
BCKDHB Homo sapiens branched chain keto acid dehydrogenase E1, beta polypeptide
(maple syrup urine disease) (BCKDHB), nuclear gene encoding mitochondrial
protein, transcript variant 1, mRNA.
BEST1 Homo sapiens bestrophin 1 (BEST1), mRNA.
BST2 Homo sapiens bone marrow stromal cell antigen 2 (BST2), mRNA.
BTN2A2 Homo sapiens butyrophilin, subfamily 2, member A2 (BTN2A2), transcript
variant 1, mRNA.
C10orf35 Homo sapiens chromosome 10 open reading frame 35 (C10orf35), mRNA.
C12orf66 Homo sapiens chromosome 12 open reading frame 66 (C12orf66), mRNA.
C21orf91 Homo sapiens chromosome 21 open reading frame 91 (C21orf91), mRNA.
C5orf39 Homo sapiens chromosome 5 open reading frame 39 (C5orf39), mRNA.
CALML4 Homo sapiens calmodulin-like 4 (CALML4), transcript variant 1, mRNA.
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CCNT1 Homo sapiens cyclin T1 (CCNT1), mRNA.
CDC6 Homo sapiens cell division cycle 6 homolog (S. cerevisiae) (CDC6), mRNA.
CEACAM1 Homo sapiens carcinoembryonic antigen-related cell adhesion molecule 1
(biliary glycoprotein) (CEACAM1), transcript variant 2, mRNA.
CH25H Homo sapiens cholesterol 25-hydroxylase (CH25H), mRNA.
CHRNB1 Homo sapiens cholinergic receptor, nicotinic, beta 1 (muscle) (CHRNB1),
mRNA.
CORO7 Homo sapiens coronin 7 (CORO7), mRNA.
COX15 Homo sapiens COX15 homolog, cytochrome c oxidase assembly protein (yeast)
(COX15), nuclear gene encoding mitochondrial protein, transcript variant 1,
mRNA.
CPT1B Homo sapiens carnitine palmitoyltransferase 1B (muscle) (CPT1B), nuclear
gene encoding mitochondrial protein, transcript variant 4, mRNA.
CTH Homo sapiens cystathionase (cystathionine gamma-lyase) (CTH), transcript
variant 1, mRNA.
CXCL6 Homo sapiens chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic
protein 2) (CXCL6), mRNA.
CXCR7 Homo sapiens chemokine (C-X-C motif) receptor 7 (CXCR7), mRNA.
CYP11A1 Homo sapiens cytochrome P450, family 11, subfamily A,polypeptide 1
(CYP11A1), nuclear gene encoding mitochondrial protein, transcript variant
1, mRNA.
CYP2J2 Homo sapiens cytochrome P450, family 2, subfamily J, polypeptide 2 (CYP2J2),
mRNA.
DHRS12 Homo sapiens dehydrogenase/reductase (SDR family) member 12 (DHRS12),
transcript variant 2, mRNA.
DHRS2 Homo sapiens dehydrogenase/reductase (SDR family) member 2 (DHRS2),
transcript variant 1, mRNA.
DLL1 Homo sapiens delta-like 1 (Drosophila) (DLL1), mRNA.
DMKN Homo sapiens dermokine (DMKN), transcript variant 1, mRNA.
DNASE1L1 Homo sapiens deoxyribonuclease I-like 1 (DNASE1L1), transcript variant 1,
mRNA.
DTNA Homo sapiens dystrobrevin, alpha (DTNA), transcript variant 6, mRNA.
DUSP16 Homo sapiens dual specificity phosphatase 16 (DUSP16), mRNA.
E2F6 Homo sapiens E2F transcription factor 6 (E2F6), mRNA.
EGR2 Homo sapiens early growth response 2 (Krox-20 homolog, Drosophila) (EGR2),
mRNA.
EPHB1 Homo sapiens EPH receptor B1 (EPHB1), mRNA.
FANCD2 Homo sapiens Fanconi anemia, complementation group D2 (FANCD2),
transcript variant 2, mRNA.
FKBP1B Homo sapiens FK506 binding protein 1B, 12.6 kDa (FKBP1B), transcript
variant 2, mRNA.
FLJ10357 Homo sapiens hypothetical protein FLJ10357 (FLJ10357), mRNA.
FNDC3A Homo sapiens fibronectin type III domain containing 3A (FNDC3A),
transcript variant 1, mRNA.
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FOS Homo sapiens v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS),
mRNA.
FOSB Homo sapiens FBJ murine osteosarcoma viral oncogene homolog B (FOSB),
mRNA.
FOXA1 Homo sapiens forkhead box A1 (FOXA1), mRNA.
FUZ Homo sapiens fuzzy homolog (Drosophila) (FUZ), mRNA.
FZD8 Homo sapiens frizzled homolog 8 (Drosophila) (FZD8), mRNA.
GALNT10 Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10) (GALNT10), transcript
variant 2, mRNA.
GALNT12 Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 12 (GalNAc-T12) (GALNT12), mRNA.
GRB10 Homo sapiens growth factor receptor-bound protein 10 (GRB10), transcript
variant 1, mRNA.
GSG1L Homo sapiens GSG1-like (GSG1L), mRNA.
GZF1 Homo sapiens GDNF-inducible zinc finger protein 1 (GZF1), mRNA.
HDHD3 Homo sapiens haloacid dehalogenase-like hydrolase domain containing 3
(HDHD3), mRNA.
HIST1H4H Homo sapiens histone cluster 1, H4h (HIST1H4H), mRNA.
IFI27 Homo sapiens interferon, alpha-inducible protein 27 (IFI27), transcript variant
2, mRNA.
IL1A Homo sapiens interleukin 1, alpha (IL1A), mRNA.
IL20RB Homo sapiens interleukin 20 receptor beta (IL20RB), mRNA.
IMAA Homo sapiens SLC7A5 pseudogene (IMAA), non-coding RNA.
INHBE Homo sapiens inhibin, beta E (INHBE), mRNA.
ISG20 Homo sapiens interferon stimulated exonuclease gene 20kDa (ISG20), mRNA.
ITGB2 Homo sapiens integrin, beta 2 (complement component 3 receptor 3 and 4
subunit) (ITGB2), mRNA.
JAG1 Homo sapiens jagged 1 (Alagille syndrome) (JAG1), mRNA.
KCNK1 Homo sapiens potassium channel, subfamily K, member 1 (KCNK1), mRNA.
KCNS1 Homo sapiens potassium voltage-gated channel, delayed-rectifier, subfamily S,
member 1 (KCNS1), mRNA.
KIF5C Homo sapiens kinesin family member 5C (KIF5C), mRNA.
KLHL26 Homo sapiens kelch-like 26 (Drosophila) (KLHL26), mRNA.
KLHL3 Homo sapiens kelch-like 3 (Drosophila) (KLHL3), mRNA.
LAMA1 Homo sapiens laminin, alpha 1 (LAMA1), mRNA.
LAMC2 Homo sapiens laminin, gamma 2 (LAMC2), transcript variant 2, mRNA.
LAMP3 Homo sapiens lysosomal-associated membrane protein 3 (LAMP3), mRNA.
LMO2 Homo sapiens LIM domain only 2 (rhombotin-like 1) (LMO2), mRNA.
LOC201175 Homo sapiens hypothetical protein LOC201175 (LOC201175), mRNA.
LPHN2 Homo sapiens latrophilin 2 (LPHN2), mRNA.
LRRC3 Homo sapiens leucine rich repeat containing 3 (LRRC3), mRNA.
MAD2L1BP Homo sapiens MAD2L1 binding protein (MAD2L1BP), transcript variant 2,
mRNA.
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MAGED1 Homo sapiens melanoma antigen family D, 1 (MAGED1), transcript variant 2,
mRNA.
MESDC1 Homo sapiens mesoderm development candidate 1 (MESDC1), mRNA.
MID2 Homo sapiens midline 2 (MID2), transcript variant 1, mRNA.
MIER2 Homo sapiens mesoderm induction early response 1, family member 2
(MIER2), mRNA.
MMP10 Homo sapiens matrix metallopeptidase 10 (stromelysin 2) (MMP10), mRNA.
MTO1 Homo sapiens mitochondrial translation optimization 1 homolog (S.
cerevisiae) (MTO1), nuclear gene encoding mitochondrial protein, transcript
variant 1, mRNA.
NCOR2 Homo sapiens nuclear receptor co-repressor 2 (NCOR2), transcript variant 2,
mRNA.
NDUFV3 Homo sapiens NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa
(NDUFV3), nuclear gene encoding mitochondrial protein, transcript variant 2,
mRNA.
NELL1 Homo sapiens NEL-like 1 (chicken) (NELL1), mRNA.
NFKBIE Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, epsilon (NFKBIE), mRNA.
NSUN5C Homo sapiens NOL1/NOP2/Sun domain family, member 5C (NSUN5C),
transcript variant 1, mRNA.
NUDCD1 Homo sapiens NudC domain containing 1 (NUDCD1), mRNA.
PHF2 Homo sapiens PHD finger protein 2 (PHF2), mRNA.
PHF20L1 Homo sapiens PHD finger protein 20-like 1 (PHF20L1), transcript variant 2,
mRNA.
PPIE Homo sapiens peptidylprolyl isomerase E (cyclophilin E) (PPIE), transcript
variant 1, mRNA.
PPIF Homo sapiens peptidylprolyl isomerase F (cyclophilin F) (PPIF), nuclear gene
encoding mitochondrial protein, mRNA.
PRKD2 Homo sapiens protein kinase D2 (PRKD2), mRNA.
PRKX Homo sapiens protein kinase, X-linked (PRKX), mRNA.
PTGER4 Homo sapiens prostaglandin E receptor 4 (subtype EP4) (PTGER4), mRNA.
PTHLH Homo sapiens parathyroid hormone-like hormone (PTHLH), transcript
variant 3, mRNA.
PTPRR Homo sapiens protein tyrosine phosphatase, receptor type, R (PTPRR),
transcript variant 1, mRNA.
PUS3 Homo sapiens pseudouridylate synthase 3 (PUS3), mRNA.
RARRES3 Homo sapiens retinoic acid receptor responder (tazarotene induced) 3
(RARRES3), mRNA.
RASGRP3 Homo sapiens RAS guanyl releasing protein 3 (calcium and DAG-regulated)
(RASGRP3), mRNA.
RBM38 Homo sapiens RNA binding motif protein 38 (RBM38), transcript variant 2,
mRNA.
REC8 Homo sapiens REC8 homolog (yeast) (REC8), transcript variant 1, mRNA.
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RELB Homo sapiens v-rel reticuloendotheliosis viral oncogene homolog B (RELB),
mRNA.
RFTN2 Homo sapiens raftlin family member 2 (RFTN2), mRNA.
RG9MTD3 Homo sapiens RNA (guanine-9-) methyltransferase domain containing 3
(RG9MTD3), mRNA.
RNF144B Homo sapiens ring finger 144B (RNF144B), mRNA.
RNF19B Homo sapiens ring finger protein 19B (RNF19B), mRNA.
ROR2 Homo sapiens receptor tyrosine kinase-like orphan receptor 2 (ROR2), mRNA.
RPSA Homo sapiens ribosomal protein SA (RPSA), transcript variant 1, mRNA.
RSPO2 Homo sapiens R-spondin 2 homolog (Xenopus laevis) (RSPO2), mRNA.
RSPO3 Homo sapiens R-spondin 3 homolog (Xenopus laevis) (RSPO3), mRNA.
RTKN Homo sapiens rhotekin (RTKN), transcript variant 1, mRNA.
SEMA4D Homo sapiens sema domain, immunoglobulin domain (Ig), transmembrane
domain (TM) and short cytoplasmic domain, (semaphorin) 4D (SEMA4D),
mRNA.
SH3BP1 Homo sapiens SH3-domain binding protein 1 (SH3BP1), mRNA.
SLC44A3 Homo sapiens solute carrier family 44, member 3 (SLC44A3), mRNA.
SLC46A1 Homo sapiens solute carrier family 46 (folate transporter),member 1
(SLC46A1), mRNA.
SLC6A9 Homo sapiens solute carrier family 6 (neurotransmitter transporter, glycine),
member 9 (SLC6A9), transcript variant 3, mRNA.
SLCO4A1 Homo sapiens solute carrier organic anion transporter family, member 4A1
(SLCO4A1), mRNA.
SMG6 Homo sapiens Smg-6 homolog, nonsense mediated mRNA decay factor (C.
elegans) (SMG6), mRNA.
SMOX Homo sapiens spermine oxidase (SMOX), transcript variant 2, mRNA.
SOX8 Homo sapiens SRY (sex determining region Y)-box 8 (SOX8), mRNA.
STRA6 Homo sapiens stimulated by retinoic acid gene 6 homolog (mouse) (STRA6),
mRNA.
SYT1 Homo sapiens synaptotagmin I (SYT1), mRNA.
SYT7 Homo sapiens synaptotagmin VII (SYT7), mRNA.
TAC3 Homo sapiens tachykinin 3 (neuromedin K,neurokinin beta) (TAC3),
transcript variant 1, mRNA.
TACSTD2 Homo sapiens tumor-associated calcium signal transducer 2 (TACSTD2),
mRNA.
TAGLN3 Homo sapiens transgelin 3 (TAGLN3), transcript variant 3, mRNA.
TCN2 Homo sapiens transcobalamin II; macrocytic anemia (TCN2), mRNA.
TESK2 Homo sapiens testis-specific kinase 2 (TESK2), mRNA.
TNFRSF10A Homo sapiens tumor necrosis factor receptor superfamily,member 10a
(TNFRSF10A), mRNA.
TNK2 Homo sapiens tyrosine kinase, non-receptor, 2 (TNK2), transcript variant 1,
mRNA.
TSPAN33 Homo sapiens tetraspanin 33 (TSPAN33), mRNA.
TTC7A Homo sapiens tetratricopeptide repeat domain 7A (TTC7A), mRNA.
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TXNL4B Homo sapiens thioredoxin-like 4B (TXNL4B), mRNA.
UBE2L6 Homo sapiens ubiquitin-conjugating enzyme E2L 6 (UBE2L6), transcript
variant 2, mRNA.
ULBP1 Homo sapiens UL16 binding protein 1 (ULBP1), mRNA.
VGF Homo sapiens VGF nerve growth factor inducible (VGF), mRNA.
WWC1 Homo sapiens WW and C2 domain containing 1 (WWC1), mRNA.
ZFYVE16 Homo sapiens zinc finger, FYVE domain containing 16 (ZFYVE16), mRNA.
ZNF225 Homo sapiens zinc finger protein 225 (ZNF225), mRNA.
ZNF408 Homo sapiens zinc finger protein 408 (ZNF408), mRNA.
ZNF442 Homo sapiens zinc finger protein 442 (ZNF442), mRNA.
ZNF509 Homo sapiens zinc finger protein 509 (ZNF509), mRNA.
ZNF670 Homo sapiens zinc finger protein 670 (ZNF670), mRNA.
ZSCAN12 Homo sapiens zinc finger and SCAN domain containing 12 (ZSCAN12),
mRNA.
Table B.3: Functional annotation and KEGG pathway enrichment analysis corresponding to the list
of 148 genes overlapping in reprogramming factor-transfected fibroblasts and the union of FiPSCs
and ESCs (reported in Figure 4.6 C). Modified from Drews et al. (2012).
Category Term Count % PValue
GOTERM_MF_FAT GO:0005112∼Notch binding 3 2.08 2.12E-03
GOTERM_BP_FAT GO:0051591∼response to cAMP 4 2.78 5.27E-03
SP_PIR_KEYWORDS transmembrane protein 12 8.33 8.13E-03
INTERPRO IPR013032:EGF-like region, conserved
site
8 5.56 8.84E-03
GOTERM_BP_FAT GO:0010817∼regulation of hormone
levels
6 4.17 8.99E-03
GOTERM_BP_FAT GO:0007267∼cell-cell signaling 12 8.33 1.23E-02
SP_PIR_KEYWORDS heparin-binding 4 2.78 1.23E-02
GOTERM_BP_FAT GO:0051180∼vitamin transport 3 2.08 1.72E-02
KEGG_PATHWAY hsa04010:MAPK signaling pathway 7 4.86 2.11E-02
SP_PIR_KEYWORDS membrane 59 40.97 2.24E-02
OMIM_DISEASE Systematic association mapping identifies
NELL1 as a novel IBD disease gene
2 1.39 2.27E-02
SP_PIR_KEYWORDS manganese 5 3.47 2.63E-02




SP_PIR_KEYWORDS tumor antigen 3 2.08 3.20E-02
GOTERM_BP_FAT GO:0008285∼negative regulation of cell
proliferation
8 5.56 3.30E-02
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SMART SM00051:DSL 2 1.39 3.56E-02
UP_SEQ_FEATURE domain:DSL 2 1.39 3.66E-02
GOTERM_MF_FAT GO:0016859∼cis-trans isomerase activity 3 2.08 3.75E-02
INTERPRO IPR011651:Notch ligand, N-terminal 2 1.39 3.90E-02
GOTERM_BP_FAT GO:0006865∼amino acid transport 4 2.78 4.04E-02
INTERPRO IPR008266:Tyrosine protein kinase, active
site
4 2.78 4.19E-02
GOTERM_BP_FAT GO:0055114∼oxidation reduction 11 7.64 4.32E-02
SP_PIR_KEYWORDS glycoprotein 42 29.17 4.37E-02
PIR_SUPERFAMILY PIRSF001719:fos transforming protein 2 1.39 4.38E-02
SP_PIR_KEYWORDS phosphoprotein 65 45.14 4.40E-02
GOTERM_MF_FAT GO:0008201∼heparin binding 4 2.78 4.74E-02
UP_SEQ_FEATURE domain:Leucine-zipper 4 2.78 4.88E-02
SP_PIR_KEYWORDS tyrosine-protein kinase 4 2.78 4.91E-02
GOTERM_BP_FAT GO:0030097∼hemopoiesis 6 4.17 4.93E-02
KEGG_PATHWAY hsa04010:MAPK signaling pathway 7 4.86 2.11E-02
Table B.4: List of the top 100 up-regulated genes extracted from the 662 genes significantly up-
regulated in fibroblasts upon transfection with mRNAs encoding reprogramming factors. The
complete list is available from Drews et al. (2012).
Symbol Definition Ratio padj
IFNB1 Homo sapiens interferon, beta 1, fibroblast (IFNB1),
mRNA.
967.26 1.49E-03
CCL5 Homo sapiens chemokine (C-C motif) ligand 5 (CCL5),
mRNA.
441.42 2.26E-02
RSAD2 Homo sapiens radical S-adenosyl methionine domain
containing 2 (RSAD2), mRNA.
402.81 4.38E-36
IFI27 Homo sapiens interferon, alpha-inducible protein 27 (IFI27),
transcript variant 2, mRNA.
397.68 4.38E-36
POU5F1 Homo sapiens POU class 5 homeobox 1 (POU5F1),
transcript variant 1, mRNA.
309.93 4.38E-36
IFI44L Homo sapiens interferon-induced protein 44-like (IFI44L),
mRNA.
300.15 4.38E-36
OASL Homo sapiens 2’-5’-oligoadenylate synthetase-like (OASL),
transcript variant 1, mRNA.
244.22 2.73E-07
ISG20 Homo sapiens interferon stimulated exonuclease gene
20kDa (ISG20), mRNA.
241.68 4.38E-36
MX2 Homo sapiens myxovirus (influenza virus) resistance 2
(mouse) (MX2), mRNA.
241.26 4.38E-36
IL29 Homo sapiens interleukin 29 (interferon, lambda 1) (IL29),
mRNA.
208.74 3.13E-02
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OAS2 Homo sapiens 2’-5’-oligoadenylate synthetase 2, 69/71kDa
(OAS2), transcript variant 2, mRNA.
191.33 9.28E-23
OAS1 Homo sapiens 2’,5’-oligoadenylate synthetase 1, 40/46kDa
(OAS1), transcript variant 3, mRNA.
184.42 1.52E-19
HERC5 Homo sapiens hect domain and RLD 5 (HERC5), mRNA. 183.16 4.38E-36
CMPK2 Homo sapiens cytidine monophosphate (UMP-CMP)
kinase 2, mitochondrial (CMPK2), nuclear gene encoding
mitochondrial protein, mRNA.
154.10 4.38E-36
POU5F1P1 Homo sapiens POU class 5 homeobox 1 pseudogene 1
(POU5F1P1), non-coding RNA.
151.12 4.38E-36
IL28A Homo sapiens interleukin 28A (interferon, lambda 2)
(IL28A), mRNA.
135.51 4.33E-08
TNFSF10 Homo sapiens tumor necrosis factor (ligand) superfamily,
member 10 (TNFSF10), mRNA.
115.84 4.38E-36
TNFSF13B Homo sapiens tumor necrosis factor (ligand) superfamily,
member 13b (TNFSF13B), mRNA.
115.74 9.89E-05
IFIT2 Homo sapiens interferon-induced protein with
tetratricopeptide repeats 2 (IFIT2), mRNA.
95.23 4.38E-36
BST2 Homo sapiens bone marrow stromal cell antigen 2 (BST2),
mRNA.
92.81 4.38E-36
IFIH1 Homo sapiens interferon induced with helicase C domain 1
(IFIH1), mRNA.
72.29 4.38E-36
HERC6 Homo sapiens hect domain and RLD 6 (HERC6), mRNA. 71.71 4.89E-11
MX1 Homo sapiens myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse) (MX1), mRNA.
59.49 4.38E-36
BATF2 Homo sapiens basic leucine zipper transcription factor,
ATF-like 2 (BATF2), mRNA.
59.03 4.38E-36
LGALS9 Homo sapiens lectin, galactoside-binding, soluble, 9
(LGALS9), transcript variant 1, mRNA.
58.45 3.42E-04
DDX58 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide
58 (DDX58), mRNA.
47.10 4.38E-36
EPSTI1 Homo sapiens epithelial stromal interaction 1 (breast)
(EPSTI1), transcript variant 2, mRNA.
45.13 4.38E-36
RARRES3 Homo sapiens retinoic acid receptor responder (tazarotene
induced) 3 (RARRES3), mRNA.
44.18 8.73E-04
CYP2J2 Homo sapiens cytochrome P450, family 2, subfamily J,
polypeptide 2 (CYP2J2), mRNA.
41.39 4.41E-09
ISG15 Homo sapiens ISG15 ubiquitin-like modifier (ISG15),
mRNA.
40.07 4.38E-36
IFIT3 Homo sapiens interferon-induced protein with
tetratricopeptide repeats 3 (IFIT3), mRNA.
39.92 4.38E-36
IRF7 Homo sapiens interferon regulatory factor 7 (IRF7),
transcript variant b, mRNA.
35.81 2.55E-25
GBP4 Homo sapiens guanylate binding protein 4 (GBP4), mRNA. 35.75 4.11E-02
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PSMB9 Homo sapiens proteasome (prosome, macropain) subunit,
beta type, 9 (large multifunctional peptidase 2) (PSMB9),
transcript variant 1, mRNA.
35.42 5.24E-19
IL28B Homo sapiens interleukin 28B (interferon, lambda 3)
(IL28B), mRNA.
33.83 2.03E-02
CFB Homo sapiens complement factor B (CFB), mRNA. 32.60 5.19E-06
IFI35 Homo sapiens interferon-induced protein 35 (IFI35),
mRNA.
32.54 4.38E-36
IFIT1 Homo sapiens interferon-induced protein with
tetratricopeptide repeats 1 (IFIT1), transcript variant 2,
mRNA.
31.23 4.38E-36
SLC15A3 Homo sapiens solute carrier family 15,member 3
(SLC15A3), mRNA.
30.54 4.38E-36
XAF1 Homo sapiens XIAP associated factor 1 (XAF1), transcript
variant 2, mRNA.
29.57 6.87E-24
C15orf48 Homo sapiens chromosome 15 open reading frame 48
(C15orf48), transcript variant 2, mRNA.
26.12 9.36E-14
RTP4 Homo sapiens receptor (chemosensory) transporter protein
4 (RTP4), mRNA.
25.65 1.81E-03
DHX58 Homo sapiens DEXH (Asp-Glu-X-His) box polypeptide 58
(DHX58), mRNA.
24.58 4.38E-36
GMPR Homo sapiens guanosine monophosphate reductase
(GMPR), mRNA.
23.90 4.38E-36
PRIC285 Homo sapiens peroxisomal proliferator-activated receptor
A interacting complex 285 (PRIC285), transcript variant 2,
mRNA.
23.89 4.38E-36
IFI44 Homo sapiens interferon-induced protein 44 (IFI44),
mRNA.
23.75 4.38E-36
APOBEC3G Homo sapiens apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 3G (APOBEC3G), mRNA.
23.45 4.38E-36
PARP10 PREDICTED: Homo sapiens poly (ADP-ribose)
polymerase family, member 10 (PARP10), mRNA.
23.18 4.38E-36
TMEM140 Homo sapiens transmembrane protein 140 (TMEM140),
mRNA.
23.18 4.38E-36
DTX3L Homo sapiens deltex 3-like (Drosophila) (DTX3L), mRNA. 21.84 2.31E-07
IFITM1 Homo sapiens interferon induced transmembrane protein 1
(9-27) (IFITM1), mRNA.
21.36 4.38E-36
PARP14 Homo sapiens poly (ADP-ribose) polymerase family,
member 14 (PARP14), mRNA.
20.29 4.38E-36
PARP12 Homo sapiens poly (ADP-ribose) polymerase family,
member 12 (PARP12), mRNA.
19.92 4.38E-36
CXCL16 Homo sapiens chemokine (C-X-C motif) ligand 16
(CXCL16), mRNA.
19.00 2.07E-18
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ECGF1 Homo sapiens endothelial cell growth factor 1 (platelet-
derived) (ECGF1), mRNA.
18.93 5.89E-09
IL18BP Homo sapiens interleukin 18 binding protein (IL18BP),
transcript variant A, mRNA.
18.12 2.97E-03
UBA7 Homo sapiens ubiquitin-like modifier activating enzyme 7
(UBA7), mRNA.
18.01 4.38E-36
LAMP3 Homo sapiens lysosomal-associated membrane protein 3
(LAMP3), mRNA.
17.15 6.02E-03
TRIM22 Homo sapiens tripartite motif-containing 22 (TRIM22),
mRNA.
17.12 4.38E-36
DDX60 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide
60 (DDX60), mRNA.
17.11 4.38E-36
SAMD9L Homo sapiens sterile alpha motif domain containing 9-like
(SAMD9L), mRNA.
17.02 4.38E-36
INDO Homo sapiens indoleamine-pyrrole 2,3 dioxygenase
(INDO), mRNA.
15.77 5.63E-06
PLSCR1 Homo sapiens phospholipid scramblase 1 (PLSCR1),
mRNA.
15.72 4.38E-36
SP110 Homo sapiens SP110 nuclear body protein (SP110),
transcript variant b, mRNA.
15.42 2.97E-27
SAMHD1 Homo sapiens SAM domain and HD domain 1 (SAMHD1),
mRNA.
15.36 4.38E-36
ZMYND15 Homo sapiens zinc finger, MYND-type containing 15
(ZMYND15), mRNA.
15.26 7.60E-05
IFI6 Homo sapiens interferon, alpha-inducible protein 6 (IFI6),
transcript variant 2, mRNA.
14.88 1.12E-23
KIAA1618 Homo sapiens KIAA1618 (KIAA1618), mRNA. 14.55 4.38E-36
UBE2L6 Homo sapiens ubiquitin-conjugating enzyme E2L 6
(UBE2L6), transcript variant 2, mRNA.
14.16 1.99E-07
PLEKHA4 Homo sapiens pleckstrin homology domain containing,
family A (phosphoinositide binding specific) member 4
(PLEKHA4), mRNA.
13.25 4.38E-36
C19orf66 Homo sapiens chromosome 19 open reading frame 66
(C19orf66), mRNA.
13.14 4.38E-36
TAP1 Homo sapiens transporter 1, ATP-binding cassette, sub-
family B (MDR/TAP) (TAP1), mRNA.
13.07 4.38E-36
MT1M Homo sapiens metallothionein 1M (MT1M), mRNA. 12.41 4.38E-36
GBP5 Homo sapiens guanylate binding protein 5 (GBP5), mRNA. 12.00 4.22E-14
FBXO6 Homo sapiens F-box protein 6 (FBXO6), mRNA. 11.78 4.38E-36
RASGRP3 Homo sapiens RAS guanyl releasing protein 3 (calcium and
DAG-regulated) (RASGRP3), mRNA.
11.26 8.33E-05
IFI30 Homo sapiens interferon, gamma-inducible protein 30
(IFI30), mRNA.
10.95 4.38E-36
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TRIM21 Homo sapiens tripartite motif-containing 21 (TRIM21),
mRNA.
10.82 4.38E-36
LGALS3BP Homo sapiens lectin, galactoside-binding, soluble, 3 binding
protein (LGALS3BP), mRNA.
10.72 4.38E-36
SAMD9 Homo sapiens sterile alpha motif domain containing 9
(SAMD9), mRNA.
10.56 4.38E-36
MAFA Homo sapiens v-maf musculoaponeurotic fibrosarcoma
oncogene homolog A (avian) (MAFA), mRNA.
10.45 8.62E-05
MYD88 Homo sapiens myeloid differentiation primary response
gene (88) (MYD88), mRNA.
10.25 4.38E-36
HIST1H4H Homo sapiens histone cluster 1,H4h (HIST1H4H),
mRNA.
10.12 3.59E-06
NCOA7 Homo sapiens nuclear receptor coactivator 7 (NCOA7),
mRNA.
10.02 4.38E-36
HSH2D Homo sapiens hematopoietic SH2 domain containing
(HSH2D), mRNA.
9.97 1.48E-07
PARP9 Homo sapiens poly (ADP-ribose) polymerase family,
member 9 (PARP9), mRNA.
9.84 7.06E-09
NELL1 Homo sapiens NEL-like 1 (chicken) (NELL1), mRNA. 9.56 4.38E-36
CD274 Homo sapiens CD274 molecule (CD274), mRNA. 9.56 4.38E-36
TAP2 Homo sapiens transporter 2, ATP-binding cassette, sub-
family B (MDR/TAP) (TAP2), transcript variant 1, mRNA.
9.03 1.82E-19
NMI Homo sapiens N-myc (and STAT) interactor (NMI),
mRNA.
8.80 4.38E-36
MLKL Homo sapiens mixed lineage kinase domain-like (MLKL),
mRNA.
8.74 6.17E-04
CEACAM1 Homo sapiens carcinoembryonic antigen-related cell
adhesion molecule 1 (biliary glycoprotein) (CEACAM1),
transcript variant 2, mRNA.
8.69 9.79E-17
UNC93B1 Homo sapiens unc-93 homolog B1 (C. elegans) (UNC93B1),
mRNA.
8.67 1.89E-12
GBP1 Homo sapiens guanylate binding protein 1, interferon-
inducible, 67kDa (GBP1), mRNA.
8.66 4.38E-36
STAT1 Homo sapiens signal transducer and activator of
transcription 1, 91kDa (STAT1), transcript variant alpha,
mRNA.
8.32 4.38E-36
HES4 Homo sapiens hairy and enhancer of split 4 (Drosophila)
(HES4), mRNA.
8.31 4.38E-36
WARS Homo sapiens tryptophanyl-tRNA synthetase (WARS),
transcript variant 2, mRNA.
8.30 4.38E-36
ZNFX1 Homo sapiens zinc finger,NFX1-type containing 1
(ZNFX1), mRNA.
8.02 4.38E-36
APOL6 Homo sapiens apolipoprotein L, 6 (APOL6), mRNA. 7.90 4.38E-36
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CXCL2 Homo sapiens chemokine (C-X-C motif) ligand 2 (CXCL2),
mRNA.
7.78 4.61E-02
Table B.5: List of the top 100 down-regulated genes extracted from the 331 genes significantly
down-regulated in fibroblasts upon transfection with mRNAs encoding reprogramming factors.
The complete list is available from Drews et al. (2012).
Symbol Definition Ratio padj
TNFRSF10D Homo sapiens tumor necrosis factor receptor superfamily,
member 10d,decoy with truncated death domain
(TNFRSF10D), mRNA.
0.09 1.13E-03
ACO1 Homo sapiens aconitase 1, soluble (ACO1), mRNA. 0.15 2.16E-33
PIF1 Homo sapiens PIF1 5’-to-3’ DNA helicase homolog (S.
cerevisiae) (PIF1), mRNA.
0.18 1.19E-02
TNFAIP8L1 Homo sapiens tumor necrosis factor, alpha-induced protein
8-like 1 (TNFAIP8L1), mRNA.
0.19 2.73E-04
GSTM3 Homo sapiens glutathione S-transferase M3 (brain)
(GSTM3), mRNA.
0.20 9.37E-04
FAM3C Homo sapiens family with sequence similarity 3, member C
(FAM3C), transcript variant 2, mRNA.
0.20 2.41E-13
NFIA Homo sapiens nuclear factor I/A (NFIA), mRNA. 0.23 7.05E-03
MIB1 Homo sapiens mindbomb homolog 1 (Drosophila) (MIB1),
mRNA.
0.24 8.14E-03
CEP70 Homo sapiens centrosomal protein 70kDa (CEP70),
mRNA.
0.25 1.29E-11
NT5DC2 Homo sapiens 5’-nucleotidase domain containing 2
(NT5DC2), mRNA.
0.25 8.67E-36
C7orf41 Homo sapiens chromosome 7 open reading frame 41
(C7orf41), mRNA.
0.25 8.93E-07
PELI2 Homo sapiens pellino homolog 2 (Drosophila) (PELI2),
mRNA.
0.25 4.45E-02
STK11 Homo sapiens serine/threonine kinase 11 (STK11), mRNA. 0.26 1.35E-02
NR2F6 Homo sapiens nuclear receptor subfamily 2, group F,
member 6 (NR2F6), mRNA.
0.28 3.36E-21
HSPA12A Homo sapiens heat shock 70kDa protein 12A (HSPA12A),
mRNA.
0.29 2.07E-12
C9orf140 Homo sapiens chromosome 9 open reading frame 140
(C9orf140), mRNA.
0.29 4.09E-04
PRKCA Homo sapiens protein kinase C, alpha (PRKCA), mRNA. 0.29 8.67E-36
FAM102B Homo sapiens family with sequence similarity 102, member
B (FAM102B), mRNA.
0.30 3.93E-05
BAX Homo sapiens BCL2-associated X protein (BAX), transcript
variant sigma, mRNA.
0.30 7.79E-06
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CERK Homo sapiens ceramide kinase (CERK), transcript variant
2, mRNA.
0.30 3.83E-18
GREM2 Homo sapiens gremlin 2, cysteine knot superfamily,
homolog (Xenopuslaevis) (GREM2), mRNA.
0.31 6.01E-04
HMGB3 Homo sapiens high-mobility group box 3 (HMGB3),
mRNA.
0.31 5.01E-15
MEX3B Homo sapiens mex-3 homolog B (C. elegans) (MEX3B),
mRNA.
0.32 9.47E-04
VGLL3 Homo sapiens vestigial like 3 (Drosophila) (VGLL3),
mRNA.
0.32 7.32E-09
USP47 Homo sapiens ubiquitin specific peptidase 47 (USP47),
mRNA.
0.32 1.76E-02
HSD17B6 Homo sapiens hydroxysteroid (17-beta) dehydrogenase 6
homolog (mouse) (HSD17B6), mRNA.
0.32 1.85E-02
PCBD2 Homo sapiens pterin-4 alpha-
carbinolaminedehydratase/dimerization cofactor of
hepatocyte nuclear factor 1 alpha (TCF1) 2 (PCBD2),
mRNA.
0.33 4.00E-02
SOX11 Homo sapiens SRY (sex determining region Y)-box 11
(SOX11), mRNA.
0.33 2.95E-16
TMEM168 Homo sapiens transmembrane protein 168 (TMEM168),
mRNA.
0.34 5.88E-10
CDCA3 Homo sapiens cell division cycle associated 3 (CDCA3),
mRNA.
0.34 2.96E-14
DLG7 Homo sapiens discs, large homolog 7 (Drosophila) (DLG7),
mRNA.
0.34 2.25E-22
H2AFV Homo sapiens H2A histone family, member V (H2AFV),
transcript variant 2, mRNA.
0.34 1.47E-03
C19orf54 Homo sapiens chromosome 19 open reading frame 54
(C19orf54), mRNA.
0.35 9.44E-03
MAP4K2 Homo sapiens mitogen-activated protein kinase kinase
kinase kinase 2 (MAP4K2), mRNA.
0.35 1.83E-33
OLFML2B Homo sapiens olfactomedin-like 2B (OLFML2B), mRNA. 0.35 8.72E-07
FAM101B Homo sapiens family with sequence similarity 101, member
B (FAM101B), mRNA.
0.36 7.49E-19
NEK2 Homo sapiens NIMA (never in mitosis gene a)-related
kinase 2 (NEK2), mRNA.
0.36 5.75E-05
RAB40B Homo sapiens RAB40B, member RAS oncogene family
(RAB40B), mRNA.
0.37 1.37E-07
GPSM2 Homo sapiens G-protein signalling modulator 2 (AGS3-like,
C. elegans) (GPSM2), mRNA.
0.37 3.06E-11
GSTA4 Homo sapiens glutathione S-transferase A4 (GSTA4),
mRNA.
0.38 1.79E-08
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ABHD8 Homo sapiens abhydrolase domain containing 8 (ABHD8),
mRNA.
0.38 3.62E-11
CCNB1 Homo sapiens cyclin B1 (CCNB1), mRNA. 0.38 9.58E-06
PIM1 Homo sapiens pim-1 oncogene (PIM1), mRNA. 0.38 2.60E-05
HNRPA1L-2 Homo sapiens heterogeneous nuclear ribonucleoprotein A1
pseudogene (HNRPA1L-2), non-coding RNA.
0.39 3.01E-17
ARHGAP10 Homo sapiens Rho GTPase activating protein 10
(ARHGAP10), mRNA.
0.39 2.92E-16
ATXN1 Homo sapiens ataxin 1 (ATXN1), mRNA. 0.39 4.22E-02
KIF20A Homo sapiens kinesin family member 20A (KIF20A),
mRNA.
0.39 1.41E-16
TBC1D4 Homo sapiens TBC1 domain family, member 4 (TBC1D4),
mRNA.
0.39 1.93E-03
TSHZ1 Homo sapiens teashirt zinc finger homeobox 1 (TSHZ1),
mRNA.
0.40 1.34E-03
CNN1 Homo sapiens calponin 1, basic, smooth muscle (CNN1),
mRNA.
0.40 4.31E-02
FHL1 Homo sapiens four and a half LIM domains 1 (FHL1),
mRNA.
0.40 2.82E-04
SNAP23 Homo sapiens synaptosomal-associated protein, 23kDa
(SNAP23), transcript variant 1, mRNA.
0.40 8.95E-05
DIXDC1 Homo sapiens DIX domain containing 1 (DIXDC1),
transcript variant 1, mRNA.
0.40 3.30E-02
TBL1XR1 Homo sapiens transducin (beta)-like 1X-linked receptor 1
(TBL1XR1), mRNA.
0.40 7.46E-05
SDC2 Homo sapiens syndecan 2 (SDC2), mRNA. 0.41 8.02E-03
TXNDC12 Homo sapiens thioredoxin domain containing 12
(endoplasmic reticulum) (TXNDC12), mRNA.
0.41 1.80E-13
FAM171A1 Homo sapiens family with sequence similarity 171, member
A1 (FAM171A1), mRNA.
0.41 1.65E-26
GAS2L3 Homo sapiens growth arrest-specific 2 like 3 (GAS2L3),
mRNA.
0.41 1.10E-04
CENPF Homo sapiens centromere protein F, 350/400ka (mitosin)
(CENPF), mRNA.
0.41 2.07E-12
FAM64A Homo sapiens family with sequence similarity 64, member
A (FAM64A), mRNA.
0.41 1.25E-17
ASPM Homo sapiens asp (abnormal spindle) homolog,
microcephaly associated (Drosophila) (ASPM), mRNA.
0.41 5.33E-06
C5orf21 Homo sapiens chromosome 5 open reading frame 21
(C5orf21), mRNA.
0.41 1.09E-22
ITGAE Homo sapiens integrin, alpha E (antigen CD103, human
mucosal lymphocyte antigen 1; alpha polypeptide)
(ITGAE), mRNA.
0.41 3.49E-20
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RAB22A Homo sapiens RAB22A, member RAS oncogene family
(RAB22A), mRNA.
0.41 6.76E-21
WNT5A Homo sapiens wingless-type MMTV integration site family,
member 5A (WNT5A), mRNA.
0.41 9.39E-20
MACF1 Homo sapiens microtubule-actin crosslinking factor 1
(MACF1), transcript variant 2, mRNA.
0.42 4.95E-03
PLK1 Homo sapiens polo-like kinase 1 (Drosophila) (PLK1),
mRNA.
0.42 5.02E-12
FAM83D Homo sapiens family with sequence similarity 83, member
D (FAM83D), mRNA.
0.42 3.95E-21
C15orf23 Homo sapiens chromosome 15 open reading frame 23
(C15orf23), mRNA.
0.42 5.00E-09
APOLD1 Homo sapiens apolipoprotein L domain containing 1
(APOLD1), mRNA.
0.42 1.58E-07
EPHB4 Homo sapiens EPH receptor B4 (EPHB4), mRNA. 0.42 3.94E-06
PRRT2 Homo sapiens proline-rich transmembrane protein 2
(PRRT2), mRNA.
0.43 4.02E-06
WRB Homo sapiens tryptophan rich basic protein (WRB),
mRNA.
0.43 1.43E-11
AURKA Homo sapiens aurora kinase A (AURKA), transcript variant
5, mRNA.
0.43 1.61E-13
CDC2L6 Homo sapiens cell division cycle 2-like 6 (CDK8-like)
(CDC2L6), mRNA.
0.43 2.38E-22
HNRNPA0 Homo sapiens heterogeneous nuclear ribonucleoprotein A0
(HNRNPA0), mRNA.
0.43 4.13E-10
MKI67 Homo sapiens antigen identified by monoclonal antibody
Ki-67 (MKI67), mRNA.
0.43 1.91E-03
CENPA Homo sapiens centromere protein A (CENPA), transcript
variant 2, mRNA.
0.43 1.45E-10
SLC35B4 Homo sapiens solute carrier family 35,member B4
(SLC35B4), mRNA.
0.43 8.27E-03
PREPL Homo sapiens prolylendopeptidase-like (PREPL), transcript
variant C, mRNA.
0.44 2.17E-08
CNTROB Homo sapiens centrobin, centrosomal BRCA2 interacting
protein (CNTROB), transcript variant 1, mRNA.
0.44 4.57E-03
PSRC1 Homo sapiens proline/serine-rich coiled-coil 1 (PSRC1),
transcript variant 4, mRNA.
0.45 6.64E-05
TACC3 Homo sapiens transforming, acidic coiled-coil containing
protein 3 (TACC3), mRNA.
0.45 1.65E-18
CCNB2 Homo sapiens cyclin B2 (CCNB2), mRNA. 0.45 7.04E-15
NEDD4L Homo sapiens neural precursorcell expressed,
developmentally down-regulated 4-like (NEDD4L), mRNA.
0.45 1.21E-05
YIF1A Homo sapiens Yip1 interacting factor homolog A (S.
cerevisiae) (YIF1A), mRNA.
0.45 1.50E-02
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DLEU1 Homo sapiens deleted in lymphocytic leukemia 1 (non-
protein coding) (DLEU1), non-coding RNA.
0.45 1.05E-07
CENPE Homo sapiens centromere protein E, 312kDa (CENPE),
mRNA.
0.45 9.26E-05
SNRPD3 Homo sapiens small nuclear ribonucleoprotein D3
polypeptide 18kDa (SNRPD3), mRNA.
0.45 9.67E-04
CXXC5 Homo sapiens CXXC finger 5 (CXXC5), mRNA. 0.46 1.19E-02
CDCA8 Homo sapiens cell division cycle associated 8 (CDCA8),
mRNA.
0.46 2.19E-08
ODF2 Homo sapiens outer dense fiber of sperm tails 2 (ODF2),
transcript variant 2, mRNA.
0.46 9.48E-04
MXD3 Homo sapiens MAX dimerization protein 3 (MXD3),
mRNA.
0.46 7.00E-03
SEPHS1 Homo sapiens selenophosphate synthetase 1 (SEPHS1),
mRNA.
0.46 5.08E-19
PKNOX1 Homo sapiens PBX/knotted 1 homeobox 1 (PKNOX1),
mRNA.
0.47 3.56E-04





TMEM119 Homo sapiens transmembrane protein 119 (TMEM119),
mRNA.
0.47 9.75E-13
CYB5B Homo sapiens cytochrome b5 type B (outer mitochondrial
membrane) (CYB5B), nuclear gene encoding mitochondrial
protein, mRNA.
0.47 5.77E-22
PPP2R5D Homo sapiens protein phosphatase 2, regulatory subunit B’,
delta isoform (PPP2R5D), transcript variant 2, mRNA.
0.47 4.78E-07
KLHDC8B Homo sapiens kelch domain containing 8B (KLHDC8B),
mRNA.
0.47 3.53E-09
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Figure B.1: Complex secondary structures of the reprogramming factor-encoding mRNAs.
The depicted minimum free energy structures were predicted by the RNAfold WebServer




Figure B.2: KEGG pathway enrichment analysis of significantly differentially expressed genes in reprogramming factor-transfected fibroblasts with respect
to mock-transfected control cells. The lists of 662 significantly up-regulated and 331 significantly down-regulated genes, obtained from the microarray-
based transcriptome analysis of reprogramming factor mRNA vs. mock-transfected fibroblasts, were assessed for enrichment of genes involved in distinct
cellular pathways using the DAVID database. (A, B, C) Selection of three KEGG pathways, which the list of 662 up-regulated genes was enriched for
(Table 4.1). (D, E) Selection of two KEGG pathways the list of 331 down-regulated genes was significantly enriched for (Table 4.2. Genes, which are
up-regulated in reprogramming factor mRNA-transfected fibroblasts in comparison to mock-transfected fibroblasts are highlighted in red, down-regulated
genes are highlighted in green. Taken from Drews et al. (2012). – Continued on next page
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Table B.6: List of 249 interferon-regulated genes derived from the list of 662 genes up-regulated in
reprogramming factor mRNA-transfected fibroblasts with respect to mock-transfected control cells.
The numbers on the right refer to the number of datasets that have shown the different types of
interferons to regulate the listed genes. Taken from Drews et al. (2012).
Symbol Chromosome Definition Type 1 Type 2 Type 3
ADAM17 2 ADAM 17 precursor (EC
3.4.24.86)
1 0 0
ADAR 1 Double-stranded RNA-specific
adenosine deaminase (EC 3.5.4.-
)
6 3 1
ANKFY1 17 Ankyrin repeat and FYVE
domain-containing protein 1
1 0 1
APOBEC3G 22 DNA dC→dU-editing enzyme
APOBEC-3G (EC 3.5.4.-)
3 2 1
APOL2 22 Apolipoprotein-L2 2 1 1
APOL6 22 Apolipoprotein-L6 4 1 3
AZI2 3 5-azacytidine-induced protein 2 2 0 1
B2M 15 Beta-2-microglobulin precursor 4 1 1




BST2 19 Bonemarrowstromalantigen 2
precursor
13 4 3
BTN3A2 6 Butyrophilin subfamily 3
member A2 precursor
2 1 0
BTN3A3 6 Butyrophilin subfamily 3
member A3 precursor
1 1 0
C19orf28 19 Putative transporter C19orf28 1 0 0




CALCOCO2 17 calcium binding and coiled-coil
domain 2
0 1 0
CASP7 10 Caspase-7 precursor 5 4 1
CCL2 17 Small inducible cytokine A2
precursor
6 3 0
CCL5 17 Small inducible cytokine A5
precursor
3 2 0
CCND3 6 G1/S-specific cyclin-D3 1 1 0
CCNL1 3 Cyclin-L1 1 0 0
CD274 9 Programmed cell death 1 ligand
1 precursor
0 1 0
CD58 1 Lymphocyte function-
associated antigen 3 precursor
1 1 0
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CDC5L 6 Cell division cycle 5-like
protein
1 0 0
CEACAM1 19 Carcinoembryonic antigen-






CFB c6_COX Complement factor B
precursor (EC 3.4.21.47)
5 3 0
CFLAR 2 CASP8 and FADD-like
apoptosis regulator precursor
1 0 1
CHMP5 9 Charged multivesicular body
protein 5
1 0 0
CLDN1 3 Claudin-1 1 0 0
COMT 22 Catechol O-methyltransferase
(EC 2.1.1.6)
2 1 0
CTGF 6 Connective tissue growth factor
precursor
3 2 0
CTSL1 9 Cathepsin L precursor (EC
3.4.22.15)
1 0 0
CXCL16 17 Small inducible cytokine B16
precursor
1 0 0
CXCL2 4 Macrophage inflammatory
protein 2-alpha precursor
2 2 0
CYP2J2 1 Cytochrome P450 2J2 (EC
1.14.14.1)
1 1 0
DDX58 9 Probable ATP-dependent RNA
helicase DDX58 (EC 3.6.1.-)
10 4 3
DEDD 1 Death effector domain-
containing protein
1 0 0
DHX58 17 Probable ATP-dependent
helicase LGP2 (EC 3.6.1.-)
0 1 0
DNAJA1 9 DnaJ homolog subfamily A
member 1
1 1 0
DTX3L 3 Protein deltex 3-like protein 1 0 0
DUSP1 5 Dual specificity protein
phosphatase 1 (EC 3.1.3.48)
(EC 3.1.3.16)
3 3 0
DUSP5 10 Dual specificity protein
phosphatase 5 (EC 3.1.3.48)
(EC 3.1.3.16)
1 0 1
DYNLT1 6 Dynein light chain Tctex-type
1
1 1 0
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EDN1 6 Endothelin-1 precursor 0 1 0
EFR3_HU-
MAN
8 Protein EFR3-like 0 1 0
EHD4 15 EH domain-containing protein
4
1 0 1
EIF2AK2 2 Interferon-induced, double-
stranded RNA-activated
protein kinase (EC 2.7.11.1)
15 3 3
ELF1 13 ETS-related transcription factor
Elf-1
1 1 0
EPHA2 1 Ephrin type-A receptor 2
precursor (EC 2.7.10.1)
1 0 0
EPSTI1 13 epithelial stromal interaction 1
isoform 2
1 0 1
EXOSC9 4 Exosome complex exonuclease
RRP45 (EC 3.1.13.-)
1 1 0
F3 1 Tissue factor precursor 2 3 0
FAM125A 19 Protein FAM125A 1 0 1
FAM46A 6 Protein FAM46A 0 1 0
FOSL1 11 Fos-related antigen 1 2 1 0
FST 5 Follistatin precursor 1 0 0








GBP1 1 Interferon-induced guanylate-
binding protein 1
15 6 2
GBP2 1 Interferon-induced guanylate-
binding protein 2
8 2 0
GBP3 1 Guanylate-binding protein 3 4 3 0
GBP4 1 Guanylate-binding protein 4 3 1 0
GBP5 1 Guanylate-binding protein 5 4 0 1
GCA 2 Grancalcin 2 0 1
GLIPR1 12 Glioma pathogenesis-related
protein 1 precursor
1 1 0
GMPR 6 GMP reductase 1 (EC 1.7.1.7) 4 3 0
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GSDMDC1 8 Gasdermin domain-containing
protein 1
1 0 0
H1F0 22 Histone H1.0 2 1 0
H4_HUMAN 6 Histone H4 0 1 0
HAX1 1 HS1-associating protein X-1 1 1 0
HBEGF 5 Heparin-binding EGF-like
growth factor precursor
0 1 0
HERC5 4 Probable E3 ubiquitin-protein
ligase HERC5 (EC 6.3.2.-)
6 1 2
HERC6 4 Probable E3 ubiquitin-protein
ligase HERC6 (EC 6.3.2.-)
2 0 1
HES4 1 Transcription factor HES-4 1 0 0
HIST1H2AC 6 Histone H2A type 1-C 2 1 0
HIST3H2A 1 Histone H2A type 3 1 0 0
HSH2D 19 Hematopoietic SH2 domain-
containing protein
1 0 1
HSPA1B 6 Heatshock 70 kDa protein 1 2 2 0
ICAM2 17 Intercellular adhesion molecule
2 precursor
1 0 0






IFI27 14 Interferon-alpha-induced 11.5
kDa protein
13 3 3
IFI35 17 Interferon-induced 35 kDa
protein
14 3 2
IFI44 1 Interferon-induced protein 44 11 5 2
IFI44L 1 histocompatibility 28 8 3 2
IFI6 1 Interferon-induced protein 6-16
precursor
19 5 2




IFIT1 10 Interferon-induced protein
with tetratricopeptide repeats 1
17 3 2
IFIT2 10 Interferon-induced protein
with tetratricopeptide repeats 2
15 6 2
IFIT3 10 Interferon-induced protein
with tetratricopeptide repeats 3
15 4 3
IFIT5 10 Interferon-induced protein
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IFNB1 9 Interferon beta precursor 0 1 0
IL10 1 Interleukin-10 precursor 0 1 0
IL11 19 Interleukin-11 precursor 0 1 0
IL12A 3 Interleukin-12 subunit alpha
precursor
0 1 0
IL15 4 Interleukin-15 precursor 4 2 0
IL15RA 10 Interleukin-15 receptor alpha
chain precursor
6 3 1
IRF1 5 Interferon regulatory factor 1 12 6 1
IRF7 11 Interferon regulatory factor 7 15 4 1
IRF9 14 Transcriptional regulator
ISGF3 subunit gamma
11 3 3
ISG15 1 Interferon-induced 17 kDa
protein precursor
20 5 3
ISG20 15 Interferon-stimulated gene 20
kDa protein (EC 3.1.13.1)
15 5 3
ITGA2 5 Integrin alpha-2 precursor 1 1 0
ITGA3 17 Integrin alpha-3 precursor 1 0 0
JAK2 9 Tyrosine-protein kinase JAK2 3 1 0
JUN 1 Transcription factor AP-1 2 2 1
JUNB 19 Transcription factorjun-B 1 1 0
KCTD14 11 BTB/POZ domain-containing
protein KCTD14
1 1 0
KLF11 2 Krueppel-likefactor 11 2 0 0
LAMB1 7 Laminin subunit beta-1
precursor
1 0 0
LAMP3 3 Lysosome-associated membrane
glycoprotein 3 precursor
5 3 1
LAP3 4 Cytosol aminopeptidase (EC
3.4.11.1)
2 0 1




LGALS3BP 17 Galectin-3-binding protein
precursor
9 4 2
LGALS9 17 Galectin-9 6 4 0
LGMN 14 Legumain precursor (EC
3.4.22.34)
1 0 0
LMO2 11 Rhombotin-2 2 1 0
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LY6E 8 Lymphocyte antigen 6E
precursor
6 2 1
MAD2L1BP 6 MAD2L1-binding protein 1 1 0
MAP3K8 10 Mitogen-activated protein
kinase kinase kinase 8 (EC
2.7.11.25)
1 2 0
MCL1 1 Induced myeloid leukemia cell
differentiation protein Mcl-1
3 2 1
MOV10 1 Putative helicase MOV-10 (EC
3.6.1.-)
0 1 0
MTMR11 1 myotubularin related protein
11
1 1 0
MVP 16 Major vault protein 1 1 0
MX1 21 Interferon-induced GTP-
binding protein Mx1
15 4 2
MX2 21 Interferon-induced GTP-
binding protein Mx2
12 3 2
MYC 8 Myc proto-oncogene protein 3 2 0






16 NEDD4-binding protein 1 2 0 1










complex, class I, F isoform 3
precursor
0 1 0
NP_005507.3 6 major histocompatibility
complex, class I, E precursor
0 1 0
NP_057563.3 3 scotin 0 1 0
NP_060101.2 4 CDNA FLJ10787 fis 0 1 0
NP_060851.2 19 CDNA FLJ38823 fis 0 1 0
NP_954590.1 17 XIAP associated factor-1
isoform 2
0 1 0
NP_997198.2 2 thymidylate kinase family LPS-
inducible member
0 1 0
NRBP1 2 Nuclear receptor-binding
protein
0 1 0
NT5C3 7 Cytosolic 5-nucleotidase III
(EC 3.1.3.5)
2 0 1
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OAS1 12 2-5-oligoadenylate synthetase 1
(EC 2.7.7.-)
16 5 3
OAS2 12 2-5-oligoadenylate synthetase 2
(EC 2.7.7.-)
13 4 3
OASL 12 59 kDa 2-5-oligoadenylate
synthetase-like protein
11 5 2
OGFR 20 Opioid growth factor receptor 2 1 1
OPTN 10 Optineurin 1 0 0
PAPD4 5 PAP associated domain-
containing 4
1 0 0
PARP10 8 Poly [ADP-ribose] polymerase
10 (EC 2.4.2.30)
0 1 0
PARP12 7 Poly [ADP-ribose] polymerase
12 (EC 2.4.2.30)
0 1 0
PARP4 13 Poly [ADP-ribose] polymerase
4 (EC 2.4.2.30)
2 1 0
PBEF1 7 Nicotinamide phosphoribosyl
transferase (EC 2.4.2.12)
2 0 0
PDGFRL 8 Platelet-derived growth factor
receptor-like protein precursor
4 1 0
PHF11 13 PHD fingerprotein 11 2 0 2




PLEKHA4 19 Pleckstrin homology domain-
containing family A member
4
2 1 0















kinase D2 (EC 2.7.11.13)
2 1 1
PRNP 20 Major prion protein precursor 2 1 0
PROCR 20 Endothelial protein C receptor
precursor
1 1 0
PSCD1 17 Cytohesin-1 1 0 0
PSMA2 7 Proteasome subunit alpha type
2 (EC 3.4.25.1)
2 1 0
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PSMA3 14 Proteasome subunit alpha type
3 (EC 3.4.25.1)
2 1 0
PSMA4 15 Proteasome subunit alpha type
4 (EC 3.4.25.1)
1 1 0
PSMB10 16 Proteasome subunit beta type
10 precursor (EC 3.4.25.1)
0 1 0
PSMB2 1 Proteasome subunit beta type 2
(EC 3.4.25.1)
1 1 0
PSMB8 6 Proteasome subunit beta type 8
precursor (EC 3.4.25.1)
7 2 0
PSMB9 6 Proteasome subunit beta type 9
precursor (EC 3.4.25.1)
12 3 3
PSME1 14 Proteasome activator complex
subunit 1
2 1 0
PSME2 14 Proteasome activator complex
subunit 2
2 1 0
PTGER4 5 Prostaglandin E2 receptor EP4
subtype
1 0 0
PTGS2 1 Prostaglandin G/H synthase 2
precursor (EC 1.14.99.1)
0 1 0
RAB24 5 Ras-related protein Rab-24 0 1 0
RAB9A X Ras-related protein Rab-9 0 1 0
RARRES3 11 Retinoic acid receptor
responder protein 3
4 2 1
RBCK1 20 RanBP-type and C3HC4-type




kinase 1 (EC 2.7.11.1)
1 0 1
RNF19B 1 IBR domain-containingprotein
3
1 0 0
RNF213 17 RING fingerprotein 213 0 1 0
RNF31 14 RING fingerprotein 31 0 1 0
RSAD2 2 radical S-adenosyl methionine
domain containing 2
10 4 2
RTP4 3 Receptor-transporting protein
4
4 2 1
SAMD9 7 Sterile alpha motif domain-
containing protein 9
3 1 2
SAMD9L 7 Sterile alpha motif domain-
containing protein 9-like
1 0 1
SAMHD1 20 SAM domain and HD domain-
containing protein 1
4 2 1
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SAT1 X Diamine acetyltransferase 1
(EC 2.3.1.57)
1 1 0
SC4MOL 4 C-4 methylsteroloxidase (EC
1.14.13.72)
1 1 0
SECTM1 17 Secreted and transmembrane
protein 1 precursor
2 2 0
SERPINE1 7 Plasminogen activator inhibitor
1 precursor
2 2 0
SERPING1 11 Plasma protease C1 inhibitor
precursor
5 2 0
SERTAD1 19 SERTA domain-containing
protein 1
1 0 0
SH3GLB1 1 SH3 domain GRB2-like
protein B1
1 0 0
SLC15A3 11 solute carrier family 15,
member 3
1 1 0
SLC30A1 1 Zinc transporter 1 1 1 0
SLFN12 17 Schlafen family member 12 1 0 0
SOCS1 16 Suppressor of cytokine
signaling 1
5 3 1
SP100 2 Nuclear autoantigen Sp-100 0 1 0
SP110 2 Sp110 nuclearbodyprotein 0 1 0
SPHK1 17 Sphingosine kinase 1 (EC
2.7.1.-)
1 0 0
SPSB1 1 SPRY domain-containing
SOCS box protein 1
1 0 0
STAT1 2 Signal transducer and activator
of transcription 1-alpha/beta
18 2 3
STAT2 12 Signal transducer and activator
of transcription 2
9 3 1
STAT6 12 Signal transducer and activator
of transcription 6
1 1 0
STOML1 15 Stomatin-likeprotein 1 1 0 0
TAP1 6 Antigen peptidetransporter 1 9 2 2
TAP2 6 Antigen peptidetransporter 2 4 1 1
TAPBP 6 tapasinisoform 1 precursor 1 0 0
TCN2 22 Transcobalamin-2 precursor 1 0 0
TDRD7 9 Tudor domain-containing
protein 7
7 2 2




kinase tousled-like 2 (EC
2.7.11.1)
2 1 0
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TM4SF1 3 Transmembrane 4 L6 family
member 1
2 0 0
TMEM110 3 Transmembrane protein 110 0 1 0
TMEM140 7 Transmembrane protein 140 2 0 2




TNFSF10 3 Tumor necrosis factor ligand
superfamily member 10
0 1 0
TNFSF13B 13 Tumor necrosis factor ligand
superfamily member 13B
3 1 0










TRIM21 11 52 kDa Ro protein 8 3 1
TRIM22 11 Tripartite motif-containing
protein 22
12 4 2
TRIM25 17 Tripartite motif-containing
protein 25
5 2 1
TRIM26 6 Tripartite motif-containing
protein 26
2 1 0
TRIM38 6 Tripartite motif-containing
protein 38
4 2 1
TRIM5 11 Tripartite motif-containing
protein 5 (EC 6.3.2.-)
3 1 1






UBE1L 3 Ubiquitin-activating enzyme
E1 homolog
5 1 0
UBE2E1 3 Ubiquitin-conjugating enzyme
E2 E1 (EC 6.3.2.19)
0 1 0
UBE2L6 11 Ubiquitin/ISG15-conjugating
enzyme E2 L6 (EC 6.3.2.19)
10 2 3
UGCG 9 Ceramide glucosyl transferase
(EC 2.4.1.80)
2 1 0
UNC93B1 11 UNC93 homolog B1 1 0 1
USP42 7 Ubiquitin carboxyl-terminal
hydrolase 42 (EC 3.1.2.15)
1 0 0
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VAMP5 2 Vesicle-associated membrane
protein 5
1 1 0







XRN1 3 5-3 exoribonuclease 1 (EC
3.1.11.-)
1 0 1
ZC3HAV1 7 Zincfinger CCCH type
antiviral protein 1
4 0 2
ZFP36 19 Tristetraproline 1 1 0
ZNFX1 20 NFX1-type zinc finger-
containing protein 1
0 1 0
Table B.7: List of 40 interferon-regulated genes derived from the list of 331 genes down-regulated in
reprogramming factor mRNA-transfected fibroblasts with respect to mock-transfected control cells.
The numbers on the right refer to the number of datasets that have shown the different types of
interferons to regulate the listed genes. Taken from Drews et al. (2012).
Symbol Chromosome Definition Type 1 Type 2 Type 3
ACO1 9 Iron-responsive element-
binding protein 1
1 1 0
ALS2CR2 2 Pseudokinase ALS2CR2 1 0 0
ANLN 7 Actin-binding protein anillin 1 0 0




CCNB1 5 G2/mitotic-specific cyclin-B1 1 1 0
CCNF 16 G2/mitotic-specific cyclin-F 1 1 0






CXXC5 5 CXXC finger 5 1 0 0
DR1 1 TATA-binding protein-
associated phosphoprotein
1 1 0
FAM3C 7 Protein FAM3C precursor
(Protein GS3786)
1 1 0
FBN2 5 Fibrillin-2 precursor 1 1 0
FEZ1 11 Fasciculation and elongation
protein zeta 1 (Zygin-1) (Zygin
I)
1 1 0
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FHL1 X Four and a half LIM domains
protein 1
2 2 0
GPER 7 Chemokine receptor-like 2 0 1 0
HNRNPA1 12 Heterogeneous nuclear
ribonucleoprotein A1
1 1 0
HSPA2 14 Heat shock-related 70 kDa
protein 2
1 0 0
ICAM3 19 Intercellular adhesion molecule
3 precursor
1 0 0
ITGAE 17 Integrin alpha-E precursor 1 1 0
ITGAV 2 Integrin alpha-V precursor 1 0 0
KRT10 17 Keratin, type I cytoskeletal 10 0 1 0




kinase kinase kinase MLT (EC
2.7.11.25)
0 1 0
MYH10 17 Myosin-10 0 1 0
NEK2 1 Serine/threonine-protein




kinase Pim-1 (EC 2.7.11.1)
3 3 0
PKP4 2 Plakophilin-4 1 1 0
PTPN11 12 Tyrosine-protein phosphatase
non-receptor type 11 (EC
3.1.3.48)
1 1 0
PTPN13 4 Tyrosine-protein phosphatase
non-receptor type 13 (EC
3.1.3.48)
1 0 0
RAB40B 17 Ras-related protein Rab-40B 0 1 0
RHOBTB3 5 Rho-related BTB domain-
containing protein 3
1 1 0
SFPQ 1 Splicing factor, proline- and
glutamine-rich
1 1 0
SMAD3 15 Mothers against
decapentaplegic homolog 3
2 2 0
SPA17 11 Sperm surface protein Sp17 1 1 0
STAU2 8 Double-stranded RNA-binding
protein Staufen homolog 2
1 0 0
TCFL5 20 Transcription factor-like 5
protein
1 0 0
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TOP2B 3 DNA topoisomerase 2-beta
(EC 5.99.1.3)
1 1 0
TTK 6 Dual specificity protein kinase
TTK (EC 2.7.12.1)
1 1 0
UBE4B 1 Ubiquitin conjugation factor
E4 B
1 1 0
Figure B.3: Detection of OCT4 protein expression in HFF1 cells upon transfection of the
commercially bought, modified mRNA. HFF1 cells, grown in 24-wells, were transfected with
commercially bought, modified mRNA-encoding POU5F1 and fixed 24 h post-transfection for
the immunofluorescent labeling procedure. Microscope images of the nuclear (DAPI) signals,
the OCT4-specific signals and merged images are shown. Scale bar= 200µm.
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Figure B.4: Detection of SOX2 protein expression and quantification of PODXL transcript
levels in HFF1 cells as quality controls of the different reprogramming protocols. These
quality control assays accompany the results presented in Figures 4.8 and 4.9. HFF1 cells
were transfected with a 1:1:1:1 cocktail of mRNAs encoding POU5F1, SOX2, KLF4 and c-
MYC. Transfections were carried out once or twice with in-house synthesized mRNA (4µg
total per 6-well per transfection; ‘1 mRNA’, ‘2 mRNA’) or once with commercially bought
mRNA (4µg total per 6-well per transfection; ‘modified mRNA’). Alternatively, HFF1 cells
were transduced once with a 1:1:1:1 combination of retroviruses encoding POU5F1, SOX2,
KLF4 and c-MYC or transfected once with a 1:1:1:1:1 mix composed of the miRNAs miR-
302a, miR-302b, miR-302c, miR-302d and miR-367 (100 pmol total per 6-well). Additionally,
the total amount of mRNAs and miRNAs used for reprogramming were substituted with
the same amount of GFP-encoding mRNA or a scrambled, non-target miRNA. Similarly,
cells were transduced with a GFP-encoding retrovirus equivalent to the amount of retrovirus
encoding one of the reprogramming factors in the reprogramming cocktail. All samples were
fixed for immunofluorescence-mediated detection of protein expression or harvested for RNA
isolation at indicated time points. (A) Microscopic images of GFP expression and SOX2
protein expression detected by fluorescence-dye labeled antibodies 96 h post-transduction. (B)
Microscopic images of GFP expression and SOX2 protein expression detected by fluorescence-
dye labeled antibodies 24 h after the first transfection and (C) 24 h after the second transfection
with in-house in vitro synthesized mRNAs. Scale bars= 200µm. (D) PODXL transcript levels.
Bars and error bars represent average LOG2 ratios of transfected/transduced fibroblasts over
mock-transfected/-transduced controls and SD. n= 6 for ‘1 mRNA’; n= 4 for ‘2 mRNA’; n= 3
for ‘Retrovirus’, ‘modified mRNA’ and ‘miRNA’. Modified from Drews et al. (2012).
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